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ABSTRACT 
Background. Not enough is known about which patients suffering from major 
depressive disorder (MDD) benefit from antidepressant drug treatment or how 
temperament and character are associated with response to antidepressive treatment, 
long-term depression outcome in patient populations with substance use and anxiety 
disorder comorbidities. Earlier studies have shown that individual temperament is 
associated with psychiatric morbidity, outcome of depression, anxiety disorders, and 
substance use. However, no prior studies have addressed whether temperament 
clusters 1) predict antidepressive treatment response, 2) anxiety disorder comorbidity 
or 3) how vegetative symptoms of depression modulate the temperament clusters 
effect on response to antidepressive treatment. So far the available data on the 
differences in temperament and character profiles of depressed patients with or 
without harmful drinking has been limited. Moreover, it is not well known how 
harmful alcohol use modifies the effects of temperament and character on 
depression outcome. Knowledge of these associations could provide a method for 
enhancing more individualized treatment strategies for the diverse depressed clinical 
populations in psychiatric secondary services. 
Materials and Methods. For Study I we recruited one hundred Finnish outpatients 
in Tampere region, Southern Finland (aged 19 to 72) suffering from MDD, of whom 
86 completed the 6-week Pharmacogenetic Study on Depression (DEPGEN). We 
assessed their temperament features at baseline with the Temperament and 
Character Inventory (TCI) and used cluster analysis to determine the patients’ 
temperament profiles. We also categorized the patients according to the vegetative 
symptoms of MDD, i.e. reduced sleep and appetite and inner tension. General linear 
models (GLMs) were used for analyzing the association between temperament 
clusters and endpoint depressive symptoms measured by Montgomery Åsberg 
Depression Rating Scale scores (MADRS). 
For Studies II-IV we screened 242 depressed patients with at least moderate level 
of depressive symptoms (BDI ≥ 17) admitted to psychiatric secondary services in 
South Ostrobothnia region in Finland and giving their consent to participate in the 
Ostrobothnia Depression Study (ODS). The Alcohol Use Disorders Identification 
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Test (AUDIT) was used for identifying patients with marked alcohol use problems 
(AUP, AUDIT ≥ 11).  
For Study II 127 depressed patients without alcohol use problems (non-AUP) 
and 89 depressed patients with alcohol use problems (AUP) were eligible for the 
main analyses. We assessed all patients using the Temperament and Character 
Inventory (TCI-R) at baseline and after 6 weeks of treatment. Using univariate 
general linear models (GLMs), we analyzed differences in TCI-R between AUP and 
non-AUP. GLMs were also used in analyzing the associations between TCI-R 
changes and antidepressive treatment responses measured with ΔMADRS. 
For Study III 173 patients were assessed using the MADRS and the TCI-R after 
6 weeks of antidepressive treatment. Outcome of depression (MADRS scores across 
three follow-up points at 6 weeks, 6 months and 24 months) was predicted by AUP, 
gender, and AUP x Gender and AUP x Time (Time = repeated measures variable) 
interactions together with temperament and character dimension scores in a linear 
mixed effects model. 
For Study IV 204 patients were assessed with the TCI-R and their diagnoses with 
the Mini International Neuropsychiatric Interview. Two-step cluster analysis was 
used for defining patients’ temperament profiles and logistic regression analysis was 
used for predicting different anxiety disorders for various temperament profiles. 
Results. Study I resulted in finding an association between skewed temperament 
profile (deviations from the average general population scores in different 
temperament dimensions) and severity of MDD, but the temperament profiles alone 
did not predict antidepressant treatment response. Those with higher baseline 
vegetative symptoms score had modest treatment response. The best fitting model 
with baseline MADRS vegetative symptom scores, age and temperament clusters as 
explanatory variables explained 20% of the variance in the endpoint MADRS scores. 
In Study II alcohol use problems independently explained significant proportions 
of the variation in Novelty Seeking, Self-Directedness, and Persistence. Reward 
Dependence score change explained 14% of the ΔMADRS in AUP, while a similar 
model was non-significant in predicting ΔMADRS in non-AUP. Character score 
changes in Self-Directedness and Self-Transcendence combined explained 13% of 
ΔMADRS in non-AUP, whereas they were all non-significant in AUP. AUP patients 
had lower Self-Directedness and Persistence and higher Novelty Seeking scores than 
non-AUP patients. 
In Study III poorer outcome of depression (MADRS scores at 6 weeks, 6 months 
and 24 months) was predicted by AUP × Time interaction (p<0.001) together with 
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low Reward Dependence (p=0.003). Gender and all other temperament and 
character traits were non-significant predictors of the depression outcome in the 
mixed effects model. 
The cluster analysis in Study IV resulted in finding four temperament clusters: 1) 
Novelty seekers with highest Novelty Seeking scores (n=56), 2) Persistent with 
highest Persistence scores (n=36), 3) Reserved with lowest Novelty Seeking scores 
(n=66) and 4) Wearied with highest Harm avoidance, lowest Reward Dependence 
and lowest Persistence scores (n=58). After adjusting for clinical variables, panic 
disorder and/or agoraphobia were predicted by Novelty seekers’ temperament 
profile with odds ratio [OR]=3.5 (95% confidence interval [CI]=1.8−6.9, p<0.001), 
social anxiety disorder was predicted by Wearied temperament profile with OR=3.4 
(95% CI=1.6−7.5, p=0.002), and generalized anxiety disorder was predicted by 
Reserved temperament profile with OR=2.6 (95% CI=1.2−5.3, p=0.01). 
Conclusions. The temperament clusters were associated both with severity of 
depression and antidepressive treatment response of depression. The effect of 
temperament profile alone was modest but, combined with vegetative symptoms of 
depression, their explanatory power was more marked, suggesting a possible 
association of these two in the biological basis of MDD. (I) 
The changes detected in Reward Dependence over 6 weeks of antidepressive 
treatment and lower Self-Directedness in AUP patients could be indicative of 
different biological mechanisms associated with depressive symptomatology in 
patients with harmful alcohol use. Changes in character are associated with acute 
treatment response in non-AUP. (II) 
Possibly due to the modifying effect of alcohol use problems, high Reward 
Dependence was associated with better antidepressive treatment outcome over the 
two-year follow-up. Harm Avoidance and Self-Directedness did not predict 
depression outcome when alcohol use problems were controlled for. (III) 
Novelty seekers temperament was associated with panic disorder, Reserved with 
generalized anxiety disorder, Wearied with social anxiety disorder, and Persistent 
with lower risk of anxiety disorder comorbidities. These results suggest that TCI-R 
could offer a valuable dimensional method for predicting the risk of anxiety 
disorders in diverse depressed patients. (IV) 
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TIIVISTELMÄ 
Tausta. Tieto siitä ketkä masennuspotilaat hyötyvät masennuslääkityksestä tai siitä, 
miten temperamentti ja luonnepiirteet ovat yhteydessä masennuksen hoitotulokseen 
potilailla, jotka kärsivät samanaikaisesta ahdistuneisuushäiriöstä tai päihdehäiriöistä 
on puutteellista. Aiemmat tutkimukset ovat osoittaneet, että yksilöllinen 
temperamentti on yhteydessä psykiatriseen sairastavuuteen, masennuksen 
hoitotulokseen ja ahdistuneisuushäiriöihin, sekä päihdekäyttöön. Aikaisempi 
tutkimus ei kuitenkaan ole käsitellyt sitä, ovatko temperamenttiprofiiliklusterit 1) 
yhteydessä masennuslääkevasteeseen, 2) ahdistuneisuushäiriöiden 
samanaikaissairastavuuteen tai sitä 3) onko masennuksen vegetatiivisilla oireilla kuten 
ruokahaluttomuus tai unen häiriöt vaikutusta temperamenttiprofiiliklusterien 
mahdolliseen assosiaatioon masennuksen hoitovasteen kanssa. Tähän saakka tieto 
on ollut vähäistä myös siitä, millaisia mahdollisia eroja masennuspotilaiden 
temperamentti- ja luonnepiirreprofiilien välillä on alkoholin riskikäyttäjillä verrattuna 
alkoholia vähemmän käyttäviin. Uutta tietoa tarvitaan myös siitä, muokkaako 
alkoholin haitallinen käyttö temperamentti- ja luonnepiirteiden yhteyttä 
masennuksen hoitotulokseen. Näiden yhteyksien parempi tuntemus voisi auttaa 
yksilöllisten hoitostrategioiden kehittämisessä erilaisista oirekuvista kärsivien 
masennuspotilaiden psykiatrisen erikoissairaanhoidon suunnittelussa. 
Aineisto ja menetelmät. Tutkimusta I varten rekrytoitiin 100 suomalaista 
avohoidon masennuspotilasta Tampereen seudulla (iältään 19–72-vuotiaita), jotka 
osallistuivat masennuksen farmakogenetiikan tutkimukseen (DEPGEN-tutkimus). 
Näistä potilaista 86 pysyi tutkimuksessa 6 viikon seuranta-ajan loppuun saakka. 
Potilaiden temperamenttiominaisuudet määritettiin alkutilanteessa Temperament 
and Character Inventory -kyselyllä (TCI) ja tilastollista klusterianalyysia käytettiin 
potilaan temperamenttiprofiiliklusterien määrittämiseksi. Potilaiden 
masennusoireiden vegetatiivinen oirekomponentti määritettiin myös alkutilanteessa 
tilastollista analyysiä varten. Masennusoireiden mittarina tutkimuksessa käytettiin 
Montgomery Åsbergin masennusoirehaastatteluissa (MADRS) saatuja pistemääriä. 
Tilastollisia monimuuttujamalleja (GLM) käytettiin temperamenttiklusterien ja 
masennusoireiden loppupistemäärän välisen yhteyden analysoimisessa.  
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Tutkimuksiin II-IV seulottiin Etelä-Pohjanmaan alueella 242 vähintään 
keskivaikea-asteisista masennusoireista (BDI ≥ 17) kärsivää potilasta, jotka tulivat 
lähetteellä psykiatriseen erikoissairaanhoitoon ja jotka osallistuivat Masennustalkoot 
II -tutkimukseen (ODS). Alkoholin käytön häiriöiden tunnistamiseen suunniteltua 
AUDIT-kyselyä käytettiin merkittävistä alkoholinkäytön ongelmista kärsivien 
potilaiden tunnistamiseen (AUP, AUDIT ≥ 11). 
Tutkimuksen II pääanalyyseissä vertailtiin 127:n masennuksesta kärsivän (ilman 
alkoholinkäyttöongelmaa) potilaan ryhmää (non-AUP) 89:n merkittävistä 
alkoholinkäyttöongelmista kärsivän masennuspotilaan ryhmään (AUP). Kaikkien 
potilaiden temperamentti ja luonnepiirteet määritettiin alkutilanteessa ja 6 viikon 
seuranta-ajan päätteeksi TCI-R kyselyllä. Ryhmien välisten erojen ja toisaalta TCI-R 
muutoksien (6 viikon seuranta-aikana), sekä masennuksen hoitovasteen (ΔMADRS) 
välisen yhteyden analysointiin käytettiin tilastollisia GLM-malleja. 
Tutkimuksessa III 173:n potilaan masennusoireet (MADRS) ja temperamentti- ja 
luonnepiirteet (TCI-R) määritettiin 6 viikkoa masennuksen hoidon aloittamisen 
jälkeen. Masennuksen pitkän aikavälin tulosta (MADRS-pisteet kolmessa 
seurantapisteessä 6 viikon, 6 kuukauden ja 24 kuukauden kuluttua) ennustettiin 
tilastollisella linear mixed effects -mallilla, jossa selittävinä muuttujina käytettiin 
potilasryhmää (AUP tai non-AUP), sukupuolta, sekä AUP x sukupuoli ja AUP x aika 
-vuorovaikutusmuuttujia yhdessä temperamentti- ja luonnepiirre ulottuvuuksien 
kanssa. 
Tutkimuksessa IV 204 potilaan temperamentti (TCI-R) ja psykiatriset diagnoosit 
(Mini International neuropsykiatrinen haastattelu, MINI) määritettiin tulovaiheessa. 
Potilaiden temperamenttiprofiiliklusterien määrittelemisessä käytettiin tilastollista 
klusterianalyysiä ja tilastollista logistista regressioanalyysiä käytettiin erilaisten 
ahdistuneisuushäiriöiden ennustamiseen käyttäen eri 
temperamenttiprofiiliklustereita selittävinä muuttujina. 
Tulokset. Tutkimuksessa I löydettiin yhteys vinoutuneen temperamenttiprofiilin 
(poikkeamat yleisväestön keskiarvosta eri temperamentti ulottuvuuksissa) ja vakavan 
masennuksen (MDD) oirekuvan vakavuuden välillä, mutta temperamenttiprofiilit 
eivät itsenäisesti ennustaneet masennuslääkkeen vastetta merkittävästi. 
Alkutilanteessa vaikeimmista masennusoireista kärsivät potilaat saivat vähäisimmän 
vasteen masennuslääkkeelle. Tilastollinen GLM-malli, jossa käytettiin selittävinä 
muuttujina alkutilanteessa määritettyä masennuksen vegetatiivista oirekomponenttia, 
ikää ja temperamenttiprofiiliklustereita, selitti 20% lopputilanteen MADRS-
pistemäärän varianssista. 
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Toisessa osatutkimuksessa alkoholin käytön ongelmat (AUP) ennustivat 
tilastollisesti merkitsevästi Elämyshakuisuus (Novelty Seeking), Itseohjautuvuus 
(Self-Directedness) ja Sinnikkyys (Persistence) ominaisuuksien varianssia GLM-
malleissa. Hyväksynnän hakeminen (Reward Dependence) ominaisuuden muutos 6 
viikon seuranta-aikana selitti 14% masennuksen hoitovasteesta (ΔMADRS) 
alkoholin ongelmakäyttäjillä (AUP), mutta vastaava selitysmalli ei ollut merkitsevä 
hoitovasteen ennustamisessa vähäisemmän alkoholin käytön potilasryhmässä (non-
AUP). Itseohjautuvuus ja Henkisyys (Self-Transcendence) 
luonnepiirreominaisuuksien muutokset selittivät yhteensä 13% hoitovasteen 
(ΔMADRS) vaihtelusta non-AUP potilasryhmässä, mutta kaikki 
luonnepiirreominaisuudet olivat ei-merkitseviä hoitovasteen ennustamisessa AUP 
ryhmän potilailla. Alkoholin ongelmakäyttäjien potilasryhmällä oli alhaisempi 
Itseohjautuvuus ja Sinnikkyys, sekä korkeampi Elämyshakuisuus verrattuna 
potilaisiin, joilla ei ollut alkoholin ongelmakäyttöä. 
Tutkimuksessa III huonompaa masennuksen pitkän aikavälin hoitotulosta 
(MADRS-pisteet 6 viikkoa, 6 kuukautta ja 24 kuukautta) ennusti AUP × aika -
vuorovaikutusmuuttuja (p<0,001) yhdessä matalan Hyväksynnän hakeminen 
ominaisuuden kanssa (p=0,003). Sukupuoli ja kaikki muut temperamentti- ja 
luonnepiirre ominaisuudet olivat ei-merkitseviä masennuksen pitkän aikavälin 
hoitotuloksen selittäjinä, kun näiden yhteyksiä analysoitiin lineaarisessa sekamallissa 
(linear mixed effects model). 
Tutkimuksessa IV temperamenttiprofiilit jakautuivat neljään eri klusteriin 1) 
Elämyshakuiset, joilla oli korkeimmat Elämyshakuisuus-pistemäärät (n=56), 2) 
Sinnikkäät, joilla oli korkeimmat Sinnikkyys-pistemäärät (n=36), 3) Varautuneet, 
joilla oli alimmat Elämyshakuisuus-pistemäärät (n=66) ja 4) Uupuneet, joilla oli 
korkeimmat Vaikeuksien välttämis- (Harm Avoidance), alimmat Hyväksynnän 
hakemis- ja alimmat Sinnikkyys-pistemäärät (n=58). Kun mahdollisten sekoittavien 
muuttujien vaikutukset kontrolloitiin logistisissa regressiomalleissa Elämyshakuiset-
temperamenttiprofiili ennusti paniikkihäiriötä ja/tai julkisten paikkojen pelkoa 
vedonlyöntikertoimella [OR]=3,5 (95%:n luottamusväli [CI]=1,8-6,9, p<0,001), 
Uupuneet ennusti sosiaalisten tilanteiden pelkoa [OR]=3,4 (95% [CI]=1,6−7,5, 
p=0,002) ja Varautuneet ennusti yleistynyttä ahdistuneisuushäiriötä [OR]=2,6 (95% 
[CI]=1,2−5,3, p=0,01). 
Johtopäätökset. Temperamenttiprofiilit olivat yhteydessä sekä masennuksen 
vakavuuteen, että masennuksen lääkehoitovasteeseen. Pelkän temperamenttiprofiilin 
vaikutus oli vähäinen, mutta yhdessä masennuksen vegetatiivisen oirekomponentin 
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kanssa niiden selittävä voima oli suurempi, viitaten näiden kahden tekijän yhteyteen 
masennuksen biologisessa taustassa. (I) 
Havaitut muutokset (6 viikon seuranta-aikana) Hyväksynnän hakeminen -
temperamenttiominaisuudessa ja matalampi Itseohjautuvuus -
luonnepiirreominaisuus alkoholin ongelmakäytöstä kärsivillä potilailla voivat 
heijastaa tämän potilasryhmän muista poikkeavia masennuksen biologisia 
taustatekijöitä. Luonteenpiirreominaisuuksien muutokset näyttävät sen sijaan olevan 
yhteydessä masennuksen akuuttiin hoitovasteeseen masennuspotilailla, joilla ei ole 
merkittävää alkoholin riskikäyttöä. (II) 
Alkoholin ongelmakäyttö vaikutti mahdollisesti siihen, että korkea Hyväksynnän 
hakeminen -temperamentti ominaisuus oli yhteydessä parempaan masennuksen 
hoitovasteen kehitykseen kahden vuoden seuranta-aikana. Kun alkoholin käytön 
vaikutus otettiin huomioon, Vaikeuksien välttäminen ja Itseohjautuvuus eivät 
ennustaneet masennuksen hoitovasteen kehitystä merkitsevästi kahden vuoden 
seurannassa. (III) 
Elämyshakuiset-temperamenttiprofiili oli yhteydessä paniikkihäiriöön, 
Varautuneet yleistyneeseen ahdistuneisuushäiriöön, Uupuneet sosiaalisten 
tilanteiden pelkoon ja Sinnikkäät matalampaan kaikkien ahdistuneisuushäiriöiden 
riskiin. Tämä tulos viittaa siihen, että TCI-R voisi tarjota mittamenetelmän 
ennustamaan ahdistuneisuushäiriöiden kehittymisen riskiä masennuspotilailla. (IV) 
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1 INTRODUCTION 
Depressive disorders have been a growing public health concern in Finland during 
the 21th century and the annual prevalence for these disorders is approximately ten 
percent in the Finnish population (Markkula, Suvisaari et al. 2015). This growth in 
prevalence could be a global concern and the point prevalence of major depressive 
disorder (MDD) has been on average 5% in developed western countries (Ferrari, 
Somerville et al. 2013). Depressive disorders are a leading cause of global burden of 
disease (Wittchen, Jacobi et al. 2011) and are associated with low quality of life, sick 
leaves and high suicide risk (Alonso, Angermeyer et al. 2004, Alonso, Petukhova et 
al. 2011, Ösby, Brandt et al. 2001). Contributing to the burden of disease, the 
recurrence of depressive episodes could be associated with half of the cases and the 
duration of single episode is on average 6 months (Burcusa, Iacono 2007, 
Lewinsohn, Clarke et al. 1994). Depressive disorders are syndromes consisting of 
combinations of dysphoric, retardation and vegetative symptoms and different 
symptoms seem to be associated with different outcomes of depression (Suzuki, 
Aoshima et al. 2005, Okazaki, Tominaga et al. 2010, Kamata, Suzuki et al. 2011, 
Higuchi, Sato et al. 2008a). Alcohol consumption posits detrimental effects on vast 
number of diseases (Rehm, Gmel et al. 2017) and substance use problems, especially 
alcohol use, are another major public health and economic concern in European 
countries, including Finland (Barrio, Reynolds et al. 2017). Up to one fourth of 
patients with MDD suffer from concurrent alcohol use disorder (AUD) which can 
have a detrimental effect on recovery from depressive episodes and lead to more 
chronic disease courses (Davis, Uezato et al. 2008, Melartin, Rytsala et al. 2002, 
Melartin, Mantere et al. 2014, Burcusa, Iacono 2007, Holzel, Harter et al. 2011). 
These patients with concurrent mental illness and AUD are diagnosed with “dual 
diagnosis” and in spite of promising treatment options for these patients, more 
thorough research is needed on the possible predefined moderators and mediators 
of treatment outcome in this patient group (Riper, Andersson et al. 2014). 
Dimensional assessment of the human personality has been used in scientific 
studies and the new versions of the Diagnostic and Statistics Manual of mental 
disorders (DSM-5) and International Classification of Diseases (ICD-11) have 
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dimensional diagnostics algorithms for personality disorders (Bach, Sellbom et al. 
2018). According to Robert Cloninger’s biopsychological model, the human 
personality is composed of temperament and character (Cloninger, Svrakic et al. 
1993). Temperament is the more stable core of the personality resulting in individual 
reactions to different life-events whereas character is essential, for example, in 
determining social performance (Cloninger, Svrakic et al. 1993). Temperament and 
character traits are associated with depressive disorders, outcome of depression, 
alcohol use and anxiety disorders (Kampman, Poutanen 2011, Balestri, Porcelli et al. 
2019, Miettunen, Raevuori 2012, Howard, Kivlahan et al. 1997, Foulds, Mulder et al. 
2016). Alcohol use problems could modulate the association between temperament 
and character and depression outcome and better knowledge of this effect could 
help in developing more effective treatments for dual diagnosis patients. Better 
knowledge of the associations between temperament and anxiety disorders could 
also aid in the improvement of treatments for comorbid depression, because the 
comorbidity of anxiety disorders also has detrimental effects on recovery from 
depression (Holzel, Harter et al. 2011). 
This thesis consists of prospective clinical cohort studies predicting short-term, 
mid-term and long-term outcomes of depression with temperament (and character) 
profiles or short-term changes in temperament or character. The possible 
modulating effect of alcohol use problems or vegetative symptoms of depression on 
those associations are studied. The cross-sectional part of the study analyses the 
relationship between temperament profile and different anxiety disorder 
comorbidities in depressed patients. Moreover, the unique temperament and 
character characteristics of depressed patients with alcohol use problems are 
examined. 
 27 
2 REVIEW OF THE LITERATURE 
2.1 Depression as a dimensional concept 
Depression is a common word in everyday language. However, its meanings vary 
considerably according to the context in which it is referred to. For example, it is 
commonly used to describe a current negative mood state after an adverse life event 
or in more casual situations, but in psychiatric clinics depression often refers to a 
severe illness with low level of functioning and high risk of suicide (Ösby, Brandt et 
al. 2001, Alonso, Petukhova et al. 2011).  
As a clinical disorder depression is composed of a combination of different 
symptoms which affect mood state, ability to experience pleasure, cognitive and 
somatic functions and which negatively bias self-evaluation or cause suicidal 
ideation. These symptoms causing extensive and varied perturbations in patients are 
deemed existent or non-existent and the severity of the disorder is mainly evaluated 
in terms of how many different symptoms it causes. Another criterion for depressive 
disorders is persistence of these symptoms over a specific period of time. In this 
respect depressive disorders are defined through two non-quantitative aspects, one 
concerning the number of extant symptoms and the other concerning their duration, 
whereas the severity of symptoms is only taken slightly into account in severe cases. 
(American Psychiatric Association 2013, WHO | International Classification of 
Diseases, 11th Revision (ICD-11), World Health Organization 1992) This can be 
considered as weakness in   clinical practice, because it is widely acknowledged that 
the course of depression is more linearly associated with the severity of depressive 
symptoms (van Beljouw, Verhaak et al. 2010). Moreover, patients with subclinical 
depressive symptoms might go unnoticed in the non-quantitative assessment of 
depressive disorders even though they may constitute a clinically relevant population 
in need of treatment (Peters, Shankman et al. 2015). These shortcomings of the 
categorical assessment of depressive disorders may have led to the frequent use of 
different linear measures of symptoms of depression in evaluating patients and 
informing clinical decision-making.  
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2.1.1 Measures of symptoms of depression  
There are numerous different rating scales for gathering information on different 
depressive symptoms, some of which are brief self-report questionnaires used as 
screening tools while others gather detailed information on different symptoms of 
depression by interviews conducted by trained professionals. The general screening 
of different psychopathologies (including depressive symptoms) can be made via 
self-report questionnaires General Health Questionnaire (GHQ, (Goldberg 1972)) 
and the Symptom Checklist-90 (SCL-90, (Derogatis, Lipman et al. 1973)). 
Concentrating on symptoms of depressive disorders, the self-report questionnaire, 
the Beck Depression Inventory (BDI, (Beck, Steer et al. 1996)) has been widely used 
in screening patients in the community or in general medical population. Observer-
rated depressive symptom scales Hamilton Rating Scale for Depression (HAM-D, 
(Hamilton 1960)) and the Montgomery-Åsberg Depression Rating Scale (MADRS, 
(Montgomery, Åsberg 1979)) are more commonly used in evaluating severity of 
depression or response to treatment in patients in psychiatric secondary care or in 
research settings. 
2.1.1.1 Beck Depression Inventory 
The Beck Depression Inventory is a self-report questionnaire that collects 
information on various depressive symptoms and their severity. The original version 
was published in 1961 and contained 21 items with statements describing different 
symptom severities (Beck, Ward et al. 1961). Since then several different versions 
have been introduced to better respond to the depressive symptomatology of more 
recent diagnostics manuals or better suited for different applications, and the 
questionnaire has been validated in multiple different languages including Finnish 
(Aalto, Elovainio et al. 2012).  
The Finnish BDI-1A questionnaire consists of 21 items, each of which contain 4 
to 7 different statements corresponding to absent (a score of 0), mild (1), moderate 
(2) and severe (3) symptoms. These items are related to symptoms of sadness, 
hopelessness, feelings of failure, anhedonia, guilt, punishment, self-dislike, self-
accusation, self-harm, crying, irritability, loss of interest in other people, 
indecisiveness, impaired self-image and ability to work, problems with sleeping, 
tiredness, loss of appetite, weight loss/gain, somatic preoccupation and loss of 
libido. The Finnish interpretation guide suggests 0-9 points as corresponding to a 
subclinical level of depressive symptoms, 10-16 to mild depression, 17-29 to 
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moderate depression and 30-60 to severe depression. The internal consistency of the 
BDI has been high in various studies (mean Cronbach’s alpha value of 0.87) and 
test-retest reliability greater than 0.60 (Beck, Aaron T., Steer et al. 1988). The 
intercorrelation between the BDI and an interview-based depression severity rating 
scale, MADRS, has been moderate (r=0.65) (Tamaklo, Schubert et al. 1992).  
2.1.1.2 Montgomery-Åsberg Depression Rating Scale 
The Montgomery-Åsberg depression rating scale was introduced in 1979 as an 
instrument sensitive to change in depressive symptoms and has been widely used in 
studies on depression treatment response (Montgomery, Asberg 1979, Serretti, 
Chiesa et al. 2009, Cuijpers, Li et al. 2010). It consists of 10 items, each including 
statements guiding the evaluation of symptom severity and evaluated on an ordinal 
scale from absent to severe (0 to 6 points) as observed in an interview. This interview 
is conducted by a trained professional and includes one item that represents the 
interviewer’s subjective estimation of the level of the patient’s depressive mood. 
Other items include symptomatology reflecting the patient’s own subjective feeling 
of depressed mood, feelings of anxiety, reduced sleep and appetite, concentration 
difficulties, reduced initiative ability, anhedonia, pessimistic thoughts and suicidal 
ideation. The guidelines suggest interpretating 0-7 points as no depression, 8-14 
points as depressive symptoms, 15-24 points as mild depression, 25-30 points as 
moderate depression, 31-43 points as severe depression and 44 or more points as 
very severe depression (Montgomery, Åsberg 1979). MADRS has shown acceptable 
construct validity and test-retest reliability (r=0.76) (Davidson, Turnbull et al. 1986), 
but some items (i.e. suicidal thoughts, sleep disturbance and reduced appetite) have 
been poorly correlated with the remainder of the scale and several factor analyses 
have suggested more than one factor for MADRS (Suzuki, Aoshima et al. 2005). 
2.1.2 Symptoms of depression 
As is evident in the specifications of different symptom modalities of the BDI and 
MADRS described above, depressive symptoms have a deleterious effect on 
individual well-being on multiple different levels i.e. cognitive, affective, behavioral, 
somatic and vegetative (Kanter, Busch et al. 2008). The associations between these 
different symptoms and depressive states were originally found through 
observations and interviewing depressed patients (Paykel 2008). The criteria 
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including the core symptoms for different clinical depressive disorders in the 
diagnostics manuals (DSM and ICD) are defined by committee agreement based on 
empirical research data (Paykel 2008). The core symptoms of depression are 
depressed mood and loss of interest or pleasure (American Psychiatric Association 
2013), and fatigability or loss of energy (World Health Organization 1992). Although 
the other possible symptoms of depression are various, studies have supported the 
unidimensional structure of the symptoms of major depressive disorder (Aggen, 
Neale et al. 2005) and the wide variety of symptoms included in the BDI (Beck, Steer 
et al. 1988). However, three orthogonal genetic factors have been suggested to 
underlie MDD, one of which has been associated with vegetative symptoms of 
depression (Kendler, Aggen et al. 2013). Different subtypes of depressive disorders 
(depression with atypical or melancholic features or seasonal pattern) with 
differences in vegetative symptoms have traditionally been recognized (DSM and 
ICD) (Paykel 2008).  
2.1.2.1 Vegetative symptoms of depression 
Vegetative symptoms of depression refer to symptoms such as increased or 
decreased appetite, weight gain or loss of weight and insomnia or hypersomnia 
(Grimaldi, Partonen et al. 2009). Historically these vegetative symptoms (i.e. 
decreased appetite and insomnia) have been associated with a more “endogenous” 
type of depression defined as being less associated with life-stressors (Paykel 2008). 
Atypical vegetative symptoms (increased appetite and hypersomnia) have been 
associated with the early stages of a depressive episode in patients with seasonal 
affective disorder and seasonal changes in the vegetative functions have been 
suggested to predispose to seasonal pattern of depressive symptomatology 
(Grimaldi, Partonen et al. 2009). Vegetative symptoms seem to be associated with 
elevated levels of acute phase protein haptoglobin and immunological mediators 
such as IL-6 and IL-1 (Maes 1993), and predict the emergence of cognitive 
symptoms of depression in patients treated with proinflammatory cytokines 
(Wichers, Koek et al. 2005). Low grade inflammation is common in patients with 
depression (Osimo, Baxter et al. 2019) and it is associated with the vegetative 
symptoms, perhaps more specifically with sleep problems and energy level (Jokela, 
Virtanen et al. 2016, Fried, von Stockert et al. 2019).  
A three-factor model for MADRS in MDD has been proposed with a vegetative 
symptom factor consisting of symptoms of reduced sleep and appetite and inner 
tension (Suzuki, Aoshima et al. 2005). These vegetative symptoms have had delayed 
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response to electroconvulsive therapy (ECT) (Okazaki, Tominaga et al. 2010) and 
high scores in the vegetative factor have been associated with A allele of serotonin 
receptor 5HT2A (Kamata, Suzuki et al. 2011). Moreover, high scores on the 
vegetative factor have also been associated with poorer outcome of fluvoxamine 
treatment (Higuchi, Sato et al. 2008a), and have been suggested to be indifferent in 
predicting response to other antidepressant milnacipran (Higuchi, Sato et al. 2008b) 
in Japanese depressed patients.  
2.2 Major depressive disorder (MDD) 
Major depressive disorder first appeared in the official disease classification in 1980 
when the DSM-III was published (American Psychiatric Association 1980). This 
classification of depression was to be used to make a distinction between bipolar 
disorder and less severe dysthymia. After the publication of the DSM-III, the 
definition of MDD has gone through only minor changes (American Psychiatric 
Association 2013). The diagnostic criteria for depressive episodes and recurrent 
depressive disorder episodes in the International Classification of Diseases (ICD-10) 
are mainly similar to the DSM criteria for MDD. However, the criteria in the ICD-
10 include fatigue or loss of energy as one possible core criterion and require one 
less symptom for the diagnosis (World Health Organization 1992, American 
Psychiatric Association 2013). In Finland the ICD-10 is still used for diagnosing 
patients in clinical settings, but in research settings the use of the DSM is the gold 
standard. In this thesis depressive episodes or recurrent depression according to 
ICD-10 criteria are only referred to if specifically noted. 
2.2.1 Diagnosis of MDD 
There are five diagnostic criteria for MDD in the DSM-5. The first (I) requirement 
for the diagnosis is presence of five or more depressive symptoms over for at least 
2-week time periods and these symptoms are required to represent a change from 
previous functioning. One of the core symptoms of either 1) depressed mood or 2) 
loss of interest or pleasure must be present in addition to other possible symptoms: 
3) significant weight loss or weight gain, 4) insomnia or hypersomnia, 5) 
psychomotor agitation or retardation, 6) fatigue or loss of energy, 7) feelings of 
worthlessness or guilt, 8) diminished ability to think or concentrate or indecisiveness, 
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9) recurrent thoughts of death or suicide attempt. The second (II) diagnostic criteria 
include clinically significant distress or impairment in social or other areas of 
functioning. Third (III) the criteria to be met for a diagnosis of major depressive 
episode (MDE) include exclusion of substance abuse or depression induced by a 
medical condition. The two other criteria for MDD also concern exclusion of other 
disorders: (IV) depressive episode is not better explained by schizophrenia or other 
disorders in that spectrum, and (V) the patient has never had a manic or hypomanic 
episode. (American Psychiatric Association 2013)  
The possible depressive symptoms in diagnosing MDD have remained 
unchanged, but some other minor alterations to the diagnostic criteria exist between 
different versions of the DSM. The most notable and controversial change made to 
the DSM-5 was the removal of bereavement exclusion criteria, which may be 
associated with a minor increase in the prevalence of this disorder (Clesse, Leray et 
al. 2017).   
2.2.2 Epidemiology of MDD 
Studies on the prevalence of depression are sensitive to discrepancies in study design 
and methodology and studies using symptom scales as measures of depression result 
in markedly higher prevalence whereas there is no significant difference in 
prevalence according to the use of ICD or DSM criteria (Ferrari, Somerville et al. 
2013). A meta-analysis estimated the point prevalence of major depression in 
Western Europe to be 4.7%, which is also the global average (Ferrari, Somerville et 
al. 2013). Developing countries have mainly higher prevalence of MDD with the 
exception of a slightly lower prevalence of 4.0% found in East/Southeast Asia 
(Ferrari, Somerville et al. 2013). Depression is twice as common in females as in men 
(Culbertson 1997) and a higher prevalence is found in adults of working age 
compared to other age groups (Ferrari, Somerville et al. 2013). 
Disability adjusted life years (DALYs) are a standard measure for estimating the 
burden of disease. This is the sum of life years lost (YLL) due to premature mortality 
and years of life lived with a disability (YLD) (Murray, Lopez (editors) 1996). Even 
though no disorder specific YLL could be estimated for depression, it was the 
leading cause of YLD in the global burden of disease study in 2000 and was estimated 
as the third leading cause of global disease burden (equivalent to 4.3% of DALYs) 
(WHO | The global burden of disease: 2004 update 2008, Global Burden of Disease 
2000: version 2 methods and results. Available: 
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http://www.who.int/healthinfo/paper50.pdf. 2002). MDD and dysthymia were studied 
as separate diseases and population surveys were conducted to determine the disease 
weights used in calculating YLDs in The Burden of Disease Study 2010 (Ferrari, 
Charlson et al. 2013). In that study MDD was the second leading cause of YLDs 
(accounting for 8.2% of global YLDs) and accounted for 2.5% of global DALYs 
(Ferrari, Charlson et al. 2013). MDD also explained part of the DALYs associated 
with ischemic heart disease and suicide as it was considered a risk factor for them 
(Ferrari, Charlson et al. 2013). The overall global DALYs accounting for depression 
in the study was 3.8% and 85% of the burden was attributable to MDD (and 15% 
to dysthymia) (Ferrari, Charlson et al. 2013). 
The annual prevalence of 6.5% of depressive disorders in Finnish population was 
comparable to those in other industrialized western countries in the Health 2000 
study (Pirkola, Isometsa et al. 2005). In the follow-up Finnish Health 2011 Survey 
MDD had a higher prevalence at 7.4% and the prevalence of dysthymia was 4.5% 
(Markkula, Suvisaari et al. 2015).  
2.2.3 Etiology of MDD 
2.2.3.1 Risk factors and an integrative model for predicting depression 
Major depressive disorder is a multifaceted syndrome associated with symptoms of 
emotional, cognitive or neurovegetative functions and psychomotor activity (Fava, 
Kendler 2000). The various environmental and individual risk factors for depression 
consist of female gender (Culbertson 1997), genetic influences (Flint, Kendler 2014), 
adverse experiences in childhood (Parker 1979, Holmes, Robins 1988, Tennant 
1988, Maniglio 2010), specific personality related factors (Boyce, Parker et al. 1991, 
Kampman, Poutanen 2011), stressful life-events (Kessler 1997), low social support 
and marital difficulties (Patten, Williams et al. 2010, Whisman, Sheldon et al. 2000), 
and prior history of depression or anxiety (Harrington, Fudge et al. 1990, Breslau, 
Schultz et al. 1995).  
Kendler et al., used structural equation modelling to generate a developmental 
model for the etiology of MDD separately for men and women (Kendler, Gardner 
et al. 2002, Kendler, Gardner et al. 2006). These models included eighteen risk 
factors considered in five tiers: 1) childhood (genetic risk, disturbed family 
environment, childhood sexual abuse, and childhood parental loss), 2) early 
adolescence (neuroticism, self-esteem and early onset anxiety, and conduct disorder), 
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3) late adolescence (educational attainment, lifetime trauma, social support, and 
substance abuse), 4) adulthood (history of divorce and past history of depression), 
5) the previous year (marital problems, difficulties, and stressful life-events). The best 
fitting models using multiple correlations and paths were relatively similar for men 
and women and were able to explain half of the variance in depressive episode 
incidence in the previous year in both genders. These findings were concluded as 
reflecting the etiological complexity of MDD and suggested to indicate a mainly 
similar etiology of MDD for both genders. (Kendler, Gardner et al. 2002, Kendler, 
Gardner et al. 2006)  
2.2.3.2 Neuroimaging findings 
Magnetic resonance imaging (MRI) (Caetano, Hatch et al. 2004) and its more recent 
applications fMRI (Ogava, et al. 1993) and diffusion tensor imaging (DTI) (Peng 
Fang, Ling-Li Zeng et al. 2012) are the most widely used methods in imaging changes 
in the structure or functionality of the central nervous system (CNS) in MDD 
patients because of their high resolution and lack of radiation exposure. Other 
imaging methods include magnetic resonance spectroscopy (MRS) (Brambilla, 
Stanley et al. 2002), positron emission tomography (PET) (Alavi, et al. 1986), single 
photon emission computed tomography (SPECT) (Bhardwaj, Chakrabarti et al. 
2010), and the more recently introduced pseudo-continuous arterial spin labelling 
(pCASL) (Fazlollahi, Bourgeat et al. 2015). These methods are used in imaging 
biochemical, hemodynamic and pharmacokinetic events in vivo. The structural 
changes in the CNS of MDD patients include increased volume of lateral ventricles 
and cerebrospinal fluid (CSF), increased rate of hyperintensities of subcortical gray 
matter, and smaller volumes of basal ganglia, thalamus, hippocampus, frontal lobes 
in multiple locations including orbitofrontal cortex and gyrus rectus (Kempton, 
Salvador et al. 2011). However, according to a meta-analysis (Kempton, Salvador et 
al.  2011) there seem to be no alterations in amygdala volumes in depression. 
Functional changes associated with depressive states are described in chapters 2.2.4., 
2.2.4.1, and 2.2.4.2. 
2.2.3.3 Heritability and genetic findings 
The estimate for the heritability of MDD has been 37% according to twin studies 
(Sullivan, Neale et al. 2000) in spite of claims of heritability as high as 78% 
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(McGuffin, Katz et al. 1996). Genome-wide studies of depression have shown 
heritability rates for depression of 21 to 32% (Direk, Williams et al. 2017, Lubke 
2012). Females seem to have higher heritability of MDD (42%) than males (29%) 
(Kendler, Gatz et al. 2006) suggesting different genetic backgrounds for the two 
sexes (Flint, Kendler 2014). 
Traditional genetic studies have been hypothesis-based and searched for 
candidate genes in predicting depression and meta-analyses of these studies have 
yielded significant associations between 7 different gene variants and depression: 
5HTTP/SLC6A4, APOE, DRD4, GNB3, HTR1A, MTHFR, and SLC6A3 (Flint, 
Kendler 2014). However, these associations have not been replicated in genome-
wide association studies (GWASs) with large numbers of subjects (Flint, Kendler 
2014). In addition to findings in candidate gene studies, some new single nucleotide 
polymorphisms (SNPs) such as rs9825823, rs1863918, rs12415800 and rs35936514 
have reportedly been associated with depression symptomatology in the GWASs 
(Direk, Williams et al. 2017, Matsunami, Nishida et al. 2016, Cai, Bigdeli et al. 2015). 
It has been suggested that there are most likely a large number of different genetic 
variants with small effect sizes conferring susceptibility to depression although the 
possibility of rare variants with greater effect size is not ruled out. Nevertheless, the 
findings in GWAS have also been hard to replicate and it has been argued that even 
larger sample sizes (of over n=50,000) would be needed to show significant results 
in the search for the genetic background of MDD (Flint, Kendler 2014). Indeed, a 
recent GWAS analyzing two samples with over 70,000 subjects was able to replicate 
an association between broad depression phenotype and SNP located in an intron 
of the FHIT gene (Direk, Williams et al. 2017). Other possible methods suggested 
to obtain significant results include studying narrower subtypes of depression or 
more specific phenotypes associated with depression (Flint, Kendler 2014). 
Different genetic susceptibilities could also be associated with different aspects of 
depressive symptomatology as three differential genetic factors have been suggested 
to exist specifically reflecting the psychomotor/cognitive, mood, and 
neurovegetative features of MDD (Kendler, Aggen et al. 2013).  
2.2.3.4 Psychological theories 
The traditional cognitive model of depression (Beck 1967) proposes that depressed 
individuals have maladaptive schemas consisting of feelings of worthlessness, 
hopelessness and rejection. This causes negatively biased appraisal of life events 
leading again to reinforcement of these negative schemas and the maintenance of 
 36 
depressive state. Disrupted cognitive functions include: 1) arbitrary judgement, 2) 
selective abstracting, 3) overgeneralization, 4) over/undervaluation, 5) 
personalization and 6) splitting. 
Behavioral theory emphasizes the role of avoidance as a central causal factor in 
the etiological process of depression (Kanter, Busch et al. 2008, Carvalho, Hopko 
2011). Some theorists consider behavior as a wide concept including verbal behavior 
(also in the form of thought) as behavior of framing events rationally (Barnes-
Holmes, Hayes et al. 2001). Behavioral studies have also considered avoidance in a 
wide sense including 1) cognitive aspects of avoidance such as denying, minimizing, 
ruminating or passive “submission” to the current state of affairs as well as 2) 
behavioral avoidance in terms of participation in alternative activities. This 
behavioral avoidance may also include substance abuse, gambling, binge eating, or 
overexpression of negative emotions (e.g. shouting at others) (Carvalho, Hopko 
2011). According to the behavioral theory of depression, avoidance leads to 
depressive state via absence of reinforcement and reward caused by this passivity or 
withdrawal (Carvalho, Hopko 2011). 
The early psychological theories including psychodynamic theory are based on 
the works of Sigmund Freud. Although similarities across behavioral and 
psychodynamic theories have been suggested, the psychodynamic object loss model 
of depression has not attracted scientific interest in recent decades (Akiskal, 
McKinney 1973, Wilkins 1971). 
2.2.4 Pathogenesis of MDD 
The pathogenesis of depression is not completely understood. Although 
malfunctions in monoaminergic (serotonin, norepinephrine and dopaminergic) 
metabolism are associated with depression, the monoamine theory of depression 
developed in the 1950s and 60s is inadequate in explaining the pathogenesis of 
depression (Caldecott-Hazard, Morgan et al. 1991). Impaired corticosteroid signaling 
associated with increased production of corticotropin-releasing hormone (CRH) in 
CNS was considered an epiphenomenon of depression during 20th century but more 
recently has been proposed as a causal factor in the pathogenesis of depression 
(Holsboer 2000).  
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2.2.4.1 Newer hypotheses explaining the pathogenesis of depression 
Because no comprehensive explanation has been found, many hypotheses have 
recently been proposed to explain the phenomenology and pathogenesis of 
depression. These include disrupted neurogenesis in the hippocampus (Samuels, 
Hen 2011), fibroblast growth factor (FGF) associated neuroplasticity (Turner, 
Watson et al. 2012), GABAergic deficit (Luscher, Shen et al. 2011), nitrosative stress 
(Anderson, Berk et al. 2014), and immune-kynurenine pathway (Won, Kim 2016, 
Allison, Ditor 2014) as hypotheses for the pathogenesis of depression. These 
hypotheses are not exclusive of one another and disrupted neurogenesis can even be 
considered to be an extension of the theory of impaired corticosteroid signaling, 
whereas GABAergic functions could be associated with neurogenesis in the 
hippocampus (Holsboer 2000, Samuels, Hen 2011, Luscher, Shen et al. 2011).  
The findings supporting the hypotheses in preceding paragraph suggest chronic 
stress induced inflammatory state disrupting the neurogenesis and causing a 
neurotoxic effect on glial cells in the CNS leading to depressive state (Allison, Ditor 
2014, Won, Kim 2016, Holsboer 2000, Samuels, Hen 2011). The chronic stress could 
be induced via epigenetic regulation of the expression of glucocorticoid receptor in 
individuals with childhood abuse, leading to altered functions on the hypothalamic-
pituitary-adrenal (HPA) axis and resulting in chronically high level of cortisol 
associated with stress (McGowan, Sasaki et al. 2009, Holsboer 2000). Chronic high 
stress levels could result in higher expression of pro-inflammatory cytokines such as 
tumor necrosis factor (TNF), IL-1, IL-6 and IL-18 (Bertini, Garattini et al. 1993, 
Spengler, Chensue et al. 1994, Borovikova, Ivanova et al. 2000) and downregulation 
of anti-inflammatory IL-10 (Borovikova, Ivanova et al. 2000) via complex 
mechanisms and biochemical cascades (Pavlov, Tracey 2005, Haskó, Szabó 1998). 
Higher levels of pro-inflammatory cytokines IL-1, IL-6 and TNF are associated with 
cognitive and emotional symptoms (Reichenberg, Yirmiya et al. 2001, Strike, Wardle 
et al. 2004, Wright, Strike et al. 2005) and high levels of TNF and IL-6 and low level 
of anti-inflammatory IL-10 are found in MDD patients (Müller 2014, Kim, Na et al. 
2007, Dhabhar, Burke et al. 2009).  
The immune-kynurenine pathway hypothesis regarding the etiology of 
depression is supported by findings that demonstrate how higher concentrations of 
cytokines such as TNF result in enhanced activity of indoleamine 2,3-dioxygenase 
(IDO) enzyme (Robinson, Hale et al. 2005, Heyes, Achim et al. 1996). Increased 
activity of this enzyme may lead to increased level of extrahepatic metabolism of 
tryptophan to kynurenine (Won, Kim 2016). The extrahepatic kynurenine and one 
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of its metabolites, 3-hydroxykynurenine, penetrate the blood brain barrier (BBB) 
causing elevation in these molecules in the CNS (Won, Kim 2016). Whereas 3-
hydroxykynurenine may have neurotoxic effects per se, according to the hypothesis 
inflammatory state in CNS results in increased metabolism of kynurenine in 
microglia and macrophages by kynurenine mono-oxygenase enzyme resulting in an 
increase in another neurotoxic metabolite quinolinic acid (Won, Kim 2016, Heyes, 
Achim et al. 1996, Mellor, Munn 1999). Moreover, increased activity in the metabolic 
route described shifts the balance away from the other possible metabolic route of 
kynurenine by kynurenine amino-transferase in astrocytes, resulting in decreased 
production of kynurenic acid, a metabolite with potential neuroprotective effects 
(Won, Kim 2016). The resulting imbalance of neurotoxic and neuroprotective 
metabolites in the CNS is hypothetically linked to progressive degradation of glial 
and neuronal networks in the CNS leading to the development of depression in 
conditions of chronic stress (Won, Kim 2016). However, it is noteworthy that these 
effects are not likely pathognomonic to depression, and thus the development of 
medical agents affecting this system could facilitate the progress of developing novel 
treatments for various neurodegradative diseases (Jacobs, Castellano-Gonzalez et al. 
2017). Figure 1 illustrates the immune-kynurenine pathway theory. 
Gene x Environment (GxE) interactions could be also associated with the effect 
of serotonin transporter gene variant (5-HTTLPR) and brain derived neurotrophic 
factor (BDNF) in the pathogenesis of depression by causing impaired serotonin 
metabolism and disrupted neurogenesis in the hippocampus in patients with early or 
recent negative life-events (Brown, Craig et al. 2014, Samuels, Hen 2011). However, 
the GWASs have so far been unable to lend support to the hypotheses in this 
chapter, which has even led some researchers to question the GxE effects of the 
known candidate genes (Van der Auwera, Peyrot et al. 2018, Flint, Kendler 2014). 
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Figure 1 Illustration of immune-kynurenine pathway theory 
Abbreviations: TNF = Tumor necrosis factor, IL-1 = Interleukin-1, IL-6 = Interleukin-6, IDO = 
indoleamine 2,3-dioxygenase 
2.2.4.2 Neuroimaging findings on the pathogenesis of depression  
The central role of the hippocampus in depressive symptomatology is also supported 
by findings in MRI studies, which have demonstrated an association between smaller 
volumes of hippocampus and depression (Kempton, Salvador et al. 2011) as well as 
poorer outcome of depression at three years and an increase in the volume of the 
left hippocampus is associated with better antidepressant treatment response (Frodl, 
Jäger et al. 2008). There seem to be lateral differences in blood perfusion in the brains 
of depressed patients and the left hemisphere has been shown to be associated with 
lower perfusion than the right hemisphere (Chen, Bian et al. 2016). It has been 
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suggested that hypoactivation in left dorsolateral prefrontal cortex (dlPFC) in 
particular is associated with depressive pathology (Davidson, Pizzagalli et al. 2002). 
This could explain why rTMS treatment is administered to this particular area, 
although more recent research has suggested that the treatment effect is likely to be 
associated with the connectivity of the anterior cingulate cortex (ACC) and the 
fronto-parietal network (Tik, et al. 2017). Such hypotheses are likely to have shifted 
the interest in imaging studies to studying the connective tracts between different 
brain regions. Depressed patients have shown higher connectivity in the fronto-
limbic tract (Peng Fang, Ling-Li Zeng et al. 2012) and disrupted connectivity in the 
uncinate fasciculus (Zhang, Leow et al. 2012) connecting the anterior temporal lobe 
and inferior areas of the frontal lobe. Studying these connective tracts is interesting 
because the disrupted white matter could be associated with the neurotoxic effect 
caused by inflammation as discussed in the preceding chapter.  
2.2.4.3 Integration of neuropathological findings of depression with cognitive theories 
The accumulating body of functional brain imaging findings in studies with task-
related settings has enabled the development of integrative neurocognitive models 
of psychiatric disorders including depression. These theories aim to better explain 
the multifaceted clinical phenomenon of depression including its emotional and 
cognitive symptoms (Disner, Beevers et al. 2011, Malhi, Byrow et al. 2015, Kret, 
Ploeger 2015). These models have integrated information from a multitude of 
imaging studies and suggest that impaired brain regions and mechanisms for 
different cognitive functions are associated with the etiology of depression: 
rumination, reappraisal, attention control, reward processing, impulsivity and mood 
lability (Malhi, Byrow et al. 2015). Such integrative theories could arguably lead to a 
more profound understanding of depression (Disner, Beevers et al. 2011) and by 
integrating psychological and biological information also aid in finding novel 
hypotheses for the pathogenesis of depression. 
2.3 Comorbidity of MDD 
Major depressive disorder has a high rate of comorbidity with other psychiatric and 
substance use related disorders (Melartin, Rytsälä et al. 2002, Brown, Campbell et al. 
2001). These comorbidities are associated with poorer outcome of depression and 
more difficulties in treatment (Burcusa, Iacono 2007, Holzel, Harter et al. 2011).  
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2.3.1 Substance use 
Substance use is more common among depressed patients than in general population 
(Sullivan, Fiellin et al. 2005). Harmful substance use can predispose to depression 
and conversely depression can lead to substance use, for example in an effort to 
“self-medicate” (Pacek, Martins et al. 2013). The causal relation between substance 
use and depression is likely complex and possibly reciprocal (Lyons, Schultz et al. 
2006, Pacek, Martins et al. 2013). 
2.3.1.1 Alcohol use disorders 
Alcohol use disorders (AUDs) are the most common substance use related disorders. 
Whereas DSM-IV divided these disorders into alcohol abuse (AA) and alcohol 
dependence (AD), in the DSM-5 these disorders have been integrated into a single 
diagnosis of alcohol use disorder (American Psychiatric Association 1994, American 
Psychiatric Association 2013). According to the DSM-IV there are two higher order 
diagnostic criteria that have to be met one year prior to AUD diagnoses: 1) use of 
alcohol (both AA and AD), and 2) at least one of the four “alcohol abuse criteria” 
for AA and at least three of the seven “alcohol dependence criteria” for AD 
(American Psychiatric Association 1994). Under the DSM-5 the second higher order 
criterion required for AUD demands fulfilling at least two of the eleven “alcohol use 
disorder criteria” and the severity of this disorder is defined according to how many 
of these criteria are fulfilled (2 to 3 for mild, 4 to 5 for moderate, and 6 or more for 
severe) (American Psychiatric Association 2013). 
The Alcohol Use Disorder Identification Test (AUDIT) is an instrument 
designed for identifying alcohol use disorders and high-risk use of alcohol in clinical 
settings (Bohn, Babor et al. 1995). The cut-off points for different risk levels are 
suggested to be defined nationally (Babor, Higgins-Biddle et al. 2001) and in Finland 
scores of over 11 reflect high risk of harm due to alcohol use. AUDIT-C consists of 
questions 1-3 of AUDIT: How often do you have a drink containing alcohol? How 
many units of alcohol do you drink on a typical day when you are drinking? How 
often have you had 6 or more units if female, or 8 or more if male, on a single 
occasion in the last year?, and may also be used as a screening instrument for risk 
due to alcohol use (Bohn, Babor et al. 1995).  
The prevalence of alcohol use disorders in Finnish general population is 4.5% 
(7.3% in males and 1.4% in females) (Pirkola, Isometsa et al. 2005), whereas in 
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depressed patients in psychiatric secondary services the prevalence of alcohol use 
disorder is higher at 25% (Melartin, Rytsala et al. 2002).   
The co-occurrence of MDD and alcohol use disorder is called dual diagnosis and 
is associated with poorer treatment outcome (Agyapong 2013). Alcohol use 
disorders can lead to impaired response to treatment, more chronic disease courses 
or recurrence in depressive episodes (Burcusa, Iacono 2007, Holzel, Harter et al. 
2011). Depression and Substance Use Disorders (SUDs) seem to have an interactive 
relation and SUDs also a fluctuating course of symptoms (Agosti, Levin, 2006, 
Hasin, Liu et al. 2003, Hasin, Tsai et al. 1996). Other factors such as temperament 
and character traits are associated with the prognosis of alcohol use in depressed 
patients (Foulds, Mulder et al. 2016). 
2.3.2 Anxiety disorders 
Anxiety disorders as a group are the most highly prevalent of psychiatric disorders 
(Somers, Goldner et al. 2006, Baxter, Scott et al. 2013). It has been estimated that 
16.6% of people in developed nations suffer from at least one anxiety disorder 
during their lifetime and the reported past year prevalence rates have been even 
higher (Baxter, Scott et al. 2013, Somers, Goldner et al. 2006). There is very high rate 
of comorbidity of anxiety disorders in MDD patients (Brown, Campbell et al. 2001) 
and 57% of Finnish MDD patients suffer from anxiety disorder comorbidities 
(Melartin, Rytsala et al. 2002).  
The etiological factors of depression with anxiety disorder comorbidity are not 
completely understood, but both conditions share risk-factors such as early life 
adversity arguably resulting in neuroendocrinological and neurophysiological 
changes (Cowan, Callaghan et al. 2016, Sild, Ruthazer et al. 2017) and similar patterns 
of emotion processing deficits (Kret, Ploeger 2015). There is some evidence that 
clinical anxiety disorder episodes may predict development of depression especially 
in females (Breslau, Schultz et al. 1995) and that clinical anxiety symptoms may 
decrease in increasing age in contrast to that with depressive symptoms (Almeida, 
Draper et al. 2012). Moreover, socioeconomic stressors (poor social support and 
financial strain) may be a risk factor especially for comorbid cases of depression and 
anxiety in contrast to each of the disorders alone (Almeida, Draper et al. 2012). 
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2.3.2.1 Anxiety disorders according to DSM-IV and DSM-5 diagnostics manuals 
 
The DSM-IV anxiety disorder class includes the following anxiety disorders: 
generalized anxiety disorder (GAD), panic disorder (with or without agoraphobia), 
agoraphobia without history of panic disorder, specific phobias, social phobia (or 
social anxiety disorder), obsessive-compulsive disorder (OCD), posttraumatic stress 
disorder (PTSD), acute stress disorder, anxiety disorder due to a general medical 
condition and anxiety disorder NOS (not otherwise specified). (American Psychiatric 
Association 1994) 
Some changes were made for the DSM-5. The more pronounced changes were 
removing OCD and PTSD and including them in their own diagnostic classes and 
including separation anxiety and selective mutism in the anxiety disorder class. The 
DSM-5 diagnoses include: separation anxiety disorder, selective mutism, specific 
phobia, social anxiety disorder (social phobia), panic disorder (and panic attack 
specifier), agoraphobia, generalized anxiety disorder and substance/medication-
induced anxiety disorder, anxiety disorder due to another medical condition, other 
specified anxiety disorder and unspecified anxiety disorder. (American Psychiatric 
Association 2013) 
2.3.2.2 Panic disorder and agoraphobia 
According to DSM-IV panic disorder is characterized by recurrent unexpected panic 
attacks with intense fear that include a number of somatic hyperarousal symptoms 
and as a disorder it is also described as including persistent concern about having 
additional attacks as a characteristic (American Psychiatric Association 1994). 
Agoraphobia is described as anxiety about being in places or situations from which 
escape might be difficult or in which help may not be available in the event of having 
an unexpected or situationally predisposed panic attack or panic-like symptoms 
(American Psychiatric Association 1994). These two disorders commonly coexist 
and approximately half of panic disorder patients also have agoraphobia (Wittchen, 
Reed et al. 1998). The past-year prevalence of panic disorder in Finnish general 
population is 1.9% and the prevalence in Finnish MDD patients 17%, the respective 
proportions for agoraphobia being 1.2% and 12% (Melartin, Rytsälä et al. 2002, 
Pirkola, Isometsä et al. 2005). 
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2.3.2.3 Social anxiety disorder 
Social anxiety disorder (SAD) is characterized as representing excessive fear of social 
or performance situations in which embarrassment or negative judgements from 
others may occur (American Psychiatric Association 1994). Some researchers argue 
that there are two separate subtypes of SAD according to whether only performance 
situations are associated with anxiety or anxiety is caused by social interaction more 
generally (NaragonGainey, Prenoveau et al. 2016). The past-year prevalence of SAD 
in Finnish general population is estimated at 1.0% and the prevalence in Finnish 
MDD patients at 20% (Pirkola, Isometsä et al. 2005, Melartin, Rytsälä et al. 2002). 
2.3.2.4 Generalized anxiety disorder 
According to the diagnostics manual generalized anxiety disorder (GAD) is 
characterized by excessive, uncontrollable and often irrational worry, which 
interferes with daily living and is accompanied by a number of somatic symptoms 
(American Psychiatric Association 1994). According to the DSM-IV this diagnosis 
is excluded if the anxiety only presents during a depressive episode or if other more 
specific anxiety disorders would better explain the anxiety. However, in the DSM-5 
the exclusion criterion concerning a concurrent depressive episode has been omitted 
(American Psychiatric Association 2013). The past-year prevalence of GAD in 
Finnish general population is 1.0% and the prevalence in Finnish MDD patients is 
14% (Melartin, Rytsälä et al. 2002, Pirkola, Isometsä et al. 2005). 
2.4 Course and outcome of MDD 
MDD is a highly recurrent disorder and at least half of the patients that have MDE 
have at least one recurrent episode in their life-time (Burcusa, Iacono 2007). Often 
the course of MDD includes many recurrences and remissions of the symptoms 
(Burcusa, Iacono 2007, Kupfer 1991). Up to 50% of patients with depression do not 
respond to first antidepressant treatment and up to 20% may have a chronic course 
of depression with no remission of symptoms over a two-year period (Fava 2003). 
However, up to 32% of patients with depressive episode in primary-care samples 
may remit within six months even without treatment (Whiteford, Harris et al. 2013). 
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2.4.1 Sociodemographic and clinical factors 
Although there are many known risk factors predisposing to depressive episodes as 
reported in 2.3.3.1, not all of them are associated with recurrence of depressive 
episodes and socio-economic factors may not be marked predictors of recurrence 
(Burcusa, Iacono 2007). The known risk factors predisposing to recurrent episodes 
of depression consist of the severity of the index episode, presence of psychiatric 
comorbidity and family history of psychopathology (Burcusa, Iacono 2007). 
Negative cognitions, high neuroticism, temperament, poor social support and 
stressful life events are also associated with higher recurrence of depression, but the 
causality between these associations has not been established (Burcusa, Iacono 2007, 
Farmer, Seeley 2009, Kampman, Poutanen 2011).  
2.4.2 Complex depression 
Complex or complicated depression refers to major depressive disorders that have 
higher treatment resistance, comorbidity with other disorders (e.g. somatic, anxiety, 
personality or substance use disorders) and high level of suicidality (Behn 2019, 
Clarkin, Petrini et al. 2019, Haverkamp, Arean et al. 2004, Rice, Halperin et al. 2017). 
2.4.2.1 Alcohol use  
Substance use disorder comorbidity in MDD patients is high and roughly one fourth 
of patients with MDD also have AUD (Davis, Uezato et al. 2008, Melartin, Rytsala 
et al. 2002). The associations explaining the comorbidity of MDD and SUDs are 
complex and the data available have suggested common predisposing factors and 
reciprocal causation between the two (Lyons, Schultz et al. 2006, Fergusson, Boden 
et al. 2011). It has been suggested that the most robust evidence shows that AUDs 
may causally predict depression (Fergusson, Boden et al. 2011, Boden, Fergusson 
2011). Reflecting the reciprocal causation of MDD and AUD, in a prospective 
Finnish study the baseline severity of depression predicted AUDs at six months, 
which was further associated with less decline in depressive symptoms at 6 to 18-
month follow-up (Melartin, Mantere et al. 2014). Alcohol use disorders may 
predispose to recurrences of depressive episodes and may interfere with the response 
to antidepressive treatment (Burcusa, Iacono 2007). The comorbidity of alcohol use 
disorder is also associated with chronic course of depression (Holzel, Harter et al. 
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2011). Emerging evidence suggests that simultaneous treatment of both disorders 
(MDD and AUD) is associated with better treatment outcomes (Agyapong 2013).  
2.4.2.2 Personality and anxiety disorders as comorbidities 
The comorbidity of anxiety disorders in depression is generally associated with 
poorer treatment outcome and higher recurrence of depressive episodes or more 
chronic course of the disease (Coplan, Aaronson et al. 2015, Burcusa, Iacono 2007, 
Sild, Ruthazer et al. 2017).  
Although there are findings suggesting that the presence of personality disorder 
is associated with poorer outcome of antidepressive treatment and more chronic 
course of the disease, confirming these associations would need more studies with 
rigorous statistical methods (Bock, Bukh et al. 2010, Holzel, Harter et al. 2011, De 
Bolle, De Fruyt et al. 2011). Moreover, different personality disorders may have 
different effect on the outcome of depression and studying the associations between 
depression outcome and temperament and character dimensions could offer 
important new information on how individual personality is associated with the 
outcome of depression (Bock, Bukh et al. 2010, Holzel, Harter et al. 2011, De Bolle, 
De Fruyt et al. 2011).  
2.4.3 Examples of treatment options for MDD with and without 
comorbidities 
There are multiple general (national and international) guidelines for the treatment 
of MDD including comprehensive guidelines for the recognition and management 
of depression from the National Institute of Clinical Excellence (NICE, (Overview 
| Depression in adults: recognition and management | Guidance | NICE)) and the 
Canadian Network for Mood and Anxiety Treatments (CANMAT, (Kennedy, Lam 
et al. 2016)), a clinical practice guideline from the American College of Physicians 
(Qaseem, Barry et al. 2016), a two-part guideline for acute and maintenance 
treatment for depression from the World Federation of Societies of Biological 
Psychiatry (Bauer, Severus et al. 2015, Bauer, Pfennig et al. 2013), and the Finnish 
guideline concerning depression (Depression: Current Care Guidelines Abstract, 
2016). The first-line treatment options for depression include pharmacotherapy with 
SSRIs and various psychotherapeutic interventions, which have been extensively 
studied and proven efficient in the treatment of MDD (Cuijpers, Sijbrandij et al. 
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2013). Second line treatment options for depression include SNRI, other agents 
affecting the monoamine system or ECT (McLoughlin, Kolshus et al. 2017, Vieta, 
Loft et al. 2017, Cipriani, Geddes et al. 2007, Gaynes, Warden et al. 2009). There is 
some evidence of positive effect on antidepressive treatment outcome by 
augmenting SSRI or SNRI medication with other pharmacological agents such as 
triiodothyronine (T3) (Nierenberg, Fava et al. 2006), lithium (Bschor 2014), omega-
3-FAs (Mocking, Harmsen et al. 2016), antipsychotics (Zhou, Keitner et al. 2015) or 
by combining with a second antidepressant (Blier, Ward et al. 2010, Rush, Trivedi et 
al. 2011). The more novel treatment options with promising findings for depression 
include neuromodulatory treatments: repetitive transcranial magnetic stimulation 
(rTMS) (Zhao, Tor et al. 2018, Verma, Kumar et al. 2018), transcranial direct current 
stimulation (tDCS) (Palm, Hasan et al. 2016), vagus nerve stimulation (VNS) (Lv, 
Zhao et al. 2019), deep brain stimulation (DBS) (Dandekar, Fenoy et al. 2018), 
ketamine infusion therapy (Costi, Soleimani et al. 2019) and nasal esketamine (Daly, 
Trivedi et al. 2019). 
The treatment options for depressed patients with anxiety disorder comorbidity 
are similar as for with patients without the comorbidity, but some more 
individualized treatment strategies according to the symptom profile have been 
proposed (Coplan, Aaronson et al. 2015). Both psychotherapy and pharmacotherapy 
are effective in the treatment of depressive and anxiety disorders either as 
monotherapy or used together (Cuijpers, Sijbrandij et al. 2013). However, there 
might be a minor preference of pharmacotherapy for dysthymia and of 
psychotherapy for obsessive-compulsive disorder in terms of efficacy (Cuijpers, 
Sijbrandij et al. 2013). One study suggests that anxiety comorbidity in depressed 
patients may be associated with better rTMS treatment outcome (Durmaz, Ebrinc et 
al. 2017). However, MDD patients’ anxiety symptoms may not respond to ECT 
treatment even if the depression is alleviated (Huang, Lin et al. 2019). 
In the next chapters, some common treatment methods of MDD are introduced 
in more detail. However, e.g. the details of different forms of psychotherapy, 
occupational therapy, neuromodulation techniques, or antidepressants apart from 
the most commonly used ones, are beyond the scope of this thesis. 
2.4.3.1 Selective serotonin reuptake inhibitors (SSRIs) 
Fluoxetine was the first SSRI developed in the 1970s and became more widely used 
in the treatment of MDD in the late 1980s and early 90s (Hillhouse, Porter 2015). 
Since then many other SSRIs have been developed including citalopram, sertraline, 
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paroxetine, escitalopram and fluvoxamine (Hillhouse, Porter 2015). Currently SSRIs 
are the most often prescribed antidepressants in European countries (Forns, 
Pottegård et al. 2019). The efficacy of all available SSRIs has been widely studied and 
a recent meta-analysis suggests a modest effect size for SSRIs in the treatment of 
MDD (Cipriani, Furukawa et al. 2018). However, fluoxetine is the only SSRI that 
has shown efficacy in the treatment of child and adolescent populations with MDD 
(Cipriani, Furukawa et al. 2018). The optimal fluoxetine equivalent dose in the 
treatment of MDD with SSRIs is suggested to be between 20-40mg (Furukawa, 
Cipriani et al. 2019). 
Most SSRIs are efficacious in treatment of GAD, SAD, PTSD and OCD. 
However, the efficacy of SSRIs in the treatment of specific phobia is under studied 
and only small studies provide evidence for the efficacy of escitalopram and 
paroxetine. (Baldwin, Anderson et al. 2014) 
 SSRIs were primarily hypothesized to alleviate depression directly by inhibiting 
serotonin reuptake from the synaptic clefts and thus increasing the levels of 
serotonin in the CNS (Caldecott-Hazard, Morgan et al. 1991). However, this original 
theory has been proven inadequate to explain the antidepressant action of SSRIs and 
various secondary changes in the CNS have been suggested to cause the effects of 
SSRIs in alleviating depression (Caldecott-Hazard, Morgan et al. 1991). It has been 
proposed more recently that especially the use of SSRIs as antidepressants is 
associated with increase of BDNF in the limbic areas of the CNS (Dimitriadis, van 
den Brink et al. 2019). This effect could lead to neurotrophic consequences in the 
CNS (Maya Vetencourt, Sale et al. 2008) and would hypothetically result in 
alleviation of depression (Dimitriadis, van den Brink et al. 2019). There is evidence 
showing that serum BDNF concentrations increase after taking SSRIs (Zhou, Zhong 
et al. 2017) and that higher serum BDNF is associated with alleviation of depression 
in non-traumatized patients taking SSRIs (Dimitriadis, van den Brink et al. 2019). 
However, early life trauma could permanently reduce this hypothesized SSRI effect 
on BDNF (Dimitriadis, van den Brink et al. 2019). 
2.4.3.2 Behavioral activation 
Behavioral activation (BA) is a brief therapy that is effective in the treatment of 
MDD, also in comorbid or treatment resistant cases, or in patients with personality 
disorders (Bottonari, Roberts et al. 2008, Dimidjian, Hollon et al. 2006, Dobson, 
Hollon et al. 2008, Moradveisi, Huibers et al. 2013, Weinstock, Munroe et al. 2011). 
BA techniques include activity monitoring, assessment of goals and values and 
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activity scheduling, presenting a highly effective treatment for depression according 
to a meta-analysis (Cuijpers, van Straten et al. 2007).  
2.4.3.3 Motivational interviewing 
Motivational interviewing (MI) is a brief therapy that is effective as an adjuvant 
treatment in the treatment of various medical conditions and is most widely used in 
the management of substance use disorders (Fuangunyi 2019, DiClemente, Corno 
et al. 2017, Marker, Norton 2018). The hypothesized active elements of motivational 
interviewing include empathetic listening, non-judgemental attitude towards the 
patient, dialogue that is aimed to increase “change talk” and decrease “sustain talk” 
in patients, resulting in patients verbalizing reasons to change their habits (Miller, 
Rose 2009).  
2.5 Dimensional approach to mood and anxiety disorders 
Categorical methods for diagnosing psychiatric disorders has been the standard in 
the clinical and research settings thus far. The introduction of the DSM-III in the 
1980s distinguished between anxiety disorders and depressive disorders and made 
diagnosing patients more explicit by introducing many new categories of disorders 
(American Psychiatric Association 1980). The development of such a categorical 
diagnostic manual has had a tremendous effect in aiding research on different 
psychiatric disorders and has helped the collaboration of clinical workers due to the 
relatively good reliability of the diagnoses (Surís, Holliday et al. 2016). The later 
diagnostics manuals have further developed the categorization of disorders 
according to the latest research data and one trend has been an increase in the 
number of recognized disorders. In the development process the criteria for some 
diagnoses have been changed and some diagnoses or subdivisions have also been 
removed – while new ones have been added (Surís, Holliday et al. 2016).  In part due 
to the high number of different disorders, however, the validity of some diagnoses 
has been low (Surís, Holliday et al. 2016). In spite of the development of the 
diagnostics systems, the co-existence of more than one psychiatric disorder has been 
the new standard since the 1980s and it has been argued that more dimensional 
methods for describing psychopathology could better account for the challenges met 
in clinical situations (Surís, Holliday et al. 2016, Clark, Lee 2005). 
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In addition to categorical diagnosing of the patients, the dimensional assessment 
of patients’ functionality or symptomatology in different disorders according to 
various scales has been common practice in clinical and research settings. The 
arguments supporting the use of these more linear methods of assessment have 
emphasized the importance of the effect that subthreshold symptomatology has on 
the patients’ lives or prognoses and stressed that there would be a more linear 
association between the severity of different disorders and their outcomes (Karsten, 
Hartman et al. 2010, Zimmerman, Chelminski et al. 2012). These arguments have 
gained strength due to the lack of knowledge about or similarity of the etiological 
factors of different mood or anxiety disorders (Hughes, Heimberg et al. 2006, 
Watson, Clark et al. 1995, Clark, Lee 2005, Clark, Watson 1991). The categorical 
diagnoses may arguably advocate either too wide concepts of disorders, e.g., MDD, 
which is likely associated with a wide range of patients with different etiologies for 
the symptomatology and prognoses or too narrow concepts resulting in comorbidity 
of different disorders (e.g. MDD and generalized anxiety disorder) although the 
clinical syndrome could be better explained by a common etiology (Watson, David 
2005, Ten Have, Lamers et al. 2016). 
Comorbidity of mood and anxiety disorders has been especially high in clinical 
populations and in secondary level psychiatric clinics personality and substance use 
disorders also often co-occur with those affective disorders (Melartin, Rytsälä et al. 
2002). This high comorbidity of different disorders has inspired researchers to 
develop more integrative and dimensional approaches to assess psychiatric disorders 
aimed to better concur with the likely etiologies of these disorders. Factor analyses 
of depressive and anxiety disorders have suggested two broader categories for these 
disorders (fear and anxiety-misery) and three dimensions of symptoms (Krueger 
1999). More specifically the tripartite model suggested dimensions of general 
neurotic symptoms (common to depression and anxiety), somatic anxiety (specific 
to anxiety disorders) and low positive affect (specific to depression) (Clark, Watson 
1991). Closely resembling two of the mentioned dimensions of symptoms (neurotic 
and positive affect), two higher order personality dimensions have been proposed to 
be important in association with psychopathology, namely neuroticism or negative 
affect and extraversion or positive affect (Clark, Lee 2005). These similarities have 
led some researchers to argue that personality or temperament dimensions could 
serve as a basis for an integrative model for psychopathology (Clark, Lee 2005).  
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2.6 Towards a dimensional approach to human personality and 
temperament 
Although the categorical assessment of personality disorders has been the gold 
standard in clinical settings, over the past decades the scientific studies have utilized 
dimensional assessment of the personality for many decades. Perhaps because of the 
mounting evidence also supporting  the clinical usefulness of the dimensionally 
assessed factors of personality the DSM-5 has included the possibility of dimensional 
assessment of personality disorders and the new version of the International 
Classification of Diseases (ICD-11) has replaced the former categorical diagnostics 
algorithm for personality disorders with a dimensional equivalent (Bach, Sellbom et 
al. 2018, WHO | International Classification of Diseases, 11th Revision (ICD-11), 
Bukh, Andersen et al. 2016, Joyce, McKenzie et al. 2007, Widiger, Mullins-Sweatt 
2009).  
2.6.1 Definition of concepts 
The human temperament refers to individual predispositions for general mood and 
emotional responses that are based largely on genetically based biological processes 
and that are presented early in life (Rettew, McKee 2005, Rothbart, Ahadi 1994). 
Considering the early prelingual development of temperament, it is thought to 
represent a more biological pre-semantic core of the human personality (Cloninger, 
Svrakic et al. 1993). This biologically based temperamental core of personality is 
thought to remain fairly stable throughout an individual’s life-span although some 
aspects of personality change/develop later in life in adaptation/maladaptation to 
changes in environment (Cloninger, Svrakic et al. 1993). 
In a broad sense personality defines the consistent and unique way different 
individuals react and behave with respect to different situations in their lives. This 
definition of personality highlights two general aspects of how the modern 
psychological literature comprehends personality: 1) relatively consistent throughout 
the individual’s life-span and 2) unique to different persons with individual 
presentations of traits distributed on dimensional continuums (Roberts, DelVecchio 
2000). Personality is thought to be composed of various aspects of individual 
differences in needs, attitudes, motives, values, coping mechanisms, capabilities, 
attainments and self-esteem (Cervone, Pervin 2018). These cognitively more 
complex aspects of the human personality are thought to be moderated by 
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temperament and to develop over individual’s life-span due to experiences in 
interaction with the environment (Cloninger, Svrakic et al. 1993). 
According to trait theories of personality individuals are assumed to possess 
broader predispositions – called traits - to respond in different situations in unique 
ways. These traits are thought to be representative of the consistent differences in 
the patterns in which different individuals behave, feel or think in similar situations. 
According to these theories individuals’ responses in specific situations represent 
habits when repeated in similar situations. Different habits are thought to form traits 
when combined with other similar habits and the groups of different traits are 
thought to form dimensions or factors when combined with other associated traits. 
(Cervone, Pervin 2018)  
There are multiple different models of human personality with different numbers 
of personality trait dimensions based on statistical factor analyses of different 
personality traits. These models include the three-factor model and the five-factor 
model (FFM) of personality (Eysenck, Eysenck 1994, Costa, McCrae 1992). Due to 
the consistency of personality traits - also over time - personality profiles assessed 
with such instruments may be used to predict an individual’s future reactions and 
behavior (Masse, Tremblay 1997). 
2.7 The five-factor model of human personality 
The new diagnostics algorithms of personality disorders in the DSM-5 and ICD-11 
are based on the five-factor model (FFM) of personality although differences exist 
between the manuals (Bach, Sellbom et al. 2018). The algorithm in the DSM-5 
includes dimensions of negative affectivity, detachment, antagonism, disinhibition 
and psychoticism, whereas the ICD-11 dimensions consist of negative affectivity, 
detachment, dissociality, disinhibition and anankastia (American Psychiatric 
Association 2013, WHO | International Classification of Diseases, 11th Revision 
(ICD-11). According to the five-factor model, however, the human personality 
consists of neuroticism, extraversion, openness, agreeableness and 
conscientiousness referred to as The Big Five trait factors (Costa, McCrae 1992). 
These factors are representative of  the degree to which an individual has traits 
associated with: 1) emotional instability and negative emotionality (Neuroticism), 2) 
inclination to social interaction and positive emotionality (Extraversion), 3) proactive 
orientation and openness to new experiences (Openness), 4) being compassionate 
or antagonizing of others (Agreeableness), and 5) being persistent and organized 
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(Conscientiousness) (Costa, McCrae 1992). Costa and McRae introduced in 1992 the 
revised version of the NEO Personality Inventory (NEO-PI-R) for the assessment 
of 30 different traits that the model organizes into the five different personality 
domains (Costa, McCrae 1992). The five factors in the model have shown high 
internal consistency, interrater reliability and stability over time and the model has 
been used widely in various studies of general population as well as in clinical patient 
samples (Roberts, DelVecchio 2000). Although the factors of the five-factor model 
have shown substantial overlapping with some of the dimensions of Cloninger’s 
biopsychological model of temperament and character, the two models also have 
dissimilarities (De Fruyt, Van De Wiele et al. 2000).  
2.8 Cloninger’s biopsychological model of temperament and 
character 
Robert Cloninger’s original unified biosocial model of personality proposed a model 
with three temperament dimensions, one of them being associated with behavioral 
inhibition (Harm Avoidance, HA), another with behavioral activation (Novelty 
Seeking, NS) and a third with maintenance of behavior (Reward Dependence, RD) 
(Cloninger 1986, Cloninger 1987). Whereas the personality dimensions of the FFM 
were based on lexical analysis of different personality traits, Cloninger’s 
temperament dimensions were constituted based more on biological findings and 
animal studies (Cloninger 1986). In his theory Cloninger also stressed the importance 
of learning and social influences as being equally important as biological and genetic 
influences on personality development. In the proposal Cloninger described possible 
schemas by which the different temperament dimensions interact together to 
produce individual personality variants in interaction with life-events (Stallings, 
Hewitt et al. 1996). Temperament traits, per se, were assumed to be individually 
heritable and apparent early in life (Cloninger 1986). As originally proposed, the 
variation in each dimension would be related to monoaminergic activity (Cloninger 
1986) i.e. NS with low basal dopaminergic activity, HA with high serotonergic 
activity and RD with low basal noradrenergic activity (Stallings, Hewitt et al. 1996). 
For the assessment of the three temperament dimensions (HA, NS, RD) the 
Tridimensional Personality Questionnaire was introduced (TPQ; (Cloninger 1987)). 
However, studies with the TPQ indicated that the former RD subsection Persistence 
proved to be relatively independent of the original three temperament factors, and 
was therefore separated from RD to present a fourth temperament dimension called 
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Persistence (P) (Cloninger, Przybeck et al. 1994). To represent individual differences 
more adequately, the model was extended with three additional dimensions of the 
character, namely Self-Directedness (SD), Cooperativeness (C), and Self-
Transcendence (ST) (Cloninger, Przybeck et al. 1994, Sigvardsson, Bohman et al. 
1987, Gillespie, Cloninger et al. 2003, Cloninger, Svrakic et al. 1993). First the 
Temperament and Character Inventory (TCI) was introduced for the assessment of 
the seven personality dimensions and was followed by revised version (TCI-R) some 
years later (Cloninger, Svrakic et al. 1993, Pelissolo, Mallet et al. 2005). The revisions 
for the TCI-R included scoring of each item on a 5-point Likert scale, making 
changes to 51 items, adding three subscales to P and one to RD (Pelissolo, Mallet et 
al. 2005). TCI-R is thus a self-rated questionnaire that includes 240 items scored on 
a 5-point scale describing how well each item is representative of the subject 
(Pelissolo, Mallet et al. 2005). 
The new enhanced biopsychological model of temperament and character made 
a distinction of temperament and character dimensions (Cloninger, Svrakic et al. 
1993). Primarily Cloninger assumed that the character dimensions would be less 
inherited than temperament and that maturation of those traits would occur with age 
(Cloninger, Svrakic et al. 1993). However, the heritability of temperament and 
character dimensions has been almost equal and ageing seems to have an effect on 
both domains (Gillespie, Cloninger et al. 2003, Keller, Coventry et al. 2005, Calvet, 
Pericaud et al. 2016). A controversial 15-step model of personality development has 
been described (Cloninger, Svrakic 1997, Farmer, Goldberg 2008a).  
2.8.1 Temperament and character dimensions 
According to the biopsychological model of temperament and character, not even 
the extreme presentations of singular temperament traits inherently lead to better or 
worse adaptation and both extremes on each dimension also present adaptive 
qualities (Cloninger, Svrakic et al. 1993). The scores on each temperament dimension 
are normally divided in general population and the distribution of the scores 
represents the whole spectrum in the respective dimensions. 
The Harm Avoidance (HA) dimension represents the temperamental bias the 
individual has with respect to the inhibition of behavior in response to signs of 
punishment. Individuals with high scores on the HA dimension are pessimistic, 
fearful, shy and fatigable while low scorers are optimistic, daring, outgoing and 
energetic (Cloninger 1987). HA is composed of subdimensions: Anticipatory Worry 
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(HA1), Fear of Uncertainty (HA2), Shyness (HA3), and Fatigability (HA4) (Pelissolo, 
Mallet et al. 2005).  
The Novelty Seeking (NS) dimension represents the temperamental bias the 
individual has with respect to initiation or activation of appetitive behavior in 
response to novelty. Individuals with high scores on NS are exploratory, impulsive, 
extravagant and irritable, whereas low scorers present as reserved, deliberate, thrifty 
and stoical (Cloninger 1987). NS is composed of following subdimensions: 
Exploratory excitability (NS1), Impulsiveness (NS2), Extravagance (NS3), and 
Disorderliness (NS4) (Pelissolo, Mallet et al. 2005). 
The Reward Dependence (RD) dimension represents the temperamental bias the 
individual has with respect to maintenance of behavior in response to cues of social 
reward. Individuals with high scores on RD are described as sentimental, open, warm 
and affectionate, while low scorers are described as detached, aloof, cold and 
independent (Cloninger 1987). RD is composed of subdimensions: Sentimentality 
(RD1), Openness to warm communication (RD2), Attachment (RD3), and 
Dependence (RD4) (Pelissolo, Mallet et al. 2005). 
The Persistence (P) dimension represents the temperamental bias the individual 
has with respect to maintenance of behavior despite frustration. High scorers on P 
are industrious, determined, enthusiastic or perfectionist and low scorers lazy, 
spoiled or pragmatic (Cloninger, Svrakic et al. 1993). P is composed of 
subdimensions: Eagerness of effort (P1), Work hardened (P2), Ambitious (P3), and 
Perfectionist (P4) (Pelissolo, Mallet et al. 2005). 
The character dimensions were included in the biopsychological model of 
temperament and character mainly in order to better assess the individual capacity 
for adaptation in society. Similarly the to temperament dimensions, the scores in the 
character dimensions are normally divided in the general population. However, low 
scores on character dimensions (especially in Self-Directedness (SD) and 
Cooperativeness (C)) are usually unfavorable to the individual whereas higher scores 
are associated with better adaptation. (Cloninger, Svrakic et al. 1993)  
The Self-Directedness dimension represents the level of executive competence 
of an individual. Individuals with high scores on SD are self-sufficient, responsible, 
reliable, resourceful, goal oriented and self-accepting, whereas low scorers are 
blaming, helpless, irresponsible, unreliable, reactive and unable to set meaningful 
goals (Cloninger, Svrakic et al. 1993). SD is composed of subdimensions: 
Responsibility (SD1), Purposefulness (SD2), Resourcefulness (SD3), Self-acceptance 
(SD4), and Enlightened second nature (SD5) (Pelissolo, Mallet et al. 2005). 
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The Cooperativeness dimension represents the level of an individual’s 
cooperation skills. Individuals with high scores on C are empathetic, tolerant, 
compassionate, supportive, and principled, while low scorers are self-absorbed, 
intolerant, critical, unhelpful, revengeful and opportunistic (Cloninger, Svrakic et al. 
1993). C is composed of subdimensions: Social acceptance (C1), Empathy (C2), 
Helpfulness (C3), Compassion (C4), and Pure-hearted conscience (C5) (Pelissolo, 
Mallet et al. 2005). 
The Self-Transcendence (ST) dimension represents the level of spiritual 
affiliation of an individual. Individuals with high scores on ST are described as 
judicious, insightful, spiritual, unpretentious and humble, and low scorers instead as 
pragmatic, objective, materialistic, controlling and pretentious (Cloninger, Svrakic et 
al. 1993). ST is composed of subdimensions: Self-forgetfulness (ST1), Transpersonal 
identification (ST2), and Spiritual acceptance (ST3) (Pelissolo, Mallet et al. 2005). 
2.8.1.1 Heritability and genetics of temperament and character 
Twin studies have provided estimates for the heritability of different domains of 
temperament and character. Although Cloninger primarily assumed that 
temperament would be more genetically predefined than character, studies 
addressing heritability have shown equal estimates for heritability for temperament 
dimensions 30%-57% and character dimensions 27-44% (Gillespie, Cloninger et al. 
2003, Keller, Coventry et al. 2005). These estimates for heritability are similar to 
those found for other personality measurements e.g. Eysenck’s Personality 
Questionnaire (Keller, Coventry et al. 2005). Although the genetic overlap between 
temperament and character is estimated at 11-30%, the majority of the genetic 
variance on each temperament and character dimension has been unique (Gillespie, 
Cloninger et al. 2003). 
Although some studies have found an association between 5-HTTPLPR 
polymorphism and temperament dimension HA, meta-analyses of the available data 
have resulted in negative findings on the association (Munafò, Freimer et al. 2009, 
Minelli, Bonvicini et al. 2011). It has been suggested that including study subjects 
with mood and anxiety disorders would explain the association between 5-
HTTPLPR and HA in studies with positive findings (Minelli, Bonvicini et al. 2011). 
Another genetic correlate with temperament on which meta-analytical data exists is 
that between DRD4 C-521T polymorphism and NS. According to a meta-analysis 
C-521T polymorphism accounts for 3% of the variance in NS, whereas Extroversion 
(according to the FFM) was not associated with the polymorphism (Munafò, Yalcin 
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et al. 2008). Although temperament and character are moderately heritable and some 
candidate gene studies have reported positive associations, genome-wide studies 
(GWAS) have resulted in null findings (Verweij, Zietsch et al. 2010, Munafò, Yalcin 
et al. 2008, Service, Verweij et al. 2012). It has been suggested that combining 
different personality trait items together to better refine personality phenotypes 
could aid in the genetic mapping of the personality (Service, Verweij et al. 2012).  
2.8.1.2 Stability of temperament and character 
The majority of the evidence on the stability of personality traits has come from 
studies with the Big Five personality domains (Roberts, DelVecchio 2000). In a 
meta-analysis of test-retest correlations of personality traits the trait consistencies 
were 0.31 in childhood, 0.54 during late adolescence/early adulthood, 0.64 at the age 
of 30 and 0.74 at ages 50-70, whereas the studied temperament dimensions showed 
lower consistency in the meta-analysis (Roberts, DelVecchio 2000). However, the 
studies on temperament included in the meta-analysis consisted mostly of studies on 
children and the existent evidence of the constancy of temperament in adulthood 
using Cloninger’s temperament measures was completely missing (Roberts, 
DelVecchio 2000). The test-retest correlation for the TPQ temperament dimensions 
in adult population have ranged from 0.58 to 0.84 in a two-year follow-up (Heath, 
Bucholz et al. 1997). Adding to that data, there is some evidence of the constancy of 
temperament dimensions (TPQ) from childhood to adulthood, which has been 
suggested to indicate that the personality predispositions are stable adaptive 
tendencies, rather than fixed traits or gradually acquired habit patterns (Sigvardsson, 
Bohman et al. 1987). 
In the first failed attempt to validate the English language version of the TCI-R 
in a population sample of Oregonian home-owners, severe criticism of the TCI-R 
and the seven-factor model of temperament and character was expressed because of 
the issues associated with the internal consistency of some of the dimensions 
(Farmer, Goldberg 2008b). However, overall the TCI-R has been adapted and 
validated in over twenty countries (e.g., (Pelissolo, Mallet et al. 2005) in France; 
(Martinotti, Mandelli et al. 2008b) in Italy; (Dzamonja-Ignjatovic, Svrakic et al. 2010) 
in Serbia; (Snopek, Hublova et al. 2012) in the Czech Republic; (Brändström, Richter 
et al. 2003) in Sweden and Germany; and (Giakoumaki, Karagiannopoulou et al. 
2016) in Greece) with high coefficients of internal consistency (Fresán, Robles-
García et al. 2011, Goncalves, Cloninger 2010, Tilov, Dimitrova et al. 2012, 
Brändström, Richter et al. 2003), test-retest reliability (Hansenne, Delhez et al. 2005, 
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Martinotti, Mandelli et al. 2008b, Pelissolo, Mallet et al. 2005), construct and 
predictive validity for personality disorders (Dzamonja-Ignjatovic, Svrakic et al. 
2010, Fossati, Cloninger et al. 2007, Martinotti, Mandelli et al. 2008b). Subsequently 
also the English language version has been validated (Goncalves, Cloninger 2010). 
Although the earlier versions of the questionnaire (TPQ and TCI) have been 
validated in Finnish population, no systematic peer-reviewed evaluation of the 
revised version, TCI-R, in an adult Finnish population has been presented to date 
(Miettunen, Kantojärvi et al. 2004). 
2.8.2 Temperament and character in depression 
HA has repeatedly been higher in patients with MDD than in general population and 
HA correlates with depressive symptom scores in patients with MDD (de Winter, 
Wolterbeek et al. 2007, Farmer, Mahmood et al. 2003, Hansenne, Reggers et al. 1999, 
Hirano, Sato et al. 2002, Kimura, Sato et al. 2000, Marijnissen, Tuinier et al. 2002, 
Richter, Polak et al. 2003). High HA and more particularly its sub-scores anticipatory 
worry (HA1) and fatigability (HA4) have also manifested as trait-like markers for risk 
of depression i.e. either index episodes, relapses or recurrent episodes as well as 
impaired treatment response (Farmer, Seeley 2009, Kampman, Poutanen 2011, 
Balestri, Porcelli et al. 2019). So far, the findings concerning the associations of 
Reward Dependence in depressive symptomatology have been mixed (Farmer, 
Mahmood et al. 2003, Naito, Kijima et al. 2000, Peirson, Heuchert 2001, Farmer, 
Seeley 2009, Joffe, Bagby et al. 1993). However, low RD could be associated with 
treatment-resistant depression together with low P (Takahashi, Shirayama et al. 2013, 
Balestri, Porcelli et al. 2019), and together with high NS it is associated with dual 
diagnosis (i.e. concurrent mental illness and SUD) (Marquez-Arrico, Lopez-Vera et 
al. 2016). Combination of high HA and low SD is associated with suicide attempts 
in MDD patients, while these traits together with high NS and ST show similar 
association in depressed patients with bipolar disorder (Erić, Erić et al. 2017). In 
MDD patients with life-time alcohol dependency diagnosis NS seems to be higher 
and P and C lower than in MDD patients without alcohol dependency (Rae, Joyce 
et al. 2002). According to a recent meta-analysis high HA and low SD are found in 
patients with mood disorders (i.e. MDD and bipolar disorder), while patients with 
bipolar disorder have higher NS and ST than MDD patients (Zaninotto, Solmi et al. 
2016). 
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MDD patients have lower SD and C scores than healthy controls and SD scores 
have a negative correlation with depressive symptom scores (Bensaeed, Ghanbari 
Jolfaei et al. 2014, Hur, Kim 2009, Nery, Hatch et al. 2009). In MDD patient’s low 
SD is connected to childhood trauma, recurrence of depressive episodes and suicide 
attempts (Perna, Vanni et al. 2014, Asano, Baba et al. 2015, Erić, Erić et al. 2017). 
Further, low C could be associated with treatment resistance in depression (Balestri, 
Porcelli et al. 2019). 
Decrease in HA and increase in C and SD during the first month and increase in 
SD and decrease in ST during first year of antidepressive treatment have been 
associated with better depression recovery in one earlier study (Corruble, Duret et 
al. 2002). 
2.8.3 Temperament and character in substance use disorders 
High NS is associated with substance use problems, predicts the development of 
SUD in high risk groups (Howard, Kivlahan et al. 1997, Sher, Bartholow et al. 2000), 
is related to alcohol use relapses in males and craving in substance dependence 
(Evren, Durkaya et al. 2012, Martinotti, Cloninger et al. 2008a, Zilberman, Tavares 
et al. 2003). Low NS instead may protect against the risk of familial alcoholism 
(Grucza, Cloninger et al. 2006). High HA has been connected to alcohol dependence 
(AD) and craving in substance dependent patients (Sher, Bartholow et al. 2000, De 
Los Cobos, Siñol et al. 2011), while dually diagnosed patients have higher NS than 
MDD patients (Fernandez-Mondragon, Adan 2015). More specifically, 
temperament profile with low RD and high NS together with low SD and C seems 
to be associated with dual diagnosis (Marquez-Arrico, Lopez-Vera et al. 2016).  
SD seems to be lower in polysubstance users and low SD is associated with cluster 
B personality disorders (borderline-, antisocial-, histrionic-, and narcissistic 
personality disorders) in SUD patients (Yoon, Kim et al. 2007, Ball, Tennen et al. 
1997). In another study with exclusively detoxified alcohol dependent (AD) male 
patients high scores on HA and ST, and low scores on P, SD and C predicted the 
severity of depression and anxiety (Evren, Evren et al. 2009). 
2.8.4 Temperament in anxiety disorders 
Two meta-analyses have addressed the associations of temperament and anxiety 
disorders and high Harm Avoidance has been associated with all anxiety disorders 
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with the notion of being especially high in Social phobia (SP, according to DSM-III) 
and Social anxiety disorder (SAD, according to DSM-IV) (Miettunen, Raevuori 2012, 
Kampman, Viikki et al. 2014).  
Novelty Seeking has been at an intermediate level in Panic disorder (PD) or at 
low level in SP and SAD in patients with anxiety disorders (Kampman, Viikki et al. 
2014, Miettunen, Raevuori 2012). Reward Dependence has shown a tendency to be 
at a higher level in patients with PD when compared to controls, but the results of 
studies are mixed, which could be explained by gender differences in the direction 
of the association (low RD for women and high RD for men) (Kampman, Viikki et 
al. 2014, Starcevic, Uhlenhuth et al. 1996).  
In patients with SAD the results on RD have also been mixed and are on average 
at an intermediate level according to a meta-analysis (Kampman, Viikki et al. 2014). 
On Persistence patients with anxiety disorders have generally had intermediate 
scores, but Social phobia could be associated with low scores (Kampman, Viikki et 
al. 2014, Miettunen, Raevuori 2012). Generalized anxiety disorder is associated with 
high HA and impulsive symptoms in patients with GAD could be associated with 
high NS and low RD (Kampman, Viikki et al. 2014, Piero 2010). 
2.8.5 Temperament and character as possible endophenotypes for MDD 
Endophenotype is defined as a measurable entity of either neurophysiological, 
biochemical, endocrinological, neuroanatomical, cognitive or neuropsychological 
origin that is located between the genotype and the (clinical) phenotype in the 
association chain between the two (Gottesman, Gould 2003). Measurements with 
TCI-R could provide a neuropsychological endophenotype given that there are data 
supporting the association between both: 1) genetic markers, 2) psychiatric disorders 
and temperament and character dimensions (Munafò, Yalcin et al. 2008, Kampman, 
Poutanen 2011). However, although temperament and character have shown at least 
moderate heritability (Gillespie, Cloninger et al. 2003, Keller, Coventry et al. 2005), 
GWASs have been unable to recognize SNPs associated with temperament 
dimensions (Service, Verweij et al. 2012, Verweij, Zietsch et al. 2010). Similarly, 
GWASs have been unable to recognize replicable associations with affective 
disorders (Direk, Williams et al. 2017), and it has been suggested that more refined 
endophenotypes would be warranted to obtain significant genetic biomarkers for 
psychopathology in GWAS (Hamilton 2009, Service, Verweij et al. 2012).  
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2.9 Conclusions on the existing literature 
It has been proposed that the symptoms of MDD consist of clusters with unique 
genetic background and that the individual clinical phenotype in depression is a 
combination of these different symptom clusters (Ginsburg, Werick et al. 1996). 
Earlier studies have provided data on the associations between 1) vegetative 
symptoms of depression (Okazaki, Tominaga et al. 2010, Kamata, Suzuki et al. 2011, 
Higuchi, Sato et al. 2008a, Higuchi, Sato et al. 2008b, Suzuki, Aoshima et al. 2005) 
or 2) temperament and character (Kampman, Poutanen 2011, Balestri, Porcelli et al. 
2019) and depression outcome. Some studies have analyzed how combinations of 
different temperament dimensions are associated with depressive symptomatology 
(Matsudaira, Kitamura 2006, Grucza, Przybeck et al. 2003). However, the interactive 
effect of more complete temperament profiles and vegetative symptoms of 
depression on the short-term outcome of MDE has remained unstudied.  
The data available on the differences in temperament and character dimensions 
between depressed patients and comorbid substance users is also limited (Rae, Joyce 
et al. 2002). Knowledge does exist on how temperament and character are associated 
with MDD and SUDs (Kampman, Poutanen 2011, Yoon, Kim et al. 2007) and one 
study has analyzed the association between changes in temperament and character 
dimensions and depression outcome (Corruble, Duret et al., 2002).  However, no 
studies addressing the differences and possible changes over time in TCI-R 
dimensions in the acute phase of antidepressive treatment between depressed 
patients with or without comorbid substance abuse have been reported.  
Although there is some data on how temperament and character are associated 
with depression outcome (Kampman, Poutanen 2011, Balestri, Porcelli et al. 2019, 
Farmer, Seeley 2009), the knowledge on how TCI-R dimensions’ effect on the long-
term outcome of depression is modulated by alcohol use comorbidity has remained 
unstudied to date.  
Earlier studies and meta-analyses have provided data on how different 
temperament dimensions are associated with the risk of anxiety disorders 
(Kampman, Viikki et al. 2014, Miettunen, Raevuori 2012). It has been suggested that 
individual profile data with combinations of different dimensions of temperament 
could offer more comprehensive information on the associations between 
temperament and different anxiety disorders (Miettunen, Raevuori 2012). However, 
the associations between such more comprehensive temperament profiles and 
different anxiety disorders have not so far been studied. 
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3 AIMS OF THE STUDY 
The general aim of this dissertation was to study temperament, character, and 
vegetative symptoms of depression as predictors of depression outcome and anxiety 
disorder comorbidity in depressed patients with or without alcohol use problems. 
More specific aims were set to study: 
1. if temperament profile clusters together with vegetative symptoms of depression 
predict antidepressant treatment response at six weeks (Study I) 
2. if severity of depression is associated with temperament profile clusters (Study I) 
3. if there are differences in the temperament profiles of depressed patients with or 
without marked alcohol use problems (Study II) 
4. which specific changes in temperament or character profiles predict treatment 
response during first six weeks of antidepressive treatment in depressed patients with 
or without marked alcohol use problems (Study II) 
5. if temperament and character profiles (assessed after six weeks of antidepressive 
treatment) together with harmful alcohol use predict the outcome of depression over 
two-year follow-up (Study III) 
6. if different temperament profile clusters are associated with the likelihood of Panic 
disorder and/or Agoraphobia, Social anxiety disorder or Generalized anxiety 
disorder in depressed patients (Study IV) 
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4 MATERIALS AND METHODS 
4.1 Pharmacogenetic study on depression (the DEPGEN study) 
and Ostrobothnia Depression Study (the ODS study) 
This thesis was conducted as a part of two larger studies.  Study I is a part of the 
DEPGEN study and Studies II-IV are a part of the ODS study. 
The DEPGEN study (Andre, Kampman et al. 2013) was conducted as an effort 
to study genetics and possible associated phenotypes in major depression. The study 
was funded mainly by Pirkanmaa and Kanta-Häme hospital districts and conducted 
in 2002-2006 in Pirkanmaa Hospital District catchment area (population 300,000). 
The ODS study (Luoto, Lindholm et al. 2018, ClinicalTrials.gov Identifier 
NCT02520271) was conducted in South Ostrobothnia Hospital District (population 
200,000) in Finland during the period 2009-2014. The aim of the ODS study was to 
evaluate the efficacy of a selected assessment and treatment protocol for depressed 
and dually diagnosed (depression and alcohol use disorder) patients and to study 
possible predictors of positive outcome of antidepressive treatment in this patient 
group.  
4.2 Study design and subjects 
Study I 
Study I investigated a cohort of one hundred outpatients with major depressive 
episode recruited in Pirkanmaa Hospital District. Patients were evaluated and 
diagnosed by a psychiatrist and patients with current major depressive episode 
(MDE) according to DSM-IV criteria and MADRS scores of at least 20 (reflecting 
at least moderate depressive symptoms) were included in the study. The exclusion 
criteria consisted of severe somatic illness, psychosis, severe personality disorder, 
substance use disorders and medications likely to affect the patients’ mood 
(antidepressive medications during past 3 months, or current use of mood stabilizing 
or antipsychotic medications). The patient cohort included adult patients aged 19-72 
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(mean±SD, 40.7±14.0) and 59 (59%) of the patients were female and the rest male. 
A more detailed description of the patient cohort is presented in Table 1. 
The study protocol included three appointments in which sociodemographic data 
and baseline assessment of MADRS and TCI were collected at the first visit, 
adherence to treatment at the second visit (at 3-week timepoint) and endpoint data 
(MADRS scores) were collected at the third visit (at 6-week timepoint).  
All patients were prescribed either citalopram, fluoxetine or paroxetine at baseline 
visit and the adherence to treatment was evaluated at the second visit. Patients were 
evaluated as adherent to treatment if they had used the prescribed medication on at 
least 80% of the days during the study period. The antidepressant dose was evaluated 
as fluoxetine equivalent daily doses in Studies I-IV. Eighty-six patients completed 
the study according to the protocol and were included in the main analysis of the 
depression outcome in Study I. 
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Table 1.  Sociodemographic data of the DEPGEN patient sample 
 Men Women Total 
 N % N % N % 
Total 41 41 59 59 100 100 
Marital status1       
Single 14 34.1 21 35.6 35 35 
Married or cohabiting 21 51.2 20 33.9 41 41 
Divorced 6 14.6 14 23.7 20 20 
Widowed 0 0 4 6.8 4 4 
Education2       
Primary school 2 4.9 4 6.8 6 6 
Comprehensive school 2 9.8 10 16.9 14 14 
Tertiary education 9 22.0 10 16.9 19 19 
Vocational school 16 39.0 9 15.3 25 25 
Upper secondary education 7 17.1 19 32.2 26 26 
Polytechnic or university 3 7.3 7 11.9 10 10 
Work status before sick 
leave3   
      
Employed 24 58.5 31 52.5 55 55 
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1χ2=5.57, p=0.14; 2χ2=9.46, p=0.09; 3χ2=4.00, p=0.41; between genders 
Unemployed 7 17.1 10 16.9 17 17 
Homemaker 0 0 5 8.5 5 5 
Pensioner 5 12.2 5 8.5 10 10 
Student 5 12.2 8 13.6 13 13 
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Figure 2 Patient cohort flow and study setting chart of Study I. 
At baseline the patient cohort was divided into three patient clusters (i.e. Clusters 1,2 and 3) according 
to their temperament profiles (specific combinations of different temperament traits) 
Abbreviations: TCI-R = Temperament and Character Inventory-Revised, MADRS = Montgomery-
Åsberg Depression Rating Scale 
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Studies II-IV 
The patient sample for Studies II-IV was recruited from patients referred to 
psychiatric specialized care due to depressive symptoms, anxiety, self-
destructiveness, insomnia or alcohol-related problems. For inclusion in the study the 
patients had to have BDI scores of at least 17, reflecting at least moderate depressive 
symptoms. Exclusion criteria consisted of organic brain disease and likely or verified 
psychotic disorder. The recruited sample included 242 patients aged 17-64 years 
(38.6±12.2) and 148 (61.8%) of the patients were female and the rest male. At the 
screening patients completed the AUDIT questionnaire and were divided into two 
groups according to their scores: AUP (patients with marked Alcohol Use Problems, 
AUDIT ≥ 11) and non-AUP (AUDIT < 11). At the screening 99 (40.9%) of the 
patients met the criteria for AUP and the remaining 143 for non-AUP. The 
sociodemographic data of the patient cohort is presented in Table 2 and baseline 
BDI and AUDIT scores in Table 3. 
Table 2.  Sociodemographic data of the ODS patient sample 
 Men Women AUP non-AUP Total 
 N % N % N % N % N % 
Total 94 38.8 148 61.2 99 40.9 143 59.1 242 100 
Marital status1           
Single 34 36.2 39 29.1 38 41.8 35 25.9 73 32.3 
Married or 
cohabiting 
39 42.4 71 53.0 34 37.4 76 56.3 110 48.7 
Divorced 19 20.7 21 15.7 19 20.9 21 15.6 40 17.7 
Widowed 0 0 3 2.2 0 0 3 2.2 3 1.3 
Education2           
 71 
Primary school 4 4.3 3 2.2 2 2.2 5 3.7 7 3.1 
Comprehensive 
school 
27 29.3 28 20.7 29 31.9 26 19.1 55 24.2 
Tertiary 
education 
10 10.9 25 18.5 11 12.1 24 17.6 35 15.4 
Vocational 
school 
33 35.9 54 40.0 36 39.6 51 37.5 87 38.3 
Upper secondary 
education 
10 10.9 7 5.2 5 5.5 12 8.8 17 7.5 
Polytechnic or 
university 
8 8.7 18 13.3 8 8.8 18 13.2 26 11.5 
Work status 
before sick 
leave3 
          
Employed 39 42.9 67 50.0 39 43.3 67 49.6 106 47.1 
Unemployed 41 45.1 30 22.4 38 42.2 33 24.4 71 31.6 
Homemaker 0 0 10 7.5 0 0 10 7.4 10 4.4 
Pensioner 5 5.5 11 8.2 4 4.4 12 8.9 16 7.1 
Student 6 6.6 16 11.9 9 10.0 13 9.6 22 9.8 
Self-reported 
history of 
depressive 
episode4 
62 67.4 90 65.7 70 74.5 82 60.7 152 66.4 
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First degree 
family history of 
depression5 
33 35.9 56 41.5 33 36.3 56 41.2 89 39.2 
First degree 
family history of 
bipolar disorder6 
4 4.3 10 7.4 5 5.5 9 6.6 14 6.2 
Abbreviations: AUP = Alcohol Use Problems 
1χ2=11.12, p=0.011; 2χ2=6.95, p=0.23; 3χ2=14.04, p=0.007; 4χ2=4.68, p=0.031; 5χ2=0.55, p=0.457; 
6χ2=0.12, p=0.73 between AUP and non-AUP, significant differences are in bold-face 
Table 3.  Baseline scores of BDI and AUDIT group-wise and in the complete cohort 
 
 
Men Women AUP non-AUP Total 
Baseline BDI 
mean (±SD) 
28.5 (6.80) 27.5 (7.59) 28.1 (6.95) 27.8 (7.55) 27.9 (7.30) 
Baseline 
AUDIT 
mean (±SD) 
15.1 (10.59) 7.9 (8.30) 20.8 (7.19) 3.7 (3.07) 10.7 (9.88) 
Abbreviations: BDI = Beck Depression Inventory; AUDIT = Alcohol Use Disorder Identification 
Test; AUP = Alcohol Use Problems 
The baseline assessments were conducted during appointments with a research nurse 
and a psychiatrist. At baseline data on patients’ temperament profiles (TCI-R) and 
depressive symptoms (MADRS) were assessed and the patients were diagnosed 
using the Mini International Neuropsychiatric Interview 5.0 (MINI), validated 
diagnostic interview designed to be a short but accurate structured psychiatric 
interview (Sheehan, Lecrubier et al. 1998). In the follow-ups TCI-R and MADRS 
were assessed again at 6 weeks and MADRS also at 6 months and 24 months. 
At baseline patients had an appointment with a psychiatrist where their 
medication was evaluated and changed if necessary. All patients received behavioral 
activation (BA) therapy and the AUP group also motivational interviewing (MI) 
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according to a specific treatment intervention procedure (see ClinicalTrials.gov 
Identifier NCT02520271). For a more detailed description of the patient sample see 
sections II and IV of this dissertation. 
Dropout occurred before baseline assessments and before each of the follow-up 
timepoints. At baseline MADRS, MINI, and TCI-R were assessed in patients at two 
different appointments (with a research nurse and with a psychiatrist) and some data 
was missing on one or more of the measures. At baseline MADRS was assessed in 
228 (94%), MINI in 219 (90%), and TCI-R in 216 (89%) patients. Some TCI-R data 
was also missing at the 6-week timepoint for similar reasons due to the naturalistic 
setting of the ODS study. After the dropout at the 6-week timepoint MADRS was 
assessed in 188 (78%) and TCI-R in 177 (73%) patients. 
Studies II-IV were conducted according to an intention-to-treat protocol and all 
available data was used in the main analyses. The number of patients eligible for 
inclusion in the main analyses in Studies II-IV was determined for each study 
according to the relevant data available. The more detailed patient flow charts for 
Studies I-IV are presented in Figures 2-5. 
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Figure 3 Patient cohort flow and study setting chart of Study II. 
Abbreviations: AUP = Alcohol Use Problems, AUDIT = Alcohol Use Disorder Identification Test 
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Figure 4 Patient cohort flow and study setting chart of Study III. 
Abbreviations: TCI-R = Temperament and Character Inventory-Revised, MADRS = Montgomery-
Åsberg Depression Rating Scale, LOCF = Last Observation Carried Forward 
 76 
 
Figure 5 The patient cohort was divided into four patient clusters (i.e. Novelty seekers, Reserved, Wearied and Persistent) 
according to their temperament profiles in Study IV.  See section 4.4 for the rationale to this approach. 
Abbreviations: TCI-R = Temperament and Character Inventory-Revised, M.I.N.I. = MINI 
International Neuropsychiatric Interview 
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4.3 Measurements  
The patients were screened for Studies II-IV with BDI (Beck et al. 1996) and 
AUDIT (Bohn et al. 1995) questionnaires. Other measurements included MADRS 
(Montgomery, Åsberg 1979) at different timepoints in all studies and the 107-item 
TCI temperament questionnaire (version IX) at baseline and at 6 weeks in Study I 
and the 240-item TCI-R at baseline and at 6 weeks in patients analyzed in Studies II-
IV (Cloninger, Przybeck et al. 1994). In Study IV binary logistic regression models 
were built to predict the patients’ comorbid anxiety disorders (MINI diagnoses). For 
the main analysis in Study I the vegetative symptoms of depression were assessed as 
the sum of questions 3-5 in the MADRS (see 2.2.2.1 and (Suzuki, Aoshima et al. 
2005)). The other two factors are assessed as the sum of questions 1) 2, 9 and 10 for 
dysphoria and 2) 1, 6, 7, and 8 for retardation (Suzuki, Aoshima et al. 2005). 
4.3.1 Outcome measures 
Studies I-III were longitudinal follow-up studies predicting outcome of depression 
using MADRS scores or score changes at different timepoints and in Study III 
linearly from 6 weeks to 6 months and to 24 months as outcome measures.  
The outcome measure in the main analysis of Study I was MADRS score at 6-
week follow-up timepoint. (I) 
Study II had two sets of main analyses. In the first part of the study the main 
outcome measures were TCI-R dimension scores at baseline and at 6 weeks. The 
second set of main analyses predicted the change in the symptoms of depression 
from baseline to the 6-week follow-up (ΔMADRS). (II) 
Due to marked dropout in the follow-up, especially before the 24-month follow-
up timepoint, the last observation carried forward (LOCF) method for data 
completion was performed for the main analysis in Study III. The primary outcome 
measures in the study were LOCF MADRS total score at 6 weeks, 6 months, and 24 
months. (III) 
Study IV included a cross-sectional analysis predicting comorbid panic disorder 
and/or agoraphobia, social anxiety disorder, and generalized anxiety disorder MINI 
diagnoses. (IV) 
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4.4 Statistical analyses 
Cronbach’s α was calculated to assess the reliability of each TCI-R dimension in the 
ODS patient cohort. In Studies I and IV a two-step cluster analysis was used to 
determine patients’ temperament profiles. In the first step this method identifies 
groupings with a quick cluster algorithm and in the second step it runs a hierarchical 
cluster model. In Study I cluster analyses of all four temperament dimension scores 
(HA, RD, NS, and P) and of three temperament dimension scores (HA, RD, and 
NS) were both explored. Cluster analysis of the three temperament dimensions with 
number of clusters set as three showed highest quality for the clusters (i.e. higher 
number of temperament dimensions surpassing critical values in cluster analysis) and 
was therefore used in the main analysis of the study. In Study IV scores on each 
temperament dimension (NS, HA, RD, and P) were used in the clustering model and 
number of clusters was set to automatic to ensure natural clustering. 
In all studies the differences between discreet variables (MADRS total score (I-
IV), MADRS factor scores (i.e. vegetative, dysphoric and retardation) (I), 
antidepressant dose (as fluoxetine equivalent) (IV), AUDIT-C score and age (I-IV)), 
and grouping variables (temperament clusters (I and IV)) were calculated with 
ANOVA. Differences between grouping variables in each study were calculated with 
χ2-statistics. (I-IV) In each study Pearson’s correlation coefficients were calculated 
between MADRS total scores (and vegetative symptom scores (I)) and other clinical 
variables to explore potential covariates for general linear models (GLMs). These 
multiple analyses could arguably have posited a need for correction used for multiple 
testing. However, the main analyses were performed with GLMs and no correction 
was used. 
The main analysis with linear mixed effects model in Study III was performed 
with PROC MIXED, SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) and all 
other analyses (in Studies I-IV) were performed with current versions of SPSS for 
Windows or SPSS for Mac software (versions 17.0-24.0, IBM Inc., Armonk, New 
York, USA). 
Study I 
In Study I non-parametric tests were performed in comparisons of ordinal variables 
(patient compliance and medication prescribed) between the temperament clusters. 
Multi-nominal logistic regression model was used to analyze the possible effect of 
gender, severity of depression, prescribed antidepressant and dose, adherence to 
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treatment (use of medication on at least 80% of the days), and earlier depressive 
episode on the clusters. Two linear regression models (ANCOVA) with 1) 
temperament clusters and age, and 2) temperament clusters, age and baseline 
MADRS vegetative symptom scores were used to predict endpoint (at 6-week 
timepoint) MADRS total scores.  
Study II 
Independent samples t-tests were performed to analyze differences in TCI-R, 
MADRS, and AUDIT scores between AUP and non-AUP, between genders and in 
the dropout analysis. The changes in MADRS and TCI-R dimension scores between 
baseline and 6-week measurements were analyzed with paired samples t-tests.  
GLMs were used in the main analyses to better address the potential collinearity 
of the predictors (Dormann, Elith et al. 2013). In the first type of GLM analyses in 
Study II age, gender, and AUP were used as explanatory variables in predicting each 
of the TCI-R dimension scores (NS, HA, RD, P, SD, C, ST) at baseline and at 6 
weeks. 
The second type of GLM analyses predicted MADRS score change from baseline 
to 6 weeks (ΔMADRS) with age, gender, and AUP together with either 1) 
temperament dimension changes (ΔNS, ΔHA, ΔRD, ΔP) or 2) character dimension 
changes (ΔSD, ΔC, ΔST) used as explanatory variables. 
Study III 
In the dropout analysis differences in discreet variables between dropouts and other 
patients were calculated with independent samples t-tests. Data imputation for the 
main analysis was made with the LOCF method, which replaced missing values in 
MADRS scores in 32 (17%) cases at 6-month and in 93 (49%) cases at 24-month 
follow-up timepoints. According to this method missing values are replaced with 
their last observed values in earlier follow-up timepoints. 
A linear mixed effects model was used in the main analysis of the study. In this 
model the scores of the seven temperament and character dimensions (NS, HA, RD, 
P, SD, C, and ST; at six weeks) were used as explanatory variables to predict LOCF 
MADRS scores from 6 weeks to 6 months and to 24 months. The model was 
adjusted for AUP, gender, and AUP x gender and AUP x time interactions and 
individual-specific intercept and slope terms were used in the model. The -2 log 
likelihood information criteria were used to evaluate model fit and model with 
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unstructured covariance structure was reported. Kenward-Roger adjustment of 
degrees of freedom was applied for estimates of fixed effects. 
Study IV 
To analyze the effects of possible confounding variables on the dependent diagnosis 
three tiers of binary logistic regression models were used. Model 1 was adjusted for 
age and gender, Model 2 was adjusted for age, gender, and MADRS scores, and 
Model 3 was adjusted for age, gender, MADRS scores, and AUDIT-C scores. Panic 
disorder and/or agoraphobia (PDA), social anxiety disorder (SAD) or generalized 
anxiety disorder (GAD) were predicted in Models 1-3 with a temperament cluster 
that had the highest prevalence of the dependent diagnosis (see Table 8.) set as the 
explanatory variable. 
4.5 Informed consent and ethical approvals 
Informed consent was obtained from all participants included in this study. Approval 
for the study protocol was obtained from local ethics committees from Pirkanmaa 
(for DEPGEN) and from South Ostrobothnia (for ODS). Trial registration 
considering ODS was done through the Clinicaltrials.gov with identifier number 
NCT02520271. 
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5 RESULTS 
5.1 Temperament clusters and vegetative symptoms of 
depression as predictors of antidepressant response (I) 
The two-step cluster analysis of the DEPGEN cohort resulted in three clusters of 
patients with different temperament profiles. The first cluster (n=33) had a 
temperament profile with low NS, high HA and low RD (LNS/HHA/LRD), the 
second cluster (n=35) had intermediate NS, high HA, and high RD 
(INS/HHA/HRD), and the third cluster (n=30) had high NS, low HA, and high 
RD (HNS/LHA/(HRD)). RD did not reach statistical significance in one of the 
clusters and is therefore here presented in parentheses. Two of the clusters had 
temperament profiles with HA scores higher than NS scores in contrast to the third 
cluster, which had NS scores higher than HA scores and the first cluster showed the 
strongest sloping in the temperament dimension scores. The temperament 
dimension scores of the three clusters are reported in Figure 6 and the total MADRS 
score and sub-scores of the temperament clusters are presented in Table 4. 
 
 
Figure 6 Temperament dimension (Mean±S.E.) scores of the three temperament clusters in DEPGEN cohort. 
Abbreviations: LNS = Low Novelty Seeking, HHA = High Harm Avoidance, LRD = Low Reward 
Dependence, INS = Intermediate Novelty Seeking, HRD = High Reward Dependence, HNS = High 
Novelty Seeking, LHA = Low Harm Avoidance 
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We built two linear regression models to predict the endpoint MADRS scores. In 
the first model age and temperament clusters were used as explanatory variables. The 
whole model predicted 10% of variance in the endpoint MADRS scores (p=0.04; 
power 0.69) and the temperament clusters predicted individually 9% of the variance 
in endpoint MADRS (p=0.02), whereas age was a non-significant predictor of the 
outcome (p=0.36). In the second model the vegetative symptoms of depression at 
baseline were used as explanatory variable among temperament clusters and age. 
This model predicted 20% of the variance in the endpoint MADRS scores (p=0.001; 
power 0.96) and in this model vegetative symptoms of depression at baseline 
predicted 12% (p=0.001), temperament clusters 5% (p=0.12), and age 0.2% 
(p=0.70) of the variance. 
A high correlation was observed between total MADRS score and the vegetative 
symptom scores both at baseline (r=0.73, p<0.001) as well as at endpoint (r=0.76, 
p<0.001). The correlations between baseline vegetative symptom scores and 
endpoint total scores in MADRS were moderate (r=0.38, p<0.001) and the 
association between baseline vegetative scores and the change in the total scores of 
MADRS from baseline to endpoint non-significant (r=0.13, p=0.26). 
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Table 4.  Total and sub-factor MADRS scores for each temperament cluster at baseline and at 6 
weeks 
Abbreviations: MADRS = Montgomery-Asberg Depression Rating Scale; NS = Novelty Seeking; HA 
= Harm Avoidance; RD = Reward Dependence; L = low; H = high; I = intermediate 
*p=0.05 between groups (ANOVA) 
**p=0.01 between groups (ANOVA) 
Cluster LNS/HHA/LRD INS/HHA/HRD HNS/LHA/(HRD) 
Baseline 
MADRS score 
(mean±SD)* 
28.3 ± 6.1 27.3 ± 5.7 25.0 ± 4.4 
Factor 1 
(dysphoria) 
8.5 ± 2.6 7.8 ± 2.2 7.4 ± 1.4 
Factor 2 
(retardation) 
11.7 ± 2.2 12.1 ± 2.7 11.0 ± 2.9 
Factor 3 
(vegetative 
symptoms) 
7.8 ± 3.1 7.4 ± 2.8 6.4 ± 2.7 
MADRS scores 
at 6 weeks 
(endpoint)** 
14.1 ± 9.1 13.5 ± 8.3 8.3 ± 5.5 
Factor 1 
(dysphoria) 
3.7 ± 3.2 3.9 ± 2.7 2.5 ± 1.9 
Factor 2 
(retardation)** 
6.3 ± 4.5 6.0 ± 3.7 3.4 ± 3.0 
Factor 3 
(vegetative 
symptoms) 
3.5 ± 2.3 3.7 ± 2.9 2.4 ± 1.9 
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The patients in the first cluster were older than those in the two other clusters, but 
there were no differences in other clinical variables tested (dosages of medications 
taken in weeks 1-3, p=0.48, compliance with treatment between the clusters, 
p=0.69). The mean ages for the patients in each cluster were: cluster 1 = 45.9±11.4, 
cluster 2 = 37.4±14.4, cluster 3 = 38.2±15.3; mean±SD, p=0.03 for the difference 
in ANOVA. Age showed a trendlike effect (p=0.051) on the clusters in the 
multinominal regression model, whereas gender, severity of depression, adherence 
to antidepressant treatment or antidepressant dose, adherence to treatment, and 
earlier depressive episode were non-significant predictors.  
5.2 Effect of alcohol use problems on temperament and 
character profiles and antidepressive treatment response 
(II) 
Internal consistencies were estimated as Cronbach’s alphas for each baseline TCI-R 
dimension in the ODS patient cohort: NS 0.85, HA 0.88, RD 0.89, P 0.92, SD 0.86, 
C 0.85, ST 0.85. The differences in temperament and character profiles between 
patients with or without marked alcohol use problems (AUP and non-AUP) are 
presented in Tables 5 and 6. These tables present both the baseline and endpoint 
scores of each TCI-R dimension and the MADRS scores and changes therein also 
group-wise and for each of the genders separately. The patients in the AUP group 
had higher Novelty Seeking (p=0.001, ANOVA), lower Persistence (p=0.021), lower 
Self-Directedness, and lower Cooperativeness (p=0.001) than the non-AUP group 
at baseline. The differences were significant for NS (p=0.014, ANOVA) and SD 
(p<0.001) between the groups at six weeks. 
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Table 5.  Comparison of temperament dimension scores between groups at baseline and 6 
weeks and changes therein  
   NS (±SD) 
HA 
(±SD) 
RD (±SD) P (±SD) 
All patients Baseline (n=216) 
100.19 
(17.02) 
114.82 
(19.18) 
99.45 
(16.97) 
100.59 
(20.49) 
 6 weeks (n=177) 
99.72 
(16.70) 
113.43 
(18.90) 
100.05 
(17.58) 
99.72 
(21.52) 
 Change; p* ns ns ns ns 
Men Baseline (n=88) 
104.35 
(17.57)1 
115.15 
(18.26) 
93.80 
(16.39)2 
98.58 
(20.65) 
 
6 weeks (n=70) 
103.31 
(17.92)3 
111.46 
(16.90) 
94.74 
(17.15)4 
99.33 
(20.76) 
 
Change; p* ns 
-3.46; 
0.010 
ns ns 
Women Baseline (n=128) 
97.34 
(16.09)1 
114.59 
(19.85) 
103.34 
(16.31)2 
101.97 
(20.35) 
 
6 weeks (n=107) 
97.36 
(15.50)3 
114.72 
(20.07) 
103.52 
(17.06)4 
99.98 
(22.09) 
 
Change; p* ns ns ns 
-2.15; 
0.049 
non-AUP Baseline (n=127) 
97.05 
(17.41)5 
113.71 
(19.49) 
100.69 
(17.31) 
103.28 
(20.78)6 
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6 weeks (n=114) 
97.44 
(16.95)7 
112.44 
(19.27) 
100.97 
(17.30) 
102.02 
(21.84) 
 
Change; p* ns ns ns ns 
AUP  Baseline (n=89) 
104.69 
(15.47)5 
116.40 
(18.72) 
97.67 
(16.40) 
96.74 
(19.54)6 
 
6 weeks (n=63) 
103.84 
(15.53)7 
115.22 
(18.22) 
98.38 
(18.11) 
95.57 
(20.44) 
 
Change; p* ns ns ns ns 
Abbreviations: AUP = Alcohol use problems; NS = Novelty Seeking; HA = Harm Avoidance; RD = 
Reward Dependence; P = Persistence; ns = non-significant 
Mean differences at baseline between men and women (±SD): 1-7.02 (2.31), p=0.003; 29.54 (2.26), 
p<0.001 
Mean differences at baseline between non-AUP and AUP (±SD): 5-7.64 (2.30), p=0.001; 66.54 (2.80), 
p=0.021 
Mean differences at 6 weeks between men and women (±SD): 3-5.95 (2.54), p=0.020; 48.78 (2.63), 
p=0.001 
Mean differences at 6 weeks between non-AUP and AUP (±SD): 7-6.40 (2.59), p=0.014 
*Change from baseline to 6 weeks with paired samples t-test 
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Table 6.  Comparison of character dimensions and MADRS scores between groups at baseline 
and 6 weeks and changes therein. 
 
  
SD 
(±SD) 
C (±SD) ST (±SD) 
MADRS 
(±SD, n) 
All patients Baseline (n=216) 
122.30 
(18.42) 
131.17 
(18.85) 
66.63 (13.97) 
23.13 (6.35, 
n=213) 
 
6 weeks (n=177) 
125.36 
(17.29) 
131.89 
(18.04) 
64.93 (15.54) 
17.05 (8.01, 
n=179) 
 
Change; p* 
2.29; 
0.015 
ns -1.71; 0.014 -6.38; <0.001 
Men  Baseline (n=88) 
117.86 
(17.04)1 
123.97 
(19.26)2 
65.91 (13.64) 
24.72 (6.22, 
n=88)3 
 
6 weeks (n=70) 
120.54 
(16.35)4 
125.10 
(18.17)5 
66.03 (14.44) 
18.76 (7.81, 
n=74)6 
 
Change; p* ns ns ns -6.51; <0.001 
Women  Baseline (n=128) 
125.35 
(18.78)1 
136.12 
(16.94)2 
67.12 (14.21) 
22.01 (6.22, 
n=125)3 
 
6 weeks (n=107) 
128.50 
(17.23)4 
136.33 
(16.59)5 
64.21 (16.25) 
15.85 (7.97, 
n=105)6 
 
Change; p* 
2.30; 
0.047 
ns -2.71; 0.004 -6.28; <0.001 
non-AUP Baseline (n=127) 
125.63 
(18.94)7 
134.63 
(17.91)8 
67.47 (14.67) 
22.68 (6.21, 
n=126) 
 88 
 
6 weeks (n=114) 
129.27 
(16.14)9 
133.64 
(17.57) 
65.71 (16.13) 
17.00 (7.98, 
n=115) 
 
Change; p* 
3.54; 
0.002 
ns -2.39; 0.005 -5.90; <0.001 
AUP Baseline (n=89) 
117.55 
(16.63)7 
126.22 
(19.16)8 
65.42 (12.88) 
23.77 (6.53, 
n=87) 
 
6 weeks (n=63) 
118.27 
(17.16)9 
128.71 
(18.57) 
63.52 (14.43) 
17.14 (8.13, 
n=64) 
 
Change; p* ns ns ns -7.22; <0.001 
Abbreviations: AUP = Alcohol use problems; SD = Self-Directedness; C = Cooperativeness; ST = 
Self-Transcendence; ns = non-significant; MADRS = Montgomery-Åsberg Depression Rating Scale 
Mean differences at baseline between men and women (±SD): 17.49 (2.51), p=0.003; 212.15 (2.48), 
p<0.001; 3-2.71 (0.87), p=0.002 
Mean differences at baseline between non-AUP and AUP (±SD 78.08 (2.49), p=0.001; 88.41 (2.55), 
p=0.001 
Mean differences at 6 weeks between men and women (±SD): 47.96 (2.60), p=0.003; 511.23 (2.65), 
p<0.001; 6-2.91 (1.20), p=0.016 
Mean differences at 6 weeks between non-AUP and AUP (±SD): 911.00 (2.59), p<0.001 
*Change from baseline to 6 weeks with paired samples t-test 
The first type of GLMs used the possible predictors of temperament and character 
dimension scores (age, gender, AUP, and baseline scores of MADRS) as explanatory 
variables. These models had each of the TCI-R dimensions separately at baseline or 
at 6 weeks as the target variable. In these models AUP was a significant predictor of 
NS (p=0.027) and SD (p=0.016) at baseline and of P (p=0.047) and SD (p=0.001) 
at six weeks. All predictors and their explanatory proportions of these GLMs are 
presented in Table 7. 
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Table 7   is printed on the following two pages.
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The second type of GLMs predicted change in the MADRS scores from baseline to 
6 weeks (ΔMADRS) with either temperament or character dimension delta scores 
together with age, gender, and AUP set as explanatory variables. The temperament 
model predicted 12.2% (p=0.003) of the variance in ΔMADRS and in the model 
ΔRD 14.1% (p=0.005) and age 11.6% (p=0.012) were the only individual predictors 
of the outcome. The character model predicted 13.7% (p=0.001) of the variance in 
ΔMADRS and in the model ΔSD and ΔST were the only individual predictors of the 
outcome. Both models, without the AUP set as an explanatory variable, were then 
applied to AUP and non-AUP patients separately. The temperament model was non-
significant in predicting ΔMADRS in non-AUP (p=0.141), but highly significant 
when the model was applied to AUP patients and predicted 28.3% (p=0.006) of the 
variance of ΔMADRS in this patient group. The character model predicted 14.3% 
(p=0.007) of ΔMADRS in non-AUP and in the model ΔSD (8.0%, p=0.003) and 
ΔST (5.1%, p=0.021) were significant individual predictors of ΔMADRS (ηp2=0.08, 
p=0.003 and ηp2=0.051, p=0.021 respectively). When applied to the AUP patient 
group, a similar model predicted 19.0% (p=0.043) of the variance in ΔMADRS. In 
this model age predicted 9.7% (p=0.021) of the ΔMADRS, while none of the 
character dimension changes contributed significantly to the model. 
The Pearson’s correlation coefficients were: r=-0.185, p=0.054 between ΔRD 
and ΔMADRS in non-AUP patients and r=-0.377, p=0.003 in AUP patients; r=-
0.301, p=0.001 between ΔSD and ΔMADRS in non-AUP and r=-0.249, p=0.058 in 
AUP patients; r=0.205, p=0.032 between ΔST and ΔMADRS in non-AUP patients 
and r=-0.119, p=0.368 in AUP patients. At baseline, correlations between age and 
SD, C, and ST were r=0.260 (p<0.001), r=0.203 (p=0.003), and r=0.134 (p=0.049) 
respectively. At 6 weeks correlations between age and SD, C, and ST were r=0.233 
(p=0.002), r=0.206 (p=0.006), and r=0.193 (p=0.010) respectively. 
5.3 Temperament and character profiles as predictors and the 
effect of harmful drinking on outcome of depression over 
two-year follow-up (III) 
In Study III, the number of patients who dropped out was 65 (27%) at 6 weeks, 91 
(38%) at 6 months, and 147 (61%) at 24 months. Of the dropouts the clinical 
treatment had been concluded in cooperation with the patients in 10 (11%) during 
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the first 6 months and in 28 (19%) cases before 24 months. There were no 
differences in the gender distribution or baseline MADRS scores between dropouts 
and completed patients. Baseline AUDIT scores were higher in the dropouts than 
among completed patients in the dropout analysis: at 6 months (p<0.001, t-test) and 
at 24 months (p=0.006). Dropped out patients had lower SD in the dropout analysis 
at 6 months (dropouts 117.9±18.3 vs. other patients 124.2±18.2, p=0.02 for t-test), 
but the difference was non-significant at 24 months (p=0.09). There was no 
statistically significant difference in LOCF MADRS scores between dropped out and 
other patients at 6-month dropout analysis (p=0.2), but the LOCF MADRS scores 
were higher in dropouts at 24 months (dropouts 12.9±8.9 vs. other patients 8.3±7.6, 
p<0.001 for t-test). 
The results of the main analysis with the linear mixed effects model are presented 
in Table 8. The model predicted LOCF MADRS scores in the follow-up from 6 
weeks to 6 months and to 24 months. Reward Dependence was the only statistically 
significant TCI-R dimension in predicting the outcome in the model. The estimate 
for this variable was negative, indicating higher values of RD being a predictor of 
steeper decline in MADRS scores across the 24-month follow-up. Time x AUP and 
Time x non-AUP interaction variables were significant predictors of the outcome in 
the model and the absolute value of the estimate was higher for Time x non-AUP 
indicating a steeper decline in MADRS scores over the follow-up in non-AUP 
patients.  
Table 8.  Predictors of depression outcome (LOCF MADRS scores across follow-up from 6 
weeks to 6 months and to 24 months)a 
Fixed effects LOCF MADRS scores 
 Estimateb SE t p 
Intercept 20.07 10.04 2.00 0.049 
NS at 6 weeks 0.04 0.03 1.16 0.25 
HA at 6 
weeks 
0.06 0.04 1.70 0.09 
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RD at 6 
weeks 
-0.11 0.04 -3.03 0.003 
P at 6 weeks -0.03 0.03 -1.10 0.27 
SD at 6 weeks -0.06 0.04 -1.59 0.11 
C at 6 weeks 0.02 0.04 0.56 0.58 
ST at 6 weeks 0.05 0.03 1.49 0.14 
Male gender 0.24 1.76 0.14 0.23 
AUP 3.67 1.64 2.25 0.12 
AUP x Male 
gender 
-3.24 2.19 -1.48 0.14 
AUP x Time -0.10 0.05 -1.98 0.0002 
non-AUP x 
Time 
-0.33 0.06 -3.75 0.0002 
-2 x log-likelihood = 3530 for the SAS input code and output results 
aResults from the linear mixed effects model with temperament and character dimension scores, 
gender, AUP, and AUP x Gender and AUP x Time interactions as explanatory variables 
bB for the temperament and character variables effect on the dependent variable 
Abbreviations: LOCF = Last observation carried forward; NS = Novelty Seeking; HA = Harm 
Avoidance; RD = Reward Dependence; P = Persistence; SD = Self-Directedness; C = 
Cooperativeness; ST = Self-Transcendence; MADRS = Montgomery-Åsberg Depression Rating 
Scale; AUP = alcohol use problems 
Significant results are presented in bold face. 
The LOCF data had a lower proportion of patients reaching response and remission 
in the 6-month and 24-month follow-up points compared to the raw data (Table 9.). 
The proportion of male patients and AUP patients declined in the raw data across 
the follow-up. The TCI-R scores at 6 weeks are presented in Tables 5 and 6. 
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There were significant correlations between RD and LOCF MADRS scores at 6 
months (r=-0.32, p<0.001), HA and LOCF MADRS scores at 6 months (r=0.18, 
p=0.02), SD and LOCF MADRS scores at 6 months (r=-0.27, p<0.001), HA and 
LOCF MADRS scores at 24 months (r=0.26, p=0.001), and SD and LOCF MADRS 
scores at 24 months (r=-0.32, p<0.001). 
Table 9.  MADRS scores in raw data, LOCF data, and by patient subgroup and number of 
responders, patients in remission, and non-responders at baseline and follow-up 
  Baseline 6 weeks 6 months 24 months 
Raw data MADRS scores 
(mean±SD) 
23.2±6.7; 
n=228 
16.9±8.0; 
n=188 
13.1±8.7; 
n=156 
8.3±7.6; 
n=95 
Response* (n, %)   69, 44% 64, 67% 
Remission** (n, %)   49, 31% 50, 53% 
LOCF data MADRS 
scores, n=188 
  13.6±8.5 10.6±8.5 
Response* (n, %)   80, 43% 112, 60% 
Remission** (n, %)   52, 28% 80, 43% 
MADRS scores of patient subgroups (Raw data scores): 
non-AUP (mean±SD) 
22.9±6.7 
(n=136) 
16.7±8.0 
(n=123) 
12.8±8.7 
(n=105) 
6.7±6.2 
(n=66) 
AUP (mean±SD) 
23.7±6.7 
(n=92) 
17.2±8.1 
(n=65) 
13.7±8.7 
(n=51) 
12.0±9.2 
(n=29) 
Female (mean±SD) 
22.3±6.8 
(n=137) 
15.7±7.8 
(n=112) 
11.6±8.2 
(n=97) 
7.1±6.6 
(n=64) 
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Male (mean±SD) 
24.6±6.3 
(n=91) 
18.6±8.0 
(n=76) 
15.6±9.1 
(n=59) 
10.8±8.9 
(n=31) 
proportion of men (n, %) 91, 40% 76, 40% 59, 38% 31, 33% 
proportion of AUP 
patients (n, %) 
92, 40% 65, 35% 51, 33% 29, 31% 
Number of patients with 
increase in symptoms from 
baseline (n, %) 
  
23, 15% 3, 3% 
Abbreviations: AUP= Alcohol use problems; MADRS = Montgomery-Åsberg Depression Rating 
Scale; LOCF = last observation carried forward 
*at least 50% MADRS score decline from baseline; **MADRS scores < 8 
5.4 Association of temperament clusters with anxiety disorder 
comorbidity in depression (IV) 
The two-step cluster analysis of the ODS patient cohort resulted in four clusters with 
different temperament profiles. These clusters were given descriptive labels 
according to the individual combination of different temperament dimension scores. 
The  clusters found were: 1) Novelty seekers with high NS, n=56, (NS=119.4±9.0, 
HA=111.0±14.2, RD=103.3±13.5, P=98.0±15.5; mean±SD), 2) Persistent with low 
HA and high P, n=36, (NS=99.6±17.1, HA=87.3±11.0, RD=107.9±15.6, 
P=125.0±12.6), 3) Reserved with low NS, n=66, (NS=88.1±12.3, HA=119.9±11.5, 
RD=104.5±14.6, P=105.4±15.6), and 4) Wearied with high HA and low RD and P, 
n=58, (NS=95.7±10.4, HA=129.8±14.8, RD=84.7±14.3, P=82.4±15.3). The TCI-
R dimension scores of the different temperament profiles are presented in Figure 7. 
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Figure 7 Temperament dimension (Mean±S.E.) scores of the four temperament clusters. 
Wearied patients were younger than Persistent and Reserved patients, but there were 
no other significant differences in the clinical variables tested (gender, depression 
severity, alcohol use, use of antipsychotics or prescribed equivalent doses of 
antidepressants) between the clusters. Highest prevalence of GAD was found in 
Reserved (n=20, 31.7%), highest prevalence of SAD in Wearied (n=19, 34.5%), 
highest prevalence of PDA in Novelty seekers (n=28, 54.9%), and lowest overall 
prevalence of anxiety disorder comorbidities was found in Persistent patients. The 
chi-square values and p-values for the differences in clinical variables are presented 
in Table 10 and the chi-square values and p-values for the differences in anxiety 
disorders between the temperament clusters are presented in Table 11. 
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Table 10.  Clinical characteristics and their differences between the four temperament clusters 
(Novelty seekers, Persistent, Reserved and Wearied) 
 Clinical variables 
Temperament 
clusters 
Age * 
(mean±SD) 
Male 
gender 
(n, %) 
Antipsycho-
tics in use 
Antidepressant 
dose (mean±SD) 
AUDIT-C 
scores 
(mean±SD) 
MADRS 
scores 
(mean±SD) 
1. Novelty 
seekers  
(n=56, 26%**)  
36.7±12.5 
29, 
51.8% 
16, 28.6% 27.2±21.4 
5.64 
±3.64 
22.4±6.6 
2. Persistent 
(n=36, 17%**) 
42.5±12.2 
12, 
33.3% 
7, 19.4% 25.2±18.7 
4.31 
±3.43 
23.1±7.7 
3. Reserved 
(n=66, 30%**) 
41.4±11.6 
22, 
33.3% 
15, 22.7% 25.0±21.0 
4.39 
±3.29 
22.6±6.1 
4. Wearied  
(n=58, 27%**) 
34.8±11.4 
25, 
43.1% 
22, 37.9% 32.4±19.2 
4.93 
±3.24 
24.5±5.4 
χ2  5.28 5.08    
p 0.0031 0.152 0.1662 0.181 0.161 0.261 
Abbreviations: AUDIT-C = Alcohol use disorder identification test (questions 1–3); MADRS = 
Montgomery-Åsberg Depression Rating Scale 
Percentages in clinical variables are proportions of the temperament clusters 
*differences were significant between clusters 2 and 4, and between clusters 3 and 4 in Bonferroni 
analysis 
**proportion of the whole patient sample 
1for ANOVA between the temperament clusters 
2for chi-square between the temperament clusters  
Significant differences are presented in bold face 
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Table 11.  Distributions of anxiety disorders and differences in these between the four 
temperament clusters (Novelty seekers, Persistent, Reserved and Wearied) 
Abbreviations: PDA = Panic disorder and/or Agoraphobia; SAD = Social anxiety disorder; GAD = 
Generalized anxiety disorder  
Percentages in diagnoses are proportions of the temperament clusters 
*proportion of the whole patient sample 
1for chi-square between the temperament clusters 
Significant differences are presented in bold face 
  
 Diagnoses 
Temperament 
clusters 
PDA 
(n, %) 
SAD 
(n, %) 
GAD 
(n, %) 
1. Novelty seekers  
(n=56, 26%*) 
28, 54.9% 10, 19.6% 7, 13.7% 
2. Persistent 
(n=36, 17%*) 
5, 14.3% 1, 2.9% 8, 22.9% 
3. Reserved 
(n=66, 30%*) 
14, 22.2% 10, 15.9% 20, 31.7% 
4. Wearied  
(n=58, 27%*) 
22, 40.0% 19, 34.5% 6, 10.9% 
χ2 20.81 14.57 9.67 
p <0.0011 0.0021 0.021 
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In the three types of models built to predict the anxiety disorders Novelty seekers 
had higher odds (odds ratio [OR]=3.28–3.52, p≤0.001) for PDA,  Wearied had 
higher odds (OR=3.17–3.41, p=0.002–0.003) for SAD, and  Reserved had higher 
odds (OR=2.53–2.60, p=0.009–0.01) for GAD compared to other patients. The 
results of these regression models are presented in Table 12.  
Table 12.  Likelihood of anxiety disorders (PDA, SAD and GAD) according to temperament. 
clusters in the logistic regression models 
Model 1: adjusted for gender and age 
Model 2: adjusted for gender, age, and MADRS scores 
Model 3: adjusted for gender, age, MADRS scores, and AUDIT-C scores 
*Binominal variables: 1) Novelty seekers cluster vs. others explaining PDA, 2) Wearied cluster vs. 
others explaining SAD, and 3) Reserved cluster vs. others explaining GAD 
Abbreviations: PDA = Panic disorder and/or agoraphobia; SAD = Social anxiety disorder; GAD = 
Generalized anxiety disorder; MADRS = Montgomery Åsberg Depression Rating Scale; AUDIT-C = 
Alcohol use disorder identification test (questions 1–3), OR = odds ratio, CI = confidence interval 
 PDA SAD GAD 
 OR 95% 
CI 
p OR 95% 
CI 
p OR 95% 
CI 
p 
Model 1            
Temperament 
cluster* 
3.28 1.67-
6.41 
0.001 3.17 1.49-
6.76 
0.003 2.60 1.27-
5.33 
0.009 
Model 2             
Temperament 
cluster* 
3.52 1.78-
6.96 
<0.001 3.19 1.47-
6.90 
0.003 2.53 1.23-
5.21 
0.01 
Model 3             
Temperament 
cluster* 
3.48 1.76-
6.91 
<0.001 3.41 1.55-
7.49 
0.002 2.55 1.24-
5.27 
0.01 
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6 DISCUSSION 
6.1 Summary of the main results 
In Study I we found three clusters with different temperament profiles. These 
clusters predicted depression outcome when age was controlled for. A model in 
which vegetative symptoms of depression at baseline was used as a predictor 
together with the temperament clusters and age explained the largest proportion of 
response to antidepressant treatment. (I) 
Alcohol use problems (AUP) predicted high NS and low P and SD in GLMs 
adjusted for age, gender, and baseline severity of depression. In GLMs adjusted for 
age and gender, increase in RD (over 6-week follow-up) predicted a decline in 
MADRS specifically in the AUP group in contrast to patients without this 
comorbidity. The third main finding of the study was that after controlling for age 
and gender, increase in SD and decline in ST (over 6-week follow-up) predicted a 
decline in MADRS specifically in the non-AUP group in contrast to patients with 
marked alcohol use problems (AUP). (II) 
The main finding in Study III was that better outcome of depression was 
predicted by high Reward Dependence (score at 6 weeks) in the follow-up from 6 
weeks to 6 months and to 24 months. Alcohol use problems were associated with 
slower decline of MADRS scores in follow-up. (III) 
In Study IV four clusters of patients with unique temperament profiles were 
identified. These clusters had different associations with anxiety disorder 
comorbidities. More specifically, panic disorder and/or agoraphobia were predicted 
by the Novelty seekers temperament, social anxiety disorder by Wearied 
temperament, and generalized anxiety disorder by Reserved temperament in this 
sample of diverse depressed patients in regression models adjusted for potential 
clinical confounding variables. (IV) 
 102 
6.2 Temperament clusters and vegetative symptoms of 
depression as predictors of antidepressant response (I) 
In Study I, although in one of the temperament clusters identified the difference in 
RD was not statistically significant, the cluster model indicates that the MDD 
patients in the DEPGEN patient sample could be divided into three clusters 
according to combinations of their temperament dimensions.  
Patients with temperament profile with low NS, high HA, and low RD had the 
most modest response to antidepressant treatment, whereas patients with the 
opposite profile (HNS/LHA/(HRD)) had the best response and the level of 
response in patients with the third temperament profile with intermediate NS, high 
HA, and high RD was in between the two other clusters. These temperament profiles 
predicted response to antidepressive treatment when the patients’ age was controlled 
for. Although the model predicted only less than one tenth of the response, these 
results suggest that temperament clusters are indeed a predictor of antidepressant 
treatment response. 
Earlier studies have shown that high HA is associated with poorer outcome of 
depression and the finding of this study concurs well with those findings because the 
temperament clusters that were associated with poorer outcome had high HA 
(Kampman, Poutanen 2011). High NS could be associated with lower level of 
depressive symptomatology, but no conclusive evidence of this association is 
available in depressed populations (Kampman, Poutanen 2011, Farmer, Mahmood 
et al. 2003). The evidence of the associations between RD and depression has been 
inconsistent (de Winter, Wolterbeek et al. 2007, Farmer, Mahmood et al. 2003, 
Richter, Polak et al. 2003, Naito, Kijima et al. 2000). Arguably one possible 
explanation for these discrepancies could be that the complete profiles with different 
combinations of each temperament dimension would be more important in the 
context of depression response instead of NS or RD dimensions individually.  
Vegetative symptoms of depression (cf. melancholic type of depression) have 
historically been associated with a more “endogenous” type of depression and more 
recently with seasonal affective disorder (Paykel 2008, Grimaldi, Partonen et al. 
2009). Some evidence exists that vegetative symptoms of depression may be 
associated with early stages of depressive episode and expression of immunological 
mediators (Grimaldi, Partonen et al. 2009, Maes 1993, Wichers, Koek et al. 2005). 
In one study high level of vegetative symptoms was associated with poorer response 
to fluvoxamine (Higuchi, Sato et al. 2008a). The associations of vegetative symptoms 
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of depression and temperament clusters with depression outcome have not so far 
been studied. To analyze the possible modifying effect of vegetative symptoms on 
the association between temperament clusters and antidepressant response, the 
second model in Study I included temperament clusters and vegetative symptoms of 
depression both with age as predictors. This model predicted twice the proportion 
in the variance of antidepressant treatment response compared to the model that 
had temperament clusters as the sole predictor, along with age. However, the 
explanatory proportion of the temperament clusters was smaller and non-significant 
in this model. The increase in the explanatory proportion of the whole model when 
vegetative symptoms were added into the model as a predictor suggest that 
vegetative symptoms of depression are individually a marked predictor of 
antidepressant treatment outcome. Moreover, it is possible that the vegetative 
symptoms of depression mediate the effect of temperament clusters on the 
antidepressant treatment response because their individual explanatory proportion 
was smaller (and statistically non-significant) in the second model. However, the 
association between temperament and vegetative symptoms of depression would 
have to be established in further studies to reach that conclusion. Indeed, some data 
exists that high Reward Dependence combined with low Persistence is negatively 
associated with appetite loss and low energy (Grucza, Przybeck et al. 2003). 
Moreover, harm-avoidant individuals might be less likely to experience typical 
vegetative symptoms during episodes of clinical depression according to one study 
(Grucza, Przybeck et al. 2003). 
An analysis predicting the temperament clusters with clinical variables was 
performed to acquire information about possible confounding variables to adjust the 
model used in the main analysis predicting depression outcome. This analysis 
resulted in only age being a marginally significant predictor of the temperament 
clusters and it was therefore important to adjust the models predicting the outcome 
of depression in the main analysis for age. However, age was not significant in 
predicting antidepressant treatment outcome in the regression models. 
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6.3 The effect of alcohol use problems on temperament and 
character profiles and antidepressive treatment response 
(II) 
In the ODS cohort, patients without marked alcohol problems (non-AUP) had 
similar temperament profiles to earlier samples with MDD patients (Jylhä, Mantere 
et al. 2011, Perna, Vanni et al. 2014). At baseline patients with alcohol use problems 
(AUP) had higher NS, and lower P, SD, and C than non-AUP patients, a notion that 
resembles the earlier finding of differences between depressed patients with or 
without history of alcohol dependence (Rae, Joyce et al. 2002). These temperamental 
differences and characteristics of depressed patients with alcohol use problems could 
be reflected in clinical settings as tendencies to be more enthusiastic about trying 
new treatments (high NS) but also to have difficulties related to treatment adherence 
because of a lack of self-control, cooperation, and persistence. 
6.3.1 Temperament dimensions 
To analyze the association between alcohol use problems and temperament and 
character GLMs adjusted for gender, age, and baseline severity of depression were 
used to predict each TCI-R dimension score (at baseline and at 6 weeks) with AUP 
as explanatory variable. After controlling for other clinical variables AUP was an 
individually significant predictor of NS scores at baseline and suggested a trend close 
to significance at 6 weeks. In the GLMs predicting NS scores the severity of 
depression was not significant in predicting the scores. These findings in Study II 
are well in line with earlier knowledge of high NS being a trait-like characteristic 
increasing the risk of SUDs and highlight the role of high NS being a risk factor for 
SUDs regardless of depressive symptomatology (Sher, Bartholow et al. 2000).   
The male patients’ HA scores decreased significantly over the 6-week follow-up, 
which was an expected result as depression is known to increase the scores on that 
dimension (Kampman, Poutanen 2011). Surprisingly, female patients’ HA scores did 
not decrease markedly during follow-up, which suggests that these patients’ 
depression is associated with different disease mechanisms than those traditionally 
associated with MDD patients. It is possible that because of the more lenient 
inclusion criteria the ODS sample included greater numbers of patients with a 
differentiated depression spectrum disorder associated with female gender, family 
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history of SUDs, recurrent episodes of MDD, and greater psychiatric comorbidity 
(Davis, Frazier et al. 2007, Winokur, Coryell 1992). These patients’ depressive 
symptomatology could be more associated with the reward mechanisms in the brain, 
possibly leading to reward-seeking behavior such as substance use and the 
permanently high levels of HA could predispose them to recurrence of depressive 
episodes (Kampman, Poutanen 2011).  
Although temperament is considered to be reflective of relatively stable traits, 
depression is known to be associated with state dependent changes in HA and some 
changes in temperament and character have been associated with favorable outcome 
of depression recovery (Kampman, Poutanen 2011, Corruble, Duret et al. 2002). 
The GLMs predicting change in MADRS scores in 6-week follow-up with Δ-
variables of the TCI-R dimensions aimed to analyze the associations between the 
possible state dependent alterations of temperament or character and response to 
antidepressive treatment. In the temperament model adjusted for age, gender, and 
AUP status, the change in RD was the only individually significant predictor of the 
antidepressive treatment response. Because the earlier data on the state dependency 
of RD in depression are inconsistent, we wanted to analyze whether the association 
could be a specific characteristic of depressed patients with marked alcohol use 
problems (de Winter, Wolterbeek et al. 2007, Farmer, Mahmood et al. 2003, Richter, 
Polak et al. 2003, Naito, Kijima et al. 2000). Therefore, similar GLMs predicting 
antidepressive treatment response were also applied separately to AUP and non-
AUP patients. Indeed, the model was non-significant in predicting the outcome in 
non-AUP patients but predicted over one fourth of the variance in ΔMADRS in the 
AUP group. The finding that increase in RD correlated with decrease in MADRS 
scores in the correlation analysis together with the results in the GLMs suggests that 
increase in Reward Dependence is a predictor of antidepressive treatment response 
at 6 weeks in depressed patients with alcohol use problems. When considering earlier 
data these patients’ depressive symptoms could be more related to physical and 
vegetative symptoms of depression (Grucza, Przybeck et al. 2003) and could be 
reflective of different functions of brain antireward mechanisms associated with 
noradrenergic systems, HPA-axis, and endogenous oxytocin (Bell, Nicholson et al. 
2006, BuismanPijlman, Sumracki et al. 2014, Cloninger 1986, Koob, Le Moal 2008).  
In the GLMs AUP was a significant predictor of Persistence (P) at 6 weeks and 
showed a trend towards significance in predicting baseline P when the clinical 
variables were controlled for in the model. This is in line with earlier data suggesting 
that low P is associated with SUDs in depressed patients (Evren, Evren et al. 2009, 
Rae, Joyce et al. 2002), and according to an earlier study means that these patients 
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could suffer from more profound loss of energy and appetite loss (Grucza, Przybeck 
et al. 2003). 
6.3.2 Character dimensions  
In line with earlier evidence the depressed patients with alcohol use problems in the 
ODS cohort had lower SD than patients without this comorbidity (Fernandez-
Mondragon, Adan 2015). Self-Directedness is associated with similar traits (e.g. self-
sufficiency, responsibility, reliability, and goal orientation) as the concept of locus of 
control and these traits are suggested to be associated with the functions in the 
dorsolateral and ventral prefrontal cortex, and the cingulate cortex (Declerck, Boone 
et al. 2006, Cloninger, Svrakic et al. 1993). Interestingly, the neuropathological 
changes in the brain due to excessive alcohol use are also found in these same brain 
regions (Harris, Jaffin et al. 2008). The finding of lower SD in depressed patients 
with alcohol use problems could thus be based on neuropathology (Harris, Jaffin et 
al. 2008, Bosco, Capozzi et al. 2014) and it is possible that excessive alcohol use 
causes low SD in the long term. However, reverse causality cannot be ruled out 
either. 
There was a significant increase in the SD scores in non-AUP patients during the 
6-week follow-up and this change was a significant predictor of the antidepressive 
treatment response at 6 weeks in this patient group. This finding is in line with earlier 
evidence suggesting that state dependent changes in SD are associated with 
depressive episodes (Nery, Hatch et al. 2009, Corruble, Duret et al. 2002). All 
patients in the ODS study received behavioral activation (BA) as psychosocial 
treatment (Bottonari, Roberts et al. 2008, Dimidjian, Hollon et al. 2006, Dobson, 
Hollon et al. 2008, Weinstock, Whisman 2007). This intervention includes 
techniques aimed at improving skills associated with higher SD and may be 
associated with an increase of SD in the non-AUP patients in this study. However, 
no increase in SD was observed in patients with marked alcohol use problems and 
no association between ΔSD and antidepressive treatment response was found in 
the GLM in this patient group. These results could suggest that depressed patients 
with alcohol use problems may benefit less from BA in the acute stage of treatment, 
possibly due to lower capacity in self-reflection and self-regulation (Bosco, Capozzi 
et al. 2014, Declerck, Boone et al. 2006, Harris, Jaffin et al. 2008).   
Although, Cooperativeness scores were significantly lower in patients with 
alcohol use problems in the ODS cohort, other clinical variables (instead of the 
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patient group) explained C in the GLMs. These results of age being a predictor of C 
lends support to the hypothesis of character maturation (i.e. an increase in character 
scores during the aging process) (Cloninger, Svrakic et al. 1993). The most likely 
reason for the differences in the C scores between AUP and non-AUP is the unequal 
gender distribution between the groups because C is known to be generally higher 
in women and the non-AUP group had a higher proportion of female patients 
(Yamasue, Abe et al. 2008). The change in Cooperativeness was a non-significant 
predictor of antidepressive treatment response across 6-week follow-up in all patient 
groups, unlike the two other character dimensions. This means that alleviation of 
depressive symptoms at acute stages of treatment is more associated with changes in 
patients’ tendencies in self-governing and spiritual affiliation than with their ability 
to cooperate (Cloninger, Svrakic et al. 1993). 
Earlier studies have suggested that Self-Transcendence may be correlated with 
depressive symptoms, but other studies have reported non-significant or 
contradictory findings (Farmer, Seeley 2009, Nery, Hatch et al. 2009, Spittlehouse, 
Pearson et al. 2010, Richter, Polak et al. 2003). One possible explanation for these 
discrepancies is differences between different demographic areas (Farmer, 
Mahmood et al. 2003). Another explanation could be that the ODS sample may have 
included more patients with subclinical bipolar disorder, because high ST is found 
in patients with bipolar disorder (Zaninotto, Souery et al. 2015, Zaninotto, Solmi et 
al. 2016). In this study ST decreased in the non-AUP group during 6-week follow-
up and the decrease in ST also predicted antidepressive treatment response in this 
patient group. These results suggest that higher levels of depressive symptoms are 
associated with higher ST in depressed patients in psychiatric secondary services. 
6.4 Association of temperament and character profiles with 
depression outcome across two-year follow-up in patients 
with harmful drinking (III) 
In contrast to some other studies the results of Studies II and III suggest that Reward 
Dependence is associated with acute stage antidepressive treatment response and 
more long-term outcome of depression across follow-up from 6 weeks to 6 and 24 
months (Farmer, Seeley 2009, Corruble, Duret et al. 2002). The difference between 
the present results and the results in earlier studies could be explained by differences 
in the patient samples studied because patients with SUDs had been excluded earlier 
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but AUDs were highly prevalent in the ODS sample (Corruble, Duret et al. 2002, 
Farmer, Seeley 2009). The results in Study II showed that increase in RD during 
acute stage of antidepressive treatment predicts alleviation of depressive symptoms 
specifically in patients with marked alcohol use problems and the finding of high RD 
as a predictor of long-term outcome of depression in Study III is likely a 
characteristic of that same group of patients. In line with our results, one earlier study 
that did not exclude patients with SUDs found an association between low RD and 
current depressive symptoms (Nery, Hatch et al. 2009). The results of another earlier 
study suggested an association between lower levels in RD and specifically dual 
diagnosis (comorbidity of severe mental illness and substance use disorder) 
(Fernandez-Mondragon, Adan 2015). The finding of an association between high 
RD (at 6 weeks) and better outcome of depression together with the results in Study 
II may be explained by depression state-dependent alterations in brain reward 
pathway functions (i.e. dysfunctional reward processing, e.g. deficit in reinforcement 
learning or impaired ability to modify behavior as a function of positive 
reinforcement) in patients comorbid with SUD (Höflich, Michenthaler et al. 2019, 
Admon, Pizzagalli 2015, Koob, Le Moal 2008). These findings support a possible 
association between Reward Dependence and depression treatment outcome when 
alcohol use problems are taken into account.  
In contrast to repeated earlier findings on the associations between depression 
and HA or SD, the scores in these TCI-R dimensions did not predict outcome of 
depression on a significant level in this study (Farmer, Seeley 2009, Kampman, 
Poutanen 2011, Asano, Baba et al. 2015). Because there are well documented 
associations between AUDs and 1) the development of more chronic courses of 
depressive symptomatology (Holzel, Harter et al. 2011) and 2) high HA and low SD 
(Fernandez-Mondragon, Adan 2015, Sher, Bartholow et al. 2000), it is possible that 
alcohol use problems are a mediator between the effect of these temperament and 
character factors on the outcome of depression. Moreover, it is plausible that lower 
capacity for organized problem solving (i.e. low SD) or the distress associated with 
behavioral inhibition (i.e. high HA) could predispose these individuals to developing 
alcohol use problems (Cloninger, Svrakic et al. 1993). Because AUP x time 
interaction had a significant effect on the MADRS scores in the linear mixed effects 
model, whereas HA and SD were non-significant predictors, the present results 
support the hypothesis that alcohol use problems mediate the effect of these 
temperament and character dimensions on the outcome of depression. 
The interactions of AUP x time and non-AUP x time were highly significant in 
predicting the outcome of depression across the follow-up from 6 weeks to 6 
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months and 24 months. The estimate for AUP x time was negative and of higher 
absolute value compared to the estimate for non-AUP x time indicating inferior 
outcome of depression recovery in patients with alcohol use problems compared to 
patients without the comorbidity. This finding demonstrates the disruptive effect of 
alcohol use problems on the outcome of depression and is in line with earlier 
findings on the detrimental effect of AUDs on the course depression (Holzel, Harter 
et al. 2011, Burcusa, Iacono 2007). Temperament dimensions Novelty Seeking and 
Persistence and character dimensions Cooperativeness and Self-Transcendence were 
all non-significant predictors of the outcome of depression in the mixed effects 
model. These results suggest that in diverse populations with depression individual 
personality profile biased on one of these dimensions is not a predictor of the long-
term outcome of depression when alcohol use problems are taken into account. 
6.5 Association of temperament clusters with anxiety disorder 
comorbidity in depression (IV) 
6.5.1 Temperament profile and Panic disorder 
Panic disorder had the highest prevalence in the Novelty seekers having 
temperament profiles including highest NS, high HA, and intermediate levels in RD 
and P. According to Cloninger’s original theory Novelty Seeking is associated with 
somatic anxiety and Harm Avoidance with cognitive anxiety (Cloninger 1986). 
Arguably panic attacks are a response to somatic anxiety and continuous concern 
about attacks to cognitive anxiety in the clinical picture of panic disorder. Finding 
the highest prevalence of PDA in the Novelty seekers cluster was an anticipated 
result because the patients in this cluster had presumably a high level of both types 
of anxiety according to Cloninger’s theory reflected as having the highest NS and 
HA scores above the population norm (Cloninger 1986, Jylhä, Isometsä 2006). When 
possible confounding variables were controlled in the regression model, the Novelty 
seekers had three times as high odds for PDA compared to other patients, which 
suggests a strong association between this temperament profile and panic disorder. 
The majority of earlier studies have found no association between high NS and panic 
disorder in depressed patients and one study actually reported an inverse relation 
between the two (Ampollini, Marchesi et al. 1999, Ongur, Farabaugh et al. 2005, 
Kennedy, Schwab et al. 2001).  
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The explanation for finding a strong association between temperament profile 
with high NS and panic disorder in Study IV and not in earlier studies could be in 
the differences in the patient samples studied. Whereas earlier studies have excluded 
patients with SUDs (Kennedy, Schwab et al. 2001, Ongur, Farabaugh et al. 2005, 
Ampollini, Marchesi et al. 1999), the prevalence of alcohol use disorder in the ODS 
sample was high. Because patients with SUDs are likely to have higher NS scores 
(Howard, Kivlahan et al. 1997) and high predisposition for panic disorder 
(Zvolensky, Bernstein et al. 2006) the earlier studies may have excluded many 
patients with high NS and panic disorder, whereas the present study is likely to have 
included these patients, thus explaining the  association found in this study. 
Moreover, the present study analyzed the association between the complete 
temperament profiles (combination of all temperament dimensions) and it is 
probable that the combination of high levels in NS and HA is important in 
explaining the high prevalence of panic disorder (and SAD) found in this group of 
depressed patients. Supporting this argument, a meta-analysis has suggested that 
panic disorder is associated with high HA (Kampman, Viikki et al. 2014).  
Interoceptive functions (e.g. interoceptive conditioning and/or catastrophic 
misappraisals of bodily sensations) are central in the development of panic attacks 
and panic disorder according to some psychological theories (Craske, Waters 2005, 
Bouton, Mineka et al. 2001). High Novelty Seeking could be a moderator of the 
association between interoceptive functions and panic disorder hypothetically via the 
“histrionic” information processing style associated with high NS (Cloninger 1986), 
and because NS is associated with functions of the same brain regions (e.g. the right 
anterior cingulate cortex and the anterior/posterior insula) as interoception and 
panic disorder (Cui, Zhang et al. 2016, De Cristofaro, Sessarego et al. 1993, LeDoux, 
Pine 2016, Sugiura, Kawashima et al. 2000). Such a moderating effect would be in 
line with our finding of highest risk of PDA in patients with temperament profile 
including the highest NS (Novelty seekers) compared to patients with temperament 
profile with lower NS. 
6.5.2 Temperament profile and Social anxiety disorder 
Social anxiety disorder had the highest prevalence in Wearied subjects with 
temperament profiles including highest HA, low NS, RD, and P. With a control for 
possible confounding variables in the regression model, Wearied temperament 
showed three times as high odds for SAD compared to other profiles. This finding 
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was well in line with earlier evidence that highest levels of HA are associated with 
SAD in contrast to other anxiety disorders (Kampman, Viikki et al. 2014, Miettunen, 
Raevuori 2012) because Wearied temperament profile included the highest HA 
found in the clusters. As the severity of depression is also associated with higher 
scores in HA (Kampman, Poutanen 2011), these findings together suggest that the 
highest scores in HA are associated with more severe depression and SAD. 
According to Cloninger high HA is associated with behavioral inhibition and 
avoidance, as well as an obsessional information processing type (Cloninger 1987, 
Cloninger 1986). It is possible that the effect of high HA on SAD and depression is 
in part mediated by these traits of avoidant behavior and repetitive unconstructive 
thinking patterns (Kanter, Busch et al. 2008, Watkins 2008, Weinstock, Whisman 
2007). Thus, the preceding findings could suggest that more profound cognitive bias 
towards repetitive and ruminative thinking patterns and avoidance are etiological 
factors more strongly associated with severe depression and SAD compared to other 
anxiety disorders. Moreover, the neurobiological correlates of high HA could 
resemble those of rumination and include heightened activity in the default mode 
network (Graham, Salimi-Khorshidi et al. 2013, Malhi, Byrow et al. 2015). 
It has been suggested earlier that there is a higher order personality trait common 
to depressive and anxiety disorders and that other unique factors differentiate 
between the more specific separate disorders (Clark, Watson 1991, Craske, Waters 
2005). Although the highest levels of HA could be associated especially with SAD 
and severe depression, in light of earlier evidence it is likely that high HA also 
presents more generally traits predisposing to psychopathology associated with 
mood and anxiety disorders (Kampman, Poutanen 2011, Kampman, Viikki et al. 
2014, Miettunen, Raevuori 2012). Moreover, our results suggest that emotional 
detachment and low ambition (reflected as lower RD and P in the Wearied patients’ 
temperament profile), compared with other features, could be important distinctive 
characteristics of this temperament profile that is associated specifically with higher 
risk for SAD. 
6.5.3 Temperament profile and Generalized anxiety disorder 
Generalized anxiety disorder had the highest prevalence in Reserved cluster and 
GAD was predicted by Reserved temperament with over two times as high odds 
compared to other patient groups in the regression models. Reserved patients had 
temperament profile with lowest NS scores, high HA and intermediate RD and P 
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(similar levels found in Finnish general population) (Jylhä, Isometsä 2006). These 
results are in line with earlier evidence reporting an association between GAD and 
high HA (Kampman, Viikki et al. 2014). Although no association between low NS 
and GAD has been found earlier (Ongur, Farabaugh et al. 2005, Piero 2010), our 
results suggest that a combination of high HA and low NS could be an important 
phenotype associated with GAD because Reserved patients’ temperament profile 
included these characteristics and the profile had a higher risk for GAD. According 
to Cloninger’s original theory Reserved patients would be less affected with 
“histrionic” or impulsive information processing, but instead could show a proclivity 
to slow or rigid decision-making, slow engagement in new interests or to be detail 
oriented due to low NS (Cloninger 1987, Cloninger 1986). It is possible that the 
difference in low/high NS found in the temperament profiles between Novelty 
seekers and Reserved is important in modulating the predisposition of these patients 
either to panic disorder or GAD when experienced together with other risk factors 
of developing psychopathology such as high HA (Cloninger 1987, Miettunen, 
Raevuori 2012).   
6.5.4 Persistent temperament profile 
The patients with Persistent temperament profile had the lowest prevalence of any 
anxiety disorders. Their temperament profile included lowest HA and highest P and 
the P scores in this patient group were even higher than those found earlier in a 
Finnish general population sample (Jylhä, Isometsä 2006). The finding of an 
association between temperament profile and a combination of low HA and high P 
and lower predisposition to anxiety disorder comorbidities was in line with earlier 
evidence suggesting that this profile together with character trait high SD is 
associated with positive emotionality and well-being (Cloninger, Bayon et al. 1998, 
Garcia 2011, Cloninger, Zohar et al. 2012). These results suggest that Persistent 
temperament profile is associated with less severe psychiatric symptomatology than 
are other temperament profiles. 
6.6 Synthesis of the results of the four sub-studies (I-IV) 
Together with earlier data the results in this study indicate that Reward Dependence 
is markedly associated with depression symptom alleviation in short-term follow-up 
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and low scores in RD are the most marked temperamental predictor (within the TCI-
R instrument) of depression outcome, also in the long term (in two-year follow-up) 
in patient populations with diverse depressive symptomatology in psychiatric 
secondary services. Moreover, low RD seems to be a(n) (endo)phenotypical marker 
for depressive symptomatology with more marked treatment resistance and higher 
rate of comorbid substance use (Takahashi, Shirayama et al. 2013, Balestri, Porcelli 
et al. 2019). Whereas high HA could be more associated with the cognitive 
component of depressive symptomatology, RD could be more associated with the 
vegetative symptoms perhaps associated with neurobiological changes during 
depressive episode (Grucza, Przybeck et al. 2003). Together with high HA and low 
P, low RD presents Wearied temperament profile which is strongly associated with 
higher prevalence of comorbid anxiety disorders, especially social anxiety disorder. 
6.7 Strengths and limitations 
6.7.1 Strengths and methodological considerations 
The approach of using TCI temperament clusters to predict the response to 
antidepressant treatment in MDD patients is novel. Some studies have been 
conducted using the individual dimensions of temperament as predictors, but only 
two earlier studies with general population samples have used combinations of high 
or low temperament traits to predict different clinical features. However, in these 
studies no cluster analysis methods have been used in classifying the temperament 
traits (Matsudaira, Kitamura 2006, Grucza, Przybeck et al. 2003). In this study the 
possible association between temperament and vegetative symptoms of depression 
was studied as a novel focus. This was done by separating the vegetative symptoms 
from the other symptom scales of depression (dysphoria and retardation), which was 
based on the study by Suzuki et al. 2005 (Suzuki, Aoshima et al. 2005). (I) 
Studies regarding the differences in temperament and character dimensions 
between depressed patients with comorbid substance use and depressed patients 
without this comorbidity are limited (Rae, Joyce et al. 2002, Fernandez-Mondragon, 
Adan 2015). In Study II differences in TCI-R scores at baseline and after 6 weeks of 
treatment between these two groups were explored in a sample with larger numbers 
of patients than in the earlier study (Fernandez-Mondragon, Adan 2015) and the 
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prospective design of Study II provided information about different phenotypes of 
these disorders with a novel method. (II) 
The associations between different temperament and character dimensions and 
depression recovery have been widely studied, but the associations between changes 
in these dimensions and antidepressive treatment outcome is a less studied subject 
although some findings have been reported (Corruble, Duret et al. 2002). In Study 
II the focus was particularly on the possible interactive effects of AUP with 
temperament and character change on antidepressive treatment response as a novel 
focus. (II) 
In Study III a mixed effects multivariate model was used to analyze the factors 
predicting the outcome of depression (MADRS scores) across three different time-
points (at 6 weeks, 6 months, and 24 months). This statistical method made it 
possible to fit individual-specific slope and intercept terms and to achieve greater 
precision in model fitting and parameter estimation than in earlier studies with a 
multiple model approach. (III) 
Because the average duration of depressive episodes is 6 months, the follow-up 
period up to 6 months is an appropriate juncture to assess response to antidepressive 
treatment, whereas a follow-up period up to 24 months is likely to reflect the long-
term outcome considerably better, also including relapses and recurrences of 
depressive episodes (Kupfer 1991, Solomon, Keller et al. 1997). Therefore it was 
important to study the outcome across both stretches of time in Study III to analyze 
the predictors of depression recovery more comprehensively (Solomon, Keller et al. 
1997). However, it is possible that traits associated with response to treatment could 
be different from traits predisposing to recurrence of episodes and such a hypothesis 
could be tested in future studies in naturalistic samples (Farmer, Seeley 2009). (III) 
The cluster model yielded four different combinations of the four temperament 
dimensions. Such a method arguably provides profiles that reflect a more 
comprehensive combinations of individual temperament-oriented behaviors in 
patients (Miettunen, Raevuori 2012). There are only few earlier studies in which more 
comprehensive temperament profiles have been analyzed in the context of 
psychopathology and to the best of our knowledge there are no earlier studies 
predicting anxiety disorder comorbidity with the temperament profiles provided by 
cluster analysis (Matsudaira, Kitamura 2006, Grucza, Przybeck et al. 2003). (IV) 
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6.7.2 Limitations 
In the studies within the ODS cohort (II-IV) the ‘real-life’ setting, broad inclusion 
criteria, and few exclusion criteria posed some challenges and limitations. However, 
this broad inclusion approach provided results of high clinical relevance and 
generalizability. The studied cohort comprised diverse patients with at least moderate 
depressive symptomatology with marked comorbidity and recurrent MDD episodes, 
however, a vast majority of patients had a diagnosis of MDD. Some of the patients 
studied used other substances besides alcohol, which may have affected the results 
in this study on the effects of alcohol use. Although the use of other substances was 
infrequent and monitored with MINI as well as a question of use of other substances 
during the prior year, no data was collected on the type of substances used, nor were 
any biological samples studied to verify the accuracy of the self-reports. The 
prescribed psychopharmacological medications were diverse, but most of the 
patients were prescribed either SSRI or SNRI. The clinical efficacy of the prescribed 
medication was evaluated by a psychiatrist (and changed if necessary) and adherence 
to medical treatment was monitored. (II-IV) 
We observed the anticipated uneven gender distributions between the non-AUP 
and AUP groups. Because of this, however, multivariate analyses as well as gender-
wise divisions were required in addition to bivariate comparisons in analyzing the 
patients’ temperamental differences. These multiple statistical analyses could lead to 
type 1 errors as Bonferroni correction (or equivalent) was not used. However, the 
bivariate analyses were only exploratory in nature and the final interpretation of the 
results was made according to the multivariate analysis. (II) 
In Study III there was marked dropout, especially by the 24-month follow-up, 
which necessitated data imputation for the main analysis. The method of last 
observation carried forward was considered suitable in the follow-up with multiple 
measurement points. Because the naturalistic study setting allowed patients to 
continue in the study even if they had failed to attend at some earlier point, the risk 
that the LOCF protocol would have markedly influenced the results study by not 
detecting relapses in patients was considered low. (III) 
The lack of non-depressed controls in Study IV limits the generalizability of these 
results outside depressed populations, i.e. these temperament clusters may only be a 
characteristic of depressed patients. Because of the high level of alcohol use problem 
comorbidities in the ODS sample the results may be applicable only to depressed 
populations in which patients with SUD comorbidities are not excluded. Moreover, 
the temperament profiles were assessed when the patients displayed depressive 
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symptoms, which is likely to have resulted in higher HA scores in the studied 
population (Kampman, Poutanen 2011). However, depression severity was 
controlled for in the regression models to avoid the bias of higher risk of anxiety 
disorders found in more severely depressed patients. (IV) 
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7 CONCLUSIONS AND CLINICAL IMPLICATIONS 
1. The vegetative symptoms of depression together with temperament profiles and 
age were significant predictors of antidepressant treatment response. The effect of 
temperament profile alone was modest but, combined with vegetative symptoms of 
depression, their explanatory power was more marked. These findings suggest that 
the association between temperament profile and antidepressive treatment outcome 
could be mediated in part by the vegetative symptoms of depression and that there 
could be an association between these two in the biological background of MDD. 
(I) 
2. In Study I MDD patients could be divided into distinct temperament clusters with 
different severity of depression and outcomes of antidepressant treatment. In 
practice this means that temperament profiles could differentiate between groupings 
of MDD patients with different outcomes for antidepressant treatment. (I) 
3. Depressed patients with alcohol use problems had lower Self-Directedness and 
Persistence and higher Novelty Seeking than did depressed patients without the 
comorbidity. In clinical practice, this difference in temperament and character 
profiles could be reflected as depressed patients with alcohol use problems being 
more enthusiastic about trying new treatments, but less adherent to treatment. (II) 
4. Changes in Reward Dependence and lower Self-Directedness in AUP patients 
could reflect differences in the biological mechanisms associated with depressive 
symptomatology between patients with alcohol use problems and those without. 
Over acute treatment duration, the increase in Self-Directedness and decrease in 
Self-Transcendence were associated with alleviation of depression in depressed 
patients without marked alcohol use problems. In contrast, no changes were 
observed in any character dimensions in patients with alcohol use problems 
suggesting that these patients may benefit less from behavioral activation therapy at 
the acute stage (0 to 6 weeks) of treatment. (II) 
 118 
5. High Reward Dependence was associated with better anti-depressive treatment 
outcome in two-year follow-up, which is possibly a characteristic of depressed 
patients with alcohol use problems. Harm Avoidance and Self-Directedness were 
not predictors of depression outcome when alcohol use problems were controlled 
for. (III) 
6. Temperament clusters with unique dimensional profiles were specifically 
associated with different anxiety disorders in the depressed patients of Study IV. 
More specifically, Novelty seekers temperament was associated with panic disorder, 
Reserved with generalized anxiety disorder, Wearied with social anxiety disorder, and 
Persistent with lower risk of anxiety disorder comorbidities. The results in Study IV 
suggest that TCI-R could offer a valuable tool for predicting the risk of anxiety 
disorders in diverse depressed patients. (IV) 
7.1 Implications for future research 
In Study I the vegetative symptoms of depression together with temperament 
clusters were a marked predictor of depression outcome at 6 weeks. The follow-up 
of 6 weeks can be considered short for analyzing outcome of MDE and studies with 
6-month follow-up might yield results with more significant clinical implications. 
Another interesting line of study would be to analyze whether vegetative symptoms 
of depression are associated with depression recovery in patients in some specific 
temperament cluster. 
In Studies II and III increase in RD at early stages of antidepressive treatment as 
well as high RD at 6 weeks were associated with positive outcome in depression 
recovery over 2-year follow-up. This association between Reward Dependence and 
depression outcome could be a characteristic of depressed population with prevalent 
alcohol use problems and this finding should be confirmed in other studies with 
naturalistic samples controlling for substance use. Future studies could also analyze 
if increase in RD is associated with depression recovery in patients with some 
specific temperament profile. BA and MI were used as psychosocial interventions in 
the treatment of the patients in ODS cohort and one interesting study subject in 
future could be to analyze whether increase in RD modifies the effect of these 
interventions on depression recovery. 
It is possible that the temperament clusters found in Study IV reflect 
endophenotypes predisposing to different disorders, 1) because temperament 
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presents relatively stable traits and 2) because the temperament clusters were 
associated with different disorders. The temperament clusters could be more closely 
associated with the biological background of psychiatric symptoms than with 
categorical diagnoses or separate temperament traits and could help in the search for 
biomarkers for psychopathology (Service, Verweij et al. 2012). Testing of the 
possible associations between temperament clusters and candidate genes of anxiety 
disorders would therefore be interesting to perform in further studies (Sharma, 
Powers et al. 2016).  
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INTRODUCTION
According to the psychobiological model of temperament 
and character1 the human temperament can be divided into 
four different independent dimensions and character into 
three different dimensions. The temperamental features are: 1) 
the behavior in relation to new or pleasure-producing stimuli 
(novelty seeking, NS), 2) behavioral inhibition in relation to 
18  Copyright © 2014 Korean Neuropsychiatric Association  
issues which may lead to negative consequences (harm avoid-
ance, HA), 3) continuing of behavior that has earlier been suc-
cessful in the hope of reward (reward dependence, RD), and 
the tendency to maintain certain behavior despite frustration 
(persistence, P).1 These temperament dimensions are suggest-
ed to be connected with central neurotransmitter circuits in 
the central nervous system: dopamine (novelty seeking), se-
rotonin (harm avoidance) and norepinephrine (reward de-
pendence).2 The three dimensions of character mature in adult-
hood and influence personal and social effectiveness by insight 
learning about self-concepts. Self-concepts vary according to 
the extent to which a person identifies the self as 1) an autono-
mous individual (self-directedness, SD), 2) an integral part of 
humanity (cooperativeness, C), and 3) an integral part of the 
universe as a whole (self-transcendence, ST).1
The Temperament and Character Inventory (TCI) has been 
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used in general population studies and in studies including 
patients with major depressive disorder (MDD) to assess how 
different temperament dimensions are associated with this 
disorder.1 HA has reportedly been higher in MDD patients 
than in general population3-9 and has been state dependent 
in MDD.5,6 HA has also been associated with depressive symp-
toms in general population.10-12 HA, RD and NS have been 
found to have trait-like characteristics that are related to the 
familial occurrence of depression.4 High HA has been report-
ed to predict poor treatment outcome.8,13-15
HA also seems to have a trait-like characteristic, reflecting 
genetic susceptibility in depression prone subjects.4,16 It seems 
that HA is both a state- and trait-dependent variable in MDD.17 
However, one study using the Hospital Anxiety and Depres-
sion Scale (HAD), which excludes somatic symptoms, found 
no association between HA and MDD.18 This finding may 
suggest that HA is connected specifically to the somatic com-
ponent of MDD. The contribution of other temperament di-
mensions in MDD is somewhat controversial or limited. Low 
RD may be associated with MDD and depressive symptoms in 
general population,4 but the results are unequivocal.10,19 NS 
seems to be state dependent in MDD and altogether lower in 
MDD patients.4,11 However, high NS has been associated with 
history of suicide attempts in general population.20 In one 
study P was a state marker in depression.17 
In a study by Grucza et al.20 different combinations of tem-
perament dimensions were associated with different depres-
sive symptoms. It has been proposed that the symptoms of 
MDD consist of clusters, which are linked to distinct genetic 
mechanisms which when combined in one individual, can 
lead to a diagnosable psychopathology.21 Suzuki et al.22 pro-
posed a three-factor model of the MADRS to differentiate the 
vegetative symptoms (somatic symptoms) observed in a pa-
tient group. This three-factor model has been used in some 
studies with MDD patient samples.23-25 It has been proposed 
that the vegetative symptoms are connected to enhanced ex-
pression of 5HT2A receptors.25 We found no studies address-
ing the association of temperament and vegetative symptoms 
of MDD. The present study analyzes if temperament profiles 
in association with vegetative symptoms explain the antide-
pressant treatment response in MDD patients and if the se-
verity of depression is associated with current temperament 
clusters. 
METHODS 
A hundred Finnish outpatients were recruited from sec-
ondary outpatient services, primary health care and by news-
paper advertisements during the years 2002–2006 in the area 
of Tampere in southern Finland. The study was approved by 
the local Human Subjects Review Committee and subjects 
participated having given informed, voluntary, written con-
sent. The recruitment resulted in 41 female and 59 male out-
patients, aged 19–72 yrs (mean 40.7 years, SD±14.0). Patients 
met the criteria for major depressive episode according to 
the Diagnostic and Statistical Manual of Mental Disorders, 
fourth edition (DSM-IV). All patients were diagnosed by a 
psychiatrist and the severity of their depression was evaluat-
ed with the Montgomery-Åsberg Depression Rating Scale 
(MADRS). Those patients who scored 20 or higher at base-
line MADRS were included in the study. Patients with severe 
somatic illness or medication affecting their mood, other sig-
nificant psychiatric disorders (bipolar illness, psychosis or 
severe personality disorders) or patients with alcohol or sub-
stance abuse were excluded from the study. Eighty-six patients 
completed the entire study according to the protocol and were 
included in the final analysis.26 Study data was collected on 
three occasions. At the first visit basic sociodemographic data 
was collected: gender, age, marital status, education, workplace 
before the sick leave, somatic illnesses and their medications, 
other psychiatric disorders, and possible use of psychotrophic 
medications. The baseline MADRS form was scored and the 
patients completed the temperament section of the TCI ques-
tionnaire to assess the temperament profile.1 All patients were 
prescribed either citalopram, fluoxetine or paroxetine. Anx-
iolytics and sedative hypnotics as adjuvant treatment and oth-
er medication for concomitant general medical conditions 
were allowed. At the second visit, three weeks after initiation 
of treatment, patients’ adherence to treatment and the dosage 
of the medications were checked. Compliance was evaluated 
by a medication diary kept by the patient. Treatment compli-
ance was deemed sufficient if the patient had taken the medi-
cation on at least 80% of the days in the study period. At the 
third visit, six weeks after the initiation, patients’ adherence 
was monitored again and the MADRS and TCI forms were 
completed again (endpoint data). In the case of possible drop-
outs the necessary patient information on the reasons for 
dropout was also collected. The temperament profiles were 
determined from the baseline TCI data. The vegetative symp-
toms were assessed as the sum of questions three to five in the 
MADRS.22 These are impaired sleep, impaired appetite, and 
inner tension. 
Statistical methods
A two-step cluster analysis was used for the definition of the 
patient’s temperament profile. In our cluster model, we decid-
ed to use three temperament dimensions, NS, HA and RD 
with their baseline scores. In the statistical analysis the pa-
tients were divided into three clusters. 
The differences in continuous variables (MADRS total score, 
20  Psychiatry Investig 2014;11:18-23
A Cluster Model of Temperament in Major Depression
MADRS factor scores and age) between the clusters were cal-
culated with ANOVA. The difference in MADRS change be-
tween low and high vegetative symptom groups was analyzed 
with t-test. Differences between grouping variables were cal-
culated with χ2-statistics. Non-parametric tests were used in 
comparisons in ordinal variables between different clusters 
(used medications, patient compliance). Pearson’s correlation 
coefficients were calculated between MADRS total score and 
vegetative symptom score, both at baseline and endpoint.
In the multivariate analysis all variables included in the 
study and likely to have an impact on either depression severi-
ty or treatment response were used in the models. The effect of 
background variables on clusters was analyzed with a multi-
nominal logistic regression model. Gender, age, severity of 
depression, antidepressant taken and dose, subjective adher-
ence to treatment, and earlier depression episode were used as 
explanatory variables. A linear regression model (ANCOVA) 
was used for testing the effects of temperament clusters and 
other variables on MADRS endpoint scores. The first model 
included temperament clusters and age, and the second model 
temperament clusters, age and the MADRS vegetative symp-
toms (questions 3–5) at baseline as explanatory variables. All 
analyses were performed with SPSS for Windows software 
(version 17.0).
RESULTS
The cluster analysis resulted in the following clusters: LNS/
HHA/LRD, INS/HHA/HRD and HNS/LHA/(HRD) with H 
indicating high level, L low level and I intermediate level on 
the temperament dimensions. In the third cluster RD did not 
reach statistical significance in the clustering model. In the 
first cluster we discovered the most robust slope in the NS 
and HA at baseline. In the second cluster there were elevated 
points in HA. The results of the cluster analysis and MADRS 
scores in each cluster are presented in Table 1.
There were no differences in the distributions of gender 
between the clusters (p=0.23, chi-square test). The patients in 
cluster 1 were older than in other clusters (age mean±SD, 
cluster 1=45.9±11.4, cluster 2=37.4±14.4, cluster 3=38.2±15.3; 
p=0.03, ANOVA). There was no difference between the clus-
ters in the dosages of the medications taken in weeks one to 
three (p=0.48, Kruskal Wallis test), nor in compliance to treat-
ment (p=0.69). Gender, severity of depression, antidepres-
sant taken and dose, adherence to treatment, and earlier de-
pression episode had no effect on the clusters in the multi-
nominal regression model. Age of the patients had a marginal 
effect on clusters (p=0.051) in the multinominal regression 
model.
The correlations between MADRS vegetative symptom 
score with MADRS total score were at baseline 0.73, (p<0.001) 
and at endpoint 0.76, (p<0.001). The MADRS vegetative 
symptom score at baseline had a moderate correlation with 
MADRS endpoint scores (r=0.38, p<0.001), and a non-signifi-
cant correlation with MADRS score change (r=0.13, p=0.26). 
We also analyzed the MADRS score change between patients 
with low (1–7, n=50) and high (8 or more, n=48) vegetative 
symptoms. The difference was close to significant [MADRS 
Table 1. Results of the cluster analysis. All scores except response percentages are indicated as mean±SD
Cluster LNS/HHA/LRD, N=33 INS/HHA/HRD, N=35 HNS/LHA/(HRD), N=30
TCI baseline score
NS 13.9±5.2 19.6±7.1 25.7±4.9
HA 26.8±6.1 27.2±3.6 16.0±4.2
RD 11.8±2.2 18.2±2.5 16.6±3.6
Baseline MADRS* 28.3±6.1 27.3±5.7 25.0±4.4
Factor 1 (dysphoria) 8.5±2.6 7.8±2.2 7.4±1.4
Factor 2 (retardation) 11.7±2.2 12.1±2.7 11.0±2.9
Factor 3 (vegetative symptoms) 7.8±3.1 7.4±2.8 6.4±2.7
Endpoint MADRS** 14.1±9.1 13.5±8.3 8.3±5.5
Factor 1 (dysphoria) 3.7±3.2 3.9±2.7 2.5±1.9
Factor 2 (retardation)***** 6.3±4.5 6.0±3.7 3.4±3.0
Factor 3 (vegetative symptoms) 3.5±2.3 3.7±2.9 2.4±1.9
MADRS score change*** 14.2±7.4 14.3±8.0 16.7±6.0
Response (percentage decline in MADRS)**** 51.6% 51.9% 66.7%
*p=0.05 between groups (ANOVA), **p=0.01 between groups (ANOVA), ***p=0.36 between groups (ANOVA), ****p=0.04 between groups 
(ANOVA), *****p=0.01 between groups (ANOVA). TCI: Temperament and Character Inventory, MADRS: Montgomery-Åsberg Depression 
Rating Scale, NS: novelty seeking, HA: harm avoidance, RD: reward dependence, with H indicating high level, L low level and I intermediate 
level on the temperament dimensions
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change, mean (±SD), low symptoms=13.5 (±5.5), high symp-
toms=16.6 (±8.5), p=0.052, t-test]. There were no differences 
in the MADRS vegetative symptom score at baseline or at end-
point between the different clusters (p=0.17, baseline; p=0.14, 
endpoint, ANOVA). There was a non-significant correlation 
between baseline MADRS dysphoria symptoms and MADRS 
score change (r=0.17, p=0.11). MADRS endpoint scores were 
used as the outcome variable in two linear regression models. 
In the first model age and temperament clusters were used as 
explaining variables. This model explained 10% of the vari-
ance in the MADRS endpoint scores (p=0.04; power 0.69). 
The clusters explained 9% (p=0.02), and age explained 1% 
(p=0.36). In the second model, baseline MADRS vegetative 
symptoms, age and temperament clusters were used as ex-
planatory variables. This model explained 20% of the variance 
in the MADRS endpoint scores (p=0.001; power 0.96 for the 
complete model). In this model the baseline vegetative symp-
toms explained 12% (p=0.001), age 0.2% (p=0.70) and tem-
perament clusters 5% (p=0.12). Using the delta scores of 
MADRS as an outcome variable, and age and temperament 
clusters as explanatory variables (first model), and vegetative 
symptoms, age and temperament clusters as explanatory vari-
ables (second model) resulted in non-significant models (first 
model: ηp2=0.085, p=0.061, power=0.61; second model: ηp2= 
0.096, p=0.087, power=0.60).
DISCUSSION
Our main hypothesis was that temperament clusters in pa-
tients with MDD explain the treatment response. In practice 
this means that different temperament profiles could func-
tion as a classifying factor and that MDD patients could be di-
vided into different groups with different outcomes for anti-
depressant treatment. In our study we used primarily the MA-
DRS endpoint scores as an outcome variable in the multi-
variate analyses. Using the delta scores of MADRS as an out-
come variable resulted in non-significant models although 
there was a trend towards a better response in patients with 
high vegetative symptoms. The present results suggest that 
the combined effect of vegetative symptoms and temperament 
clusters is important in relation to the depression treatment 
outcome when measured as post-treatment symptoms. How-
ever, these factors showed a non-significant effect when pre-
dicting the change in depression scores during treatment. This 
finding may be due to both the temperament clusters and pre-
treatment vegetative symptoms representing depressive traits 
less connected with the magnitude of symptom alleviation 
during treatment.
The approach of using TCI temperament clusters for pre-
dicting the response to antidepressant treatment in MDD pa-
tients is novel. In several studies individual dimensions of tem-
perament have been used as precursors. Two earlier studies 
with general population samples have used combinations of 
high or low temperament traits for predicting different clini-
cal features, but in these studies no cluster analysis method 
was used in classifying the temperament traits.18,20 This study 
did not include the character dimensions of the TCI (SD, C, 
ST) in the explanatory model. Adding the character traits to 
the predictors in the statistical model might have increased 
its predictive value regarding antidepressant response, since 
many studies have demonstrated that SD exhibits a state/trait 
marker in depression.9,27,28 
There were some limitations concerning our patient sam-
ple and study setting. In contrast to some earlier studies, our 
patient sample comprised solely outpatients. This may have 
resulted in lower intensity of symptoms as reflected by the 
MADRS scores. Temperament profiles could have had more 
explanatory power if the patient sample had included inpa-
tients with more severe depression. The patients were deemed 
compliant with medication if they took the prescribed medica-
tion at least 80% of the time, which can be regarded as a mod-
erate level of treatment compliance, and the data were col-
lected from patient reports, which in some cases may produce 
unreliable results. Nor did the patients receive any specific 
psychological treatment during the study, but were treated in 
a standard secondary outpatient setting.
As the relationship between temperament and vegetative 
symptoms of depression has not previously been studied, a 
post-hoc analysis with vegetative symptoms was performed 
in this study. This was done by separating the vegetative symp-
toms from the other symptoms of depression (dysphoria and 
retardation) which was based on the study by Suzuki et al.22 
It has been proposed that the vegetative symptoms are con-
nected to enhanced expression of 5-HT2A receptors.25
To assess patients’ temperament profiles we used Cloninger’s 
TCI, which has been widely used, validated and shown to be 
reliable in studies on general population and MDD patients.1 
Temperament profiles were determined by clustering the dis-
tributions in the three temperament dimensions. Due to the 
limited sample size, the number of clusters was determined 
as three in the analysis to yield groups of reasonable size. The 
clustering method was able to differentiate between the three 
combinations of temperament traits, although in the third 
cluster the difference on the dimension RD did not reach sta-
tistical significance. It has been suggested that high RD corre-
lates negatively with depressive symptoms, but the evidence 
is contradictory.3,4,9,10 The clusters differed on the dimension 
NS as it was low in cluster one, intermediate in cluster two and 
high in cluster three. The third cluster (HNS/LHA/HRD) prob-
ably reflects more impulsive depression, and diverges substan-
22  Psychiatry Investig 2014;11:18-23
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tially from the typical temperament profile of an MDD patient, 
and in this study from the other two temperament clusters. 
This may explain why this subgroup of patients recovered bet-
ter from the retardation symptoms than did the other patients. 
In addition, this group showed a higher percentage of MADRS 
changes. This difference in response could be due to the pre-
dictive effect of HA on MDD remission shown in our earlier 
report.29 In the first cluster we discovered the most distinct 
sloping in the distribution of the NS and HA dimensions at 
baseline. According to earlier reports the subgroup in this 
cluster has an increased risk for MDD and their depression is 
more disease-like.4-6,9 NS has been negatively associated with 
depressive mood state and tends to be at a low level in MDD 
patients.4 The clusters might thus reflect an underlying factor 
explaining clinically different symptoms profiles and course 
of depression.
In our study the temperament clusters were associated with 
both baseline and endpoint depressive symptoms and with 
the treatment response. The findings suggested that depression 
was most severe and difficult to treat in cluster one patients. 
In clusters one and two, in which HA scores were high, the re-
sponse in percentage decline of MADRS scores was lower than 
in cluster three. These findings concur with those of earlier 
studies on the association between HA and depression.4,5,7-9,15,30 
Although the depression vegetative symptom score is only 
a subscale of MADRS, it may be considered a separate dimen-
sion in depression symptomatology.22 MADRS total scores 
and vegetative symptoms showed a strong correlation at both 
baseline and endpoint. However, the correlation between 
MADRS endpoint total score and baseline vegetative symp-
tom score was much lower, suggesting that the vegetative 
symptoms are a separate entity within depressive symptom-
atology.22 Therefore we considered it justified to study the im-
pact of baseline vegetative symptoms on total symptoms at 
endpoint.
In the linear regression models our aim was to predict the 
treatment response in MDD patients. The first model was de-
signed to reveal the impact of temperament clusters on treat-
ment outcome. When patient’s age was also taken into ac-
count as an explanatory variable, the temperament clusters 
had only modest explanatory power. Age as such did not func-
tion as an explaining variable in this model at a significant 
level. In the second model we wanted to ascertain if there 
was an interaction with temperament clusters and vegetative 
symptoms of MDD. Therefore we added the vegetative symp-
tom scores to the model as an explanatory variable. In this 
model, the vegetative symptoms explained about twice as 
much as the clusters of the variance of endpoint MADRS 
scores. However, the whole model explained as much as one 
fifth of the variance in response to SSRI treatment. The role 
of the interaction between temperament clusters and vegeta-
tive symptoms on treatment result has to be interpreted cau-
tiously, as the impact of clusters on treatment response in the 
final model was marginal. It seems that the vegetative symp-
toms of depression, in addition to a certain temperament pro-
file, is a marked predictor for antidepressive treatment out-
come. It is, however, possible that the vegetative symptoms 
alone have a more marked impact in both severity and re-
sponse of depression compared to temperament. Even though 
the differences between the clusters in depression severity 
were marginal, our findings suggest an association between 
skewed temperament profile and severity of MDD. It is pos-
sible that the temperament profile can function as a predis-
posing factor to depression or have an impact on the clinical 
profile and course of depression. 
In conclusion our study showed that MDD patients could 
be divided into different temperament clusters with different 
severity and outcomes of antidepressant treatment. The vege-
tative symptoms of depression combined with temperament 
profiles and age predicted antidepressant treatment response. 
The effect of the temperament profile alone was modest but, 
combined with vegetative symptoms of depression their ex-
planatory power was more marked, suggesting that there 
could be an association between these two in the biological 
basis of MDD. 
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a b s t r a c t
There is limited knowledge on the relationship between temperament and character proﬁles and sub-
stance abuse comorbidity in depressed patients. We recruited 127 depressed patients without alcohol
use problems (non-AUP) and 89 depressed patients with alcohol use problems (AUP). We assessed all
patients using the Temperament and Character Inventory (TCI-R) at baseline and after 6 weeks of
treatment. Using univariate general linear models (GLMs), we analyzed differences in TCI-R between AUP
and non-AUP. GLMs were also used in analyzing the associations between TCI-R changes and anti-
depressive treatment responses measured with changes in Montgomery Åsberg Depression Rating Scale
score (ΔMADRS). Alcohol use explained independently signiﬁcant proportions of the variation in Novelty
Seeking, Self-Directedness, and Persistence. Reward Dependence score change explained 14.1% of the
ΔMADRS in AUP, but was non-signiﬁcant in non-AUP. Character score changes in Self-Directedness and
Self-Transcendence explained together 14.1% of ΔMADRS in non-AUP, whereas they were all non-sig-
niﬁcant in AUP. AUP compared with non-AUP patients had lower Self-Directedness and Persistence and
higher Novelty Seeking scores. Detected changes in Reward Dependence and lower Self-Directedness in
AUP patients could be reﬂective of different biological mechanisms associated with depressive symp-
tomatology in alcohol abuse. Changes in character are associated with acute treatment response in non-
AUP.
& 2016 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Because of the extensive overlapping of different psychiatric
disorders, the need for new integrative hypotheses regarding
psychopathology has been proposed. It is argued that tempera-
ment could serve as a basis for this kind of integrative model
(Clark, 2005). Depressive and alcohol-related disorders represent a
major burden of disease in western countries (Ferrari et al., 2013;
Laramee et al., 2013). Comorbidity with other psychiatric and
substance use disorders (SUD) in patients with major depression
(MDD) is marked, and one fourth suffer from comorbid alcohol use
disorder (Davis et al., 2006; Melartin et al., 2002). Individuals with
MDD and concurrent SUD are more likely than those without SUD
to be younger, male, and either divorced or never married (Davis
et al., 2008). Familial and genetic factors seem to have an effect on
the co-occurrence of MDD and SUD, with reciprocal causation of
the two supported by a large twin-pair study (Lyons et al., 2006).
According to the psychobiological model of temperament
(Cloninger et al., 1993), human temperament is largely genetically
determined and forms in early childhood. It consists of four dif-
ferent dimensions, including 1) Novelty Seeking (NS; initiation or
activation of appetitive behavior in response to novelty), 2) Harm
Avoidance (HA; inhibition of behavior in response to signs of
punishment), 3) Reward Dependence (RD; maintenance of beha-
vior in response to cues of social reward), and 4) Persistence (P;
maintenance of behavior despite frustration). These dimensions
may be associated with neurotransmitter circuits in the central
nervous system (Cloninger, 1986). Indeed, many ﬁndings support
the biological basis of the model (Cloninger, 2000). This model also
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comprises character dimensions, which are moderately heritable,
mature in adulthood, and inﬂuence personal and societal effec-
tiveness on three levels: 1) intrapersonal (Self-Directedness, SD),
2) interpersonal (Cooperativeness, C) and 3) transpersonal (Self-
Transcendence, ST) (Cloninger et al., 1993; Cloninger, 2000).
These dimensional temperament and character proﬁles can be
assessed using the Temperament and Character Inventory (TCI-R)
(Cloninger, 2000). Several studies have suggested the presence of
differences between patients with psychiatric disorders and
healthy individuals and although temperament is considered re-
latively stable throughout human lifespan, also state-dependent
alterations are present in depression possibly because of biological
changes (Kampman and Poutanen, 2011). Studies comparing pa-
tients with MDD and the general population have shown higher
HA scores in patients, and HA has also been shown to be both
state- and trait-dependent in MDD (Kampman and Poutanen,
2011; Farmer et al., 2003; Richter et al., 2003). Patients with MDD
tend to score lower on SD and C, and SD scores are inversely
correlated with depressive symptoms (Bensaeed et al., 2014; Hur
and Kim, 2009; Nery et al., 2009). In MDD patients, low SD is as-
sociated with childhood trauma and recurrence of depressive
episodes (Asano et al., 2015; Perna et al., 2014).
High NS scores are associated with substance use problems,
predict the development of SUD in high risk groups (Sher et al.,
2000), and are related to alcohol relapses, anhedonia and craving
in detoxiﬁcation in substance dependence (Evren et al., 2012;
Martinotti et al., 2008; Zilberman et al., 2003). Additionally, high
HA scores are associated with alcohol dependence and craving in
substance dependent patients (De Los Cobos et al., 2011; Sher
et al., 2000). Conversely, SD scores tend to be lower in poly-
substance users, and low SD has been associated with DSM-IV
cluster B personality disorders in SUD patients (Ball et al., 1997;
Yoon et al., 2007).
In MDD patients with a lifetime alcohol dependency diagnosis
compared with MDD patients without alcohol dependency, NS
was found to be higher whilst P and C are lower (Rae et al., 2002).
Another study of exclusively detoxiﬁed male alcohol dependent
patients found severity of depression and anxiety were predicted
by high HA and ST scores, and low P, SD, and C scores (Evren et al.,
2009). Patients with dual diagnosis (substance use disorder and
severe mental illness) have higher NS and HA and lower RD, SD
and C when compared to population norms, and different per-
sonality traits vary according to the mental illness (MDD, bipolar
disorder or schizophrenia) (Marquez-Arrico et al., 2016; Marquez-
Arrico and Adan, 2016). One study has addressed differences in
personality between male patients with dual diagnosis and severe
mental illness and patients with dual diagnosis seem to have
higher NS and lower SD (Fernandez-Mondragon and Adan, 2015).
Studies regarding differences in temperament and character
dimensions between depressed patients with comorbid substance
use and depressed patients without the comorbidity are limited
(Rae et al., 2002) and to our knowledge only one study has ad-
dressed this earlier (Fernandez-Mondragon and Adan, 2015). In
this study, we explore differences in TCI-R scores at baseline and
after 6 weeks of treatment between these two groups with a more
signiﬁcant number of patients. We hypothesized that depressed
patients with alcohol use problems (AUP) would have different
temperament and character proﬁles compared with depressed
patients without AUP. Human personality seems to be more dy-
namic in nature than has been earlier thought and recent research
has been focused also on the changes in personality and their
association with depression outcome (Roberts and DelVecchio,
2000; Klein et al., 2011; Corruble et al., 2002). We aimed to use
changes in TCI-R dimensions to predict antidepressive treatment
outcome during the ﬁrst 6 weeks of treatment. SUD comorbidity
affects the course of depression and we hypothesized that the
different changes in temperament and character between the two
studied patient groups would associate with antidepressive
treatment outcome.
2. Methods
2.1. Participants
Between 2009 and 2013, we recruited 242 patients from ﬁve
outpatient clinics and one inpatient unit in the Seinäjoki Hospital
District in Finland (population 200,000). The patients were re-
ferred to secondary care psychiatric services (specialized care
provided by district hospitals) because of depressive symptoms,
anxiety, self-destructiveness, insomnia or alcohol-related pro-
blems. For inclusion, patients had to have a Beck Depression In-
ventory (BDI, Version 1A) score of at least 17 (Beck et al., 1996). At
screening performed by a clinician patients with a likely or veriﬁed
psychotic disorder (ICD-10 F2* diagnosis) or organic brain disease
were excluded. Patients were aged 17–64 years (mean 38.6 years,
SD712.2). Further sociodemographic data are presented in
Table 1a. The study was approved by the local Human Subjects
Review Committee and subjects gave informed written consent.
Table 1a
Sociodemographic data of the patient sample.
Men Women AUP non-AUP Total
N % N % N % N % N %
Total 88 40.7 128 59.3 89 41.2 127 58.8 216 100
Marital statusa
Single 33 37.5 37 28.9 37 41.6 33 26.0 70 32.4
Married or
cohabiting
37 42.0 67 52.3 33 37.1 71 55.9 104 48.1
Divorced 18 20.5 21 16.4 18 20.2 21 16.5 39 18.1
Widowed 0 0 2 1.6 0 0 2 1.6 2 0.9
Educationb
Primary school 4 4.5 2 1.6 2 2.2 4 3.1 6 2.8
Elementary school 26 29.5 27 21.1 28 31.5 25 19.7 53 24.5
Institute graduate 9 10.2 22 17.2 11 12.4 20 15.7 31 14.4
Vocational school 31 35.2 51 39.8 34 38.2 48 37.8 82 38.0
Graduate student 10 11.4 7 5.5 5 5.6 12 9.4 17 7.9
Polytechnic or
university
8 9.1 18 14.1 8 9.0 18 14.2 26 12.0
Work status before
sick leavec
Employed 37 42.0 65 50.8 38 42.7 64 50.4 102 47.2
Unemployed 40 45.5 28 21.9 37 41.6 31 24.4 68 31.5
Housewife/husband 0 0 8 6.3 0 0 8 6.3 8 3.7
Pensioner 4 4.5 10 7.8 3 3.4 11 8.7 14 6.5
Student 6 6.8 15 11.7 9 10.1 12 9.4 21 9.7
Self reported history
of depression
episoded
59 67.0 83 64.8 65 73.0 77 60.6 142 65.7
First degree family
history of
depressione
31 35.2 52 40.6 32 36.0 51 40.2 83 38.4
First degree family
history of bipolar
disorderf
3 3.4 10 7.8 4 4.5 9 7.1 13 6.0
Abbreviations: AUP¼alcohol use problems.
a χ2¼9.59, p¼0.02 between AUP and non-AUP.
b χ2¼5.68, p¼0.3 between AUP and non-AUP.
c χ2¼13.47, p¼0.009 between AUP and non-AUP.
d χ2¼3.50, p¼0.06 between AUP and non-AUP.
e χ2¼0.32, p¼0.6 between AUP and non-AUP.
f χ2¼0.59, p¼0.4 between AUP and non-AUP.
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2.2. Procedures
After screening 26 patients dropped out and 216 patients were
analyzed. Demographic and clinical assessments were conducted
at baseline during the ﬁrst visit at secondary care unit (socio-
demographic data; Alcohol Use Disorders Identiﬁcation Test (AU-
DIT) (Bohn et al., 1995); Montgomery Åsberg depression rating
scale (MADRS) (Montgomery and Asberg, 1979); Temperament
and Character Inventory (TCI-R) (Cloninger, 2000); and The Mini
International Neuropsychiatric Interview 5.0 (MINI) (Sheehan
et al., 1998). The MADRS and TCI-R were administered again at
6 weeks during the second visit at secondary care unit. The pa-
tients were diagnosed according to DSM-IV criteria with MINI that
was administered to 204 patients (data missing in 12 cases) by a
psychiatrist or a trained research nurse. We deﬁned the main di-
agnosis for the patients according to clinical standards and con-
sidered depressive disorders as primary, anxiety disorders as
secondary and other diagnoses as tertiary. One hundred and
eighty-one patients (88.7%) had MDD, 8 (3.9%) had dysthymic
disorder, 11 (5.4%) had an anxiety disorder, 3 (1.5%) had self-de-
structiveness, and one (0.5%) alcohol use disorder as a main di-
agnosis. Sixty-seven percent of patients with mood disorder as a
primary diagnosis had comorbid anxiety disorders. In the total
sample, 65.7% of the patients reported having recurrent episodes
of MDD.
At recruitment, patients completed the AUDIT questionnaire.
Patients were divided into two groups according to AUDIT scores:
patients with no alcohol use problems (non-AUP) had scores o11
and patients with alcohol use problems (AUP) had scores Z11.
This cut-off point was chosen because in Finnish clinical practice it
indicates signiﬁcantly increased risk of harm due to alcohol (Babor
et al., 2001). After dropout these criteria produced 127 non-AUP
patients (mean age 38.5 years, SD712.8) and 89 AUP patients
(mean age 38.7 years, SD711.4). The MINI was administered to 82
AUP patients (data missing in 7 cases) and 61 (74.4%) of these
patients ﬁlled the DSM-IV criteria for current alcohol use disorder
(AUD). Eight (9.8%) of the patients with AUD ﬁlled the criteria for
some other current SUD and 16 (19.5%) reported use of some other
substance at least once during prior year.
The AUP group had a greater proportion of male patients (AUP
64.0% vs. non-AUP 24.4%, χ2¼34.05, po0.001; odds ratio (OR)¼
5.5, 95% conﬁdence intervals (CI)¼3.0–10.0). Additional baseline
data are presented in Table 1b. All recruited patients were treated
in secondary care psychiatric services according to a speciﬁc
treatment intervention. All patients received behavioral activation
therapy (BA) (Kanter et al., 2010), whilst AUP patients also received
motivational interviewing (MI) (Miller and Rose, 2009) prior to
this. The treatment intervention procedure and related educa-
tional program have been described in more detail elsewhere (see
ClinicalTrials.gov Identiﬁer NCT02520271 (Ostrobothnia Depres-
sion Study (ODS), 2016) and (Lindholm et al., 2015)).
On entering the study, patients' medication was evaluated by a
psychiatrist. Antidepressant medication was prescribed to 184
patients (85%) with mean ﬂuoxetine equivalent daily doses of
32.5 mg (SD718.1). Of these, 80% had either a SSRI or SNRI as a
primary antidepressant. Adherence to antidepressants was as-
sessed using a paper and pencil diary during the ﬁrst 6 weeks. The
form was returned at 6 weeks by 99 of the 149 patients (66.4%)
who had been prescribed antidepressant medication and hadn't
dropped out from the study. Ninety of these (90.9%) had used 80%
or more of the medication prescribed. Sixty patients (28%) were
prescribed antipsychotic medication with daily chlorpromazine
equivalent doses of 118.3 mg (SD7133.5, median¼77.1,
IQR¼91.6). Prescribed antipsychotics included quetiapine in 33
(55%) and other atypical antipsychotics in 7 (12%). Nine patients
were treated with a dosage equal to or higher than 200 mg of
chlorpromazine per day. Antipsychotic medications were more
common in the AUP than the non-AUP group (40.4% vs. 18.9%,
χ2¼12.12, p¼0.001, OR¼2.915).
At 6 weeks, 39 patients (26.9%) dropped out of the study. The
dropout rate was greater in AUP than non-AUP patients (29% vs.
10%, χ2¼12.74, po0.001), but there were no differences between
genders. Dropouts and study completers had similar scores on the
MADRS and TCI. However, AUDIT scores were higher in the
dropout group than in the total sample (16.85710.57 vs.
9.1370.69, po0.001). Corresponding analyses revealed similar
results in male and female patients separately.
2.3. Statistical methods
Crohnbach's α was calculated to assess the reliability of each
TCI-R dimension. We used independent samples t-tests to analyze
differences between continuous variables (TCI, MADRS, and AUDIT
scores) in AUP and non-AUP, between genders, and in the dropout
analyses. We analyzed TCI dimension and MADRS changes from
baseline to 6 weeks using paired samples t-tests. Differences be-
tween grouping variables were calculated with χ2-statistics.
Potential explanatory variables for univariate analysis were
explored with Pearson correlation coefﬁcients. First, we built
univariate general linear models (GLMs) to predict each TCI di-
mension at baseline and at 6 weeks with age, and either gender or
AUP as explanatory variables. Second, we built a model which
included all three variables together with baseline MADRS as ex-
planatory variables. Third, we built GLMs to explain MADRS score
change from baseline to 6 weeks (ΔMADRS) with either 1) tem-
perament dimension changes (NS, HA, RD, P) or 2) character di-
mension changes (SD, C, ST) used as explanatory variables, and
age, gender, and AUP in all models. Effect sizes for complete
models and individual variables are reported as partial eta square
(ηp2). All analyses were performed with SPSS for Mac or SPSS for
Windows software (version 21.0, IBM Inc. Armonk, New York,
USA).
3. Results
The Crohnbach's α values for each TCI-R dimension at baseline
were: NS 0.85, HA 0.88, RD 0.89, P 0.92, SD 0.86, C 0.85, ST 0.85.
Table 2 presents scores for each TCI-R dimension and for the
MADRS at baseline and 6 weeks. AUP had higher NS and lower P,
SD and C scores at baseline compared to non-AUP. The mean dif-
ferences between non-AUP and AUP at baseline were: NS¼7.64
(SD72.30), p¼0.001; P¼6.54 (2.80), p¼0.021; SD¼8.08 (2.49),
p¼0.001; and C¼8.41 (2.55), p¼0.001. At six weeks AUP had
higher NS and lower SD compared to non-AUP. The mean differ-
ences between non-AUP and AUP at six weeks were: NS¼6.40
(SD72.59), p¼0.014; SD¼11.00 (2.59), po0.001. Proportion and
signiﬁcance of changes in each measure and differences between
groups are also presented in Table 2.
Results of the GLMs for each TCI-R dimension at baseline and
Table 1b
Baseline scores of BDI and AUDIT between groups.
Men Women AUP non-
AUP
Total
Baseline BDI mean
(7SD)
28.2 (6.70) 27.1 (7.22) 27.7
(6.88)
27.5
(7.14)
27.6
(7.02)
Baseline AUDIT
mean (7SD)
15.0
(10.53)
8.1 (8.17) 20.8
(7.03)
3.9
(3.14)
10.9
(9.79)
Abbreviations: BDI¼Beck Depression Inventory; AUDIT¼alcohol use disorder
identiﬁcation test; AUP¼alcohol use problems.
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6 weeks are presented in Tables 3a and 3b. The models reported in
Table 3a included age and either gender or AUP as explanatory
variables, and the models presented in Table 3b included age,
gender, baseline MADRS score, and patient group (AUP and non-
AUP) as explanatory variables for each TCI dimension at baseline
and at 6 weeks.
We also applied GLM analyses to MADRS score changes from
baseline to 6 weeks (ΔMADRS) as described in Section 2. The
temperament model explained 12.2% (p¼0.003) of the ΔMADRS.
In this model, RD change was the only signiﬁcant explanatory
variable, explaining 4.2% (p¼0.009) of the change. The character
model explained 13.7% (p¼0.001) of the ΔMADRS. In this model,
SD change explained 7.2% (p¼0.001) and ST change explained 3.7%
(p¼0.015) of the ΔMADRS, whilst the other explanatory variables
did not contribute signiﬁcantly to the model.
The above model was also applied to ΔMADRS in the non-AUP
and AUP groups separately. The temperament model was non-
signiﬁcant in explaining ΔMADRS in non-AUP patients (p¼0.141).
However, in AUP patients the model explained 28.3% (p¼0.006) of
theΔMADRS. In this model, RD change explained 14.1% (p¼0.005)
and age explained 11.6% (p¼0.012) of the ΔMADRS. The character
model explained 14.3% (p¼0.007) of the ΔMADRS in non-AUP
patients. In this model, SD change explained 8.0% (p¼0.003) and
ST change explained 5.1% (p¼0.021) of the ΔMADRS. The char-
acter model for the ΔMADRS in AUP patients explained 19.0%
(p¼0.043) of the change. Age explained 9.7% (p¼0.021) of the
ΔMADRS, whilst all character dimension changes did not con-
tribute signiﬁcantly to the model.
The Pearson correlation coefﬁcient between RD change and
ΔMADRS was non-signiﬁcant (r¼0.185, p¼0.054, n¼109) in
non-AUP patients and signiﬁcant (r¼0.377, p¼0.003, n¼59) in
AUP patients. There was a signiﬁcant correlation between SD
change and ΔMADRS in non-AUP (r¼0.301, p¼0.001), but non-
signiﬁcant in AUP patients (r¼0.249, p¼0.058). The correlation
Table 3a
GLM results of two models with age and either gender or AUP as explaining variables with explanatory proportions for each individual explanatory variable demonstrating
their contribution to temperament dimension scores at baseline and at 6 weeks.
Target variable Complete model with age and gen-
der as explaining variables
Age Gender Complete model with age and AUP
as explaining variables
Age AUP
ηp2b p power ηp2a p ηp2a p ηp2b p power ηp2a p ηp2a p
NS baseline 0.139 o0.001 1.000 0.102 o0.001 0.057 o0.001 0.137 o0.001 1.000 0.092 o0.001 0.054 0.001
NS 6 weeks 0.109 o0.001 0.988 0.081 o0.001 0.039 0.008 0.109 o0.001 0.988 0.077 o0.001 0.039 0.008
HA baseline 0.001 0.854 0.074 0.001 0.602 o0.001 0.804 0.006 0.526 0.157 0.001 0.611 0.005 0.310
HA 6 weeks 0.008 0.517 0.160 o0.001 0.797 0.007 0.258 0.005 0.638 0.123 o0.001 0.868 0.005 0.353
RD baseline 0.084 o0.001 0.982 0.008 0.180 0.080 o0.001 0.012 0.274 0.280 0.004 0.332 0.008 0.197
RD 6 weeks 0.068 0.002 0.895 0.008 0.225 0.063 0.001 0.011 0.389 0.213 0.006 0.315 0.005 0.336
P baseline 0.033 0.027 0.672 0.027 0.016 0.009 0.163 0.050 0.004 0.851 0.025 0.019 0.026 0.019
P 6 weeks 0.005 0.629 0.125 0.005 0.347 o0.001 0.800 0.026 0.100 0.469 0.006 0.324 0.021 0.053
SD baseline 0.117 o0.001 0.998 0.080 o0.001 0.053 0.001 0.115 o0.001 0.998 0.072 o0.001 0.051 0.001
SD 6 weeks 0.112 o0.001 0.991 0.064 0.001 0.061 0.001 0.152 o0.001 0.999 0.064 0.001 0.103 o0.001
C baseline 0.153 o0.001 1.000 0.058 o0.001 0.117 o0.001 0.090 o0.001 0.988 0.044 0.002 0.051 0.001
C 6 weeks 0.144 o0.001 0.999 0.056 0.002 0.106 o0.001 0.061 0.004 0.856 0.045 0.005 0.019 0.065
ST baseline 0.021 0.105 0.459 0.019 0.043 0.003 0.431 0.023 0.080 0.507 0.018 0.048 0.005 0.280
ST 6 weeks 0.039 0.031 0.655 0.036 0.012 0.002 0.539 0.042 0.023 0.692 0.038 0.010 0.005 0.330
AUP¼alcohol use problems; MADRS¼Montgomery-Åsberg Depression Rating Scale; NS¼Novelty Seeking, HA¼Harm Avoidance, RD¼Reward Dependence, P¼Persistence,
SD¼Self-Directedness, C¼Cooperativeness, ST¼Self-Transcendence.
Non-signiﬁcant results are in italics and signiﬁcant results are in bold.
a Explanatory proportion of the single factor or covariate for the target variable.
b Explanatory proportion of the complete model for the target variable.
Table 3b
GLM results with explanatory proportions for each individual explanatory variable (age, gender, AUP, and MADRS baseline scores) demonstrating their contribution to
temperament dimension scores at baseline and at 6 weeks.
Target variable Complete model Age Gender AUP MADRS baseline scores
ηp2a p power ηp2b p ηp2b p ηp2b p ηp2b p
NS baseline 0.157 o0.001 1.000 0.097 o0.001 0.026 0.018 0.023 0.027 0.001 0.726
NS 6 weeks 0.124 o0.001 0.984 0.082 o0.001 0.015 0.105 0.017 0.089 o0.001 0.869
HA baseline 0.029 0.185 0.479 0.004 0.355 0.001 0.605 0.006 0.270 0.021 0.036
HA 6 weeks 0.040 0.136 0.533 o0.001 0.960 0.024 0.043 0.015 0.113 0.018 0.078
RD baseline 0.132 o0.001 0.998 0.011 0.122 0.051 0.001 0.001 0.647 0.057 o0.001
RD 6 weeks 0.111 o0.001 0.970 0.009 0.214 0.033 0.018 0.002 0.570 0.053 0.002
P baseline 0.050 0.031 0.746 0.025 0.022 0.001 0.590 0.017 0.057 o0.001 0.852
P 6 weeks 0.031 0.244 0.423 0.006 0.319 0.003 0.442 0.023 0.047 0.003 0.487
SD baseline 0.180 o0.001 1.000 0.103 o0.001 0.014 0.083 0.028 0.016 0.036 0.006
SD 6 weeks 0.200 o0.001 1.000 0.083 o0.001 0.008 0.249 0.066 0.001 0.028 0.028
C baseline 0.176 o0.001 1.000 0.062 o0.001 0.061 o0.001 0.011 0.129 0.024 0.026
C 6 weeks 0.157 o0.001 0.998 0.059 0.001 0.066 0.001 o0.001 0.987 0.021 0.057
ST baseline 0.026 0.248 0.421 0.017 0.061 0.002 0.541 0.002 0.483 0.002 0.479
ST 6 weeks 0.063 0.025 0.770 0.031 0.020 0.001 0.621 0.008 0.235 0.020 0.062
AUP¼alcohol use problems; MADRS¼Montgomery-Åsberg Depression Rating Scale.
Non-signiﬁcant results are in italics and signiﬁcant results are in bold.
a Explanatory proportion of the complete model for the target variable.
b Explanatory proportion of the single factor or covariate for the target variable.
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between ST change and ΔMADRS was signiﬁcant in non-AUP pa-
tients (r¼0.205, p¼0.032), but non-signiﬁcant in AUP patients
(r¼0.119, p¼0.368).
At baseline, correlation coefﬁcients between age and SD, C, and
ST were r¼0.260 (po0.001), r¼0.203 (p¼0.003), and r¼0.134
(p¼0.049), respectively. At 6 weeks, correlation coefﬁcients be-
tween age and SD, C, and ST were r¼0.233 (p¼0.002), r¼0.206
(p¼0.006), and r¼0.193 (p¼0.010), respectively.
4. Discussion
All TCI-R dimensions showed high internal consistency. Our
GLMs to predict TCI-R scores showed the association of alcohol use
problems with high NS, and low P and SD compared to patients
without this comorbidity. Our GLMs to investigate antidepressive
treatment response (ΔMADRS) showed an association between
RD change and ΔMADRS speciﬁcally in the AUP group, high-
lighting the different psychobiological context of this patient
group.
In this study, the temperament proﬁles of non-AUP patients
were similar to previous reports of patients with MDD (Jylhä et al.,
2011; Perna et al., 2014). The baseline temperament proﬁles in our
AUP group had signiﬁcantly higher NS and signiﬁcantly lower P,
SD, and C compared with non-AUP patients, corresponding to the
temperament proﬁles of depressed patients with history of alcohol
dependence (Rae et al., 2002). Clinically, this could mean that
depressed patients with alcohol use problems are more en-
thusiastic to try new treatments, but they may show worse
treatment adherence because of a lack of self-control, cooperation,
and persistence.
High NS is a trait-like characteristic, increasing the risk for
SUDs and as such, it tends to be higher in patients with SUD (Sher
et al., 2000). Accordingly, the AUP group in this study exhibited
higher NS scores compared with non-AUP. Our explanatory model
incorporating age, gender, baseline MADRS scores, and patient
group accounted for one sixth of the variance in baseline NS
scores. Indeed, AUP was a signiﬁcant explanatory variable for
baseline NS scores and there was a trend to signiﬁcance for
6-week NS scores. Severity of depression did not seem to affect NS
scores. Our ﬁndings support the role of NS as a trait-like char-
acteristic increasing risk for SUDs, regardless of depressive
symptomatology. This emphasizes the importance of recognizing
depressed patients showing extravagant lifestyle or thrill seeking
as being in a risk of developing a SUD and ﬁt the treatment
strategy accordingly.
As expected, HA scores in male patients decreased signiﬁcantly
during the 6-week follow up. There was no signiﬁcant change in
female patients or the whole sample. This is inconsistent with
wide evidence regarding the state effect of depression on HA
(Kampman and Poutanen, 2011). However, there seems to be a
depression spectrum disorder associated with family history of
SUDs, recurrent episodes of MDD, higher psychiatric comorbidity,
and female gender (Davis et al., 2007; Winokur and Coryell, 1992).
Given the more lenient exclusion criteria our sample likely con-
sisted more female patients with recurrent depression and SUD or
other psychiatric disorder comorbidities compared to previous
studies of temperament in MDD patients. Not ﬁnding signiﬁcant
change in female patients HA in our study means that in diverse
clinically depressed female patients decrease in harm-avoidant
behavior is not associated with depression alleviation. This can
lead to high recurrence of depression in these patients because
high HA is a trait marker predisposing to depressive episodes
(Kampman and Poutanen, 2011). The alleviation of depression in
these patients might also be more associated with the reward
mechanisms in brain, possibly leading to reward-seeking behavior
such as substance use.
The associations of different temperament and character traits
with depression recovery have been widely studied, but the as-
sociations of different changes in these traits with the anti-
depressive treatment outcome is a less studied subject although
some signiﬁcant ﬁndings have been reported (Corruble et al.,
2002). We particularly wanted to investigate possible interactive
effects of AUP with temperament and character change on re-
sponse as a novel focus. Therefore, we built a GLM for ΔMADRS,
incorporating age, gender, AUP, and temperament dimension
changes as explanatory variables. In this model, RD dimension
score change was the only signiﬁcant variable in explaining
ΔMADRS. This was unexpected because there is no evidence for
RDs state dependence in depression. In a post-hoc analysis, with
corresponding GLMs applied separately to AUP and non-AUP pa-
tients, the model was non-signiﬁcant in the non-AUP group.
However, in the AUP group it explained over one fourth of the
variance in ΔMADRS, and the increase in RD contributed in-
dependently to the antidepressive treatment response. This could
mean that the depressive symptoms in patients with alcohol use
problems are more related with loss of energy, appetite loss, ve-
getative symptoms or subjective dysphoria (Grucza et al., 2003)
and could be explained with differences in the function of brain
anti-reward mechanisms associated with noradrenergic circuits
and the hypothalamic-pituitary-adrenal (HPA) axis, with potential
moderation by endogenous oxytocin (Bell et al., 2006; Buisman-
Pijlman et al., 2014; Cloninger, 1986; Koob and Le Moal, 2008).
There may be more reactive depression state dependent changes
in these functions reﬂected in altered RD scores, which are a
marked predictor of antidepressive treatment response in AUP
patients. However, these associations are speculative and further
studies would be needed for conﬁrming them. Furthermore, these
mechanisms may be more important in depressive symptoma-
tology of female AUP patients as discussed above.
Previous evidence suggests that lifetime alcohol dependence in
MDD patients is associated with low P and severity of depressive
symptoms correlates with low P in alcohol dependent patients
(Evren et al., 2009; Rae et al., 2002). In our study, age, gender,
baseline MADRS scores, and patient group only explained 5% of the
baseline P scores and were all non-signiﬁcant at 6 weeks. At
baseline AUP was trending to signiﬁcance and at 6 weeks it was
the only independently signiﬁcant variable in explaining Persis-
tence (Table 3b). These results are consistent with earlier studies,
suggesting that low P is associated with SUD in depressed patients
and that such patients' depressive symptoms may include a more
profound loss of energy and appetite (Grucza et al., 2003).
In our sample, AUP patients also had signiﬁcantly lower SD
compared with non-AUP patients and our GLM explained one ﬁfth
of the variance in SD. It has been proposed previously that control
perception (i.e. locus of control) follows from the brain's capacity
for self-regulation, leading to ﬂexible and goal-directed behaviors
(Declerck et al., 2006). The locus of control can be regarded as
reﬂecting similar traits that are associated with SD, e.g., self-suf-
ﬁciency, responsibility, reliability, and goal orientation (Cloninger
et al., 1993). It has been suggested that these self-regulatory
functions are associated with the functions in dorsolateral and
ventral prefrontal cortex, and the anterior cingulate cortex (De-
clerck et al., 2006). Neuropathological changes associated with
excessive alcohol use are partly located in these brain regions
(Harris et al., 2008). Disrupted theory of mind in patients with
alcohol use disorders could reﬂect altered brain function, which is
also reﬂected in the ﬁnding of lower SD in the AUP group (Bosco
et al., 2014; Harris et al., 2008).
There was a highly signiﬁcant positive change in SD scores in
non-AUP patients. Our GLM suggested that this change con-
tributed signiﬁcantly to ΔMADRS during the follow up. This is
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consistent with earlier evidence for the state dependence of SD in
depression (Nery et al., 2009; Corruble et al., 2002). Psychosocial
treatment in this study was standardized and we used BA as a
treatment intervention for all patients in our study because it has
proven effective in the treatment of MDD, including comorbid or
treatment resistant cases, and in patients with personality dis-
orders (Bottonari et al., 2008; Dimidjian et al., 2006; Dobson, et al.,
2008; Moradveisi et al., 2013; Weinstock et al., 2011). BA techni-
ques include activity monitoring, assessment of goals and values,
and activity scheduling. These presumably can lead to improve-
ment in traits associated with higher SD: self-sufﬁciency, respon-
sibility, reliability, and goal orientation (Cloninger et al., 1993;
Kanter et al., 2010). However, despite also receiving BA, there was
no change in SD scores in AUP patients. This might suggest that
these patients, due to lower self-reﬂecting capacity caused by
disrupted brain functions, receive a more limited beneﬁt from
psychotherapeutic interventions at the acute stage of treatment
(Bosco et al., 2014; Declerck et al., 2006; Harris et al., 2008).
Although C was signiﬁcantly higher in AUP group, AUP failed to
explain C scores in the GLM. Age was associated with C scores and
there were also signiﬁcant correlations between age and character
dimension scores, reﬂective of character maturation during
adulthood (Cloninger et al., 1993). Gender contributed the most to
variance in C scores, and C is generally higher in women (Yamasue
et al., 2008). Therefore, we suggest that unequal gender distribu-
tions in AUP and non-AUP groups explain the difference in C
scores between these groups. As mentioned, all patients received
BA. We hypothesized that BA is able to enhance a patient's self-
regulatory and social functions, which will be reﬂected in the
character traits and that trait changes result in alleviation of de-
pressive symptoms. The GLM incorporating character dimension
changes, age, gender, and AUP as explanatory variables aimed to
explain the role of character traits in the alleviation of depression.
According to this model, changes in C were non-signiﬁcant in
explaining decreases in depressive symptoms at 6 weeks, unlike
the other two character dimensions SD and ST. This means that
alleviation of depressive symptoms at the acute stage are more
associated with the enhancement in patient's self-view and de-
crease in transpersonal identiﬁcation than with their ability to
cooperate.
The role of the ST in depressive symptomatology is so far un-
clear and there are inconsistencies in ﬁndings from different de-
mographic areas (Farmer et al., 2003). There seems to be weak
correlation between ST and depressive states, but some studies
have shown non-signiﬁcant or opposite results (Farmer and See-
ley, 2009; Nery et al., 2009; Richter et al., 2003; Spittlehouse et al.,
2010). In our sample, there was a signiﬁcant decrease in ST scores
in non-AUP patients during the 6-week follow up. Furthermore,
changes in MADRS scores were partly explained by changes in ST
scores, suggesting an association between severity of depressive
symptoms and high ST.
To speciﬁcally analyze the effects and possible interactions of
age and gender, or age and AUP, separate analyses were performed
for each temperament or character dimension. These results re-
sulted in no interactive effects between age and gender or age and
AUP. In the model with age and gender as explaining variables
gender was signiﬁcant in both baseline and six-weeks models
contrary to the models also including depression severity as an
explaining variable. Otherwise the results in these models were in
line with the complete model including age, gender, patient group
and baseline MADRS scores as explaining variables. This difference
in the two models is likely to reﬂect the difference in gender
distributions between AUP and non-AUP groups.
The ‘real-life’ setting, broad inclusion criteria, and few exclu-
sion criteria posed some challenges and limitations for our study.
However, the minimal set of criteria provide results that achieve
high clinical relevance and generalizability. The patient sample
comprised quite severe cases of depression with marked co-
morbidity and recurrent MDD episodes, but almost all patients
had a diagnosis of MDD. We studied the effects of alcohol use, but
some of the patients used also other substances which could have
affected the results. Although the use of other substances was
infrequent and monitored with MINI and a question of use of other
substances during prior year, the data on the type of substances
used was not collected. The prescribed medications were diverse,
but the majority of patients were prescribed an SSRI or SNRI. The
anticipated efﬁcacy of the prescribed medication was evaluated by
a psychiatrist and adherence to medical treatment was monitored.
Six-week follow-up in the study can be considered as a short time
period for analyzing response to treatment, although marked de-
crease in MADRS scores was observed. As the primary aim of the
study was to analyze the effect of alcohol use on temperament and
character dimensions, no further analyses were performed in re-
lation to the observed changes in personality with a clinical data
and response. However, age, gender and depression severity were
taken into account as confounding factors in multivariate analysis.
We observed expected uneven gender distributions between the
non-AUP and AUP groups. This prevented interpretation of tem-
perament proﬁle differences solely through bivariate comparisons,
and required the use of multivariate analyses, as well as gender-
wise divisions. It is possible that these multiple statistical analyses
could lead to type 1 errors as no correction for multiple testing
was used. It is however notably, that the bivariate analyses were
exploratory in nature and the ﬁnal interpretation of the results
was made according to the multivariate analyses.
Depressed patients with alcohol use problems had lower Self-
Directedness and Persistence and higher Novelty Seeking com-
pared with depressed patients without the comorbidity. Clinically,
this could explain why depressed patients with alcohol use pro-
blems are more enthusiastic to try new treatments, but show
worse treatment adherence. Changes in Reward Dependence and
lower Self-Directedness in AUP patients could be reﬂective of
different biological mechanisms associated with depressive
symptomatology in substance abusive patients. The increase in
Self-Directedness and decrease in Self-Transcendence associated
with alleviation of depression in non-AUP, but there were no
changes in character dimensions in patients with alcohol use
problems suggesting that these patients could beneﬁt less from
behavioral activation therapy at acute stage of treatment.
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Temperament and character proﬁles are associated with depression
outcome in psychiatric secondary care patients with harmful drinking
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Background: Temperament and character proﬁles have been associated with depression outcome and alcohol
abuse comorbidity in depressed patients. How harmful alcohol use modiﬁes the effects of temperament and
character on depression outcome is not well known. Knowledge of these associations could provide a method
for enhancing more individualized treatment strategies for these patients.
Methods:We screened 242 depressed patients with at least moderate level of depressive symptoms. The Alcohol
Use Disorders Identiﬁcation Test (AUDIT) was used for identifying patients with marked alcohol use problems
(AUP, AUDIT≥11). After 6 weeks of antidepressive treatment 173 patients were assessed using the
Montgomery-Åsberg Depression Rating Scale (MADRS), and the Temperament and Character Inventory (TCI-
R). Outcome of depression (MADRS scores across three follow-up points at 6 weeks, 6 months and 24months)
was predicted with AUP, gender, and AUP x Gender and AUP x Time interactions together with temperament
and character dimension scores in a linear mixed effects model.
Results: Poorer outcome of depression (MADRS scores at 6 weeks, 6 months and 24 months) was predicted by
AUP × Time interaction (p = 0.0002) together with low Reward Dependence (p= 0.003). Gender and all
other temperament and character traits were non-signiﬁcant predictors of the depression outcome in the
mixed effects model.
Conclusions: Possibly due to the modifying effect of alcohol use problems, high Reward Dependence was associ-
atedwith better depression treatment outcome at 6 months. HarmAvoidance and Self-Directedness did not pre-
dict depression outcome when alcohol use problems were controlled.
© 2018 Elsevier Inc. All rights reserved.
1. Introduction
It is well known that comorbidity of major depressive disorder
(MDD) with substance use disorders (SUDs) can lead to impaired re-
sponse to treatment, more chronic disease courses or recurrence of de-
pressive episodes [1,2]. Because recurrent and chronic depression
constitute a major burden of disease [1,2], more efﬁcient treatment
strategies and means for earlier identiﬁcation of high-risk patients
are needed.
Assessment of individual temperament and character traits could
provide a method for enhancing preventive and more individualized
treatment strategies for these patients because certain traits and tem-
peraments may predispose individuals to recurrence of depression,
and are associated with different courses of depression and with
substance use disorder comorbidity and drinking outcomes [3–6]. Indi-
vidual personality could have pathoplastic effects on recovery from de-
pression; i.e., differences in temperament or character could explain
differences in the course of the illness [7]. How harmful alcohol use
modiﬁes the effects of temperament and character on depression out-
come is not well known.
The Temperament and Character inventory (TCI-R) is a 240-item
questionnaire that collects information on human personality in the
context of temperament and character. According to Cloninger's
psychobiological model, on which the TCI-R was based, temperament
is divided into four dimensions: Novelty Seeking (NS), Harm Avoidance
(HA), Reward Dependence (RD) and Persistence (P). Character is
divided into three dimensions: Self-Directedness (SD), Cooperativeness
(C) and Self-Transcendence (ST) [8]. These dimensions are thought to
Comprehensive Psychiatry 84 (2018) 26–31
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reﬂect combinations of different neurocognitive functions (e.g., memory
or reward functions), and the biological basis of this model is supported
by many ﬁndings [9,10].
According to Cloninger's theory, temperament dimensions generally
represent a stable part of personality, and only HA has shown clear
state-dependent changes during depression [4,5,8]. However, high
HA – and more particularly its sub-scores, anticipatory worry (HA1)
and fatigability (HA4) – have also manifested as trait-like markers for
risk of depression, i.e., index episodes, relapses or recurrent episodes
and impaired treatment response [4,5]. High RD could be protective
against depression in general population, but no associations have
been reported with outcome of depression in clinically depressed pa-
tients [4,11–15]. Our earlier study of this patient sample suggested
that RD is associated with depression treatment outcome in patients
with alcohol use problems as change in RD was strongly associated
with acute treatment response (0–6 weeks) to depression when
alcohol use was taken into account [16]. High NS is a trait indisputably
associated with risk of substance use disorders, more severe symptom-
atology and poorer outcome in SUD patients, and apparently experi-
enced at a higher level in patients with dual diagnosis (concurrent
SUD and mental illness) than in depressed patients [3,6,17–20]. Low
P and high HA are associated with more severe alcohol dependence
symptomatology [21–23].
Of the character traits, low SD is the trait most clearly predisposing
to depression and recurrence of episodes, possibly because individuals
with deﬁciencies in sub-traits such as self-acceptance, responsibility,
goal-directedness associated with SDmay bemore prone to depression
due to difﬁcult situations encountered in their daily lives [24,25]. There
is less evidence to suggest that lowC is associatedwith thedevelopment
of depression, whereas ﬁndings on the associations between ST and de-
pression in different patient samples have been contradictory
[4,15,26,27]. Low SD is also associated with more severe symptomatol-
ogy and drinking outcomes in SUD patients [6,28,29]. In alcohol depen-
dence character proﬁle with high ST and low SD and C is associatedwith
depression and anxiety [21].
In spite of a large body of knowledge of different associations sepa-
rately between temperament and character traits and depression or
substance use disorders, we found no follow-up studies addressing
the associations between depression outcome and temperament, char-
acter and alcohol use.We investigatedwhether temperament and char-
acter trait scores (at 6 weeks) togetherwith harmful alcohol use predict
outcome of depression in follow-up from 6 weeks to 6 months and to
24 months in a clinically diverse sample of depressed patients. In light
of earlier evidence we hypothesize that high HA and low SD and harm-
ful alcohol use together explain poorer depression treatment outcome
(measured as MADRS scores) [4,5,25]. As harmful alcohol use had a
modifying effect on both temperament and character dimensions dur-
ing acute illness, we hypothesize that RD together with alcohol use is
also associated with outcome of depression in the long-term follow-
up (from 6 weeks to 6 and 24 months) [16]. High NS has been associ-
ated with more severe SUDs, and therefore we also hypothesized that
this temperament trait might modify treatment outcome together
with harmful alcohol use in depression [6].
2. Methods
2.1. Participants
In the period 2009–2013, 242 patients were screened for the study in
the Finnish region of Southern Ostrobothnia (population 200,000). These
patients were referred to psychiatric specialized care units (5 outpatients
and 1 inpatient) due to depression, anxiety, self-destructiveness, insom-
nia or alcohol-related problems. To maximize clinical relevance, lenient
inclusion criteria were used. Patients with at least moderate depressive
symptomatology (Beck Depression Inventory [BDI] Version 1A, score
≥17; [30]) were included in the study. Patients with organic brain disease
or psychotic disorder (ICD-10 F2* diagnosis) were excluded. Their age
rangewas 17–64 years (mean38.8 years, SD±12.2). Amore detailed de-
scription of the sample is presented in Tables 1a and 1b, and of the study
setting elsewhere (see ClinicalTrials.gov Identiﬁer NCT02520271,
Ostrobothnia Depression Study [ODS] [43]). The study was approved by
the local Human Subjects Review Committee, and patients gave their in-
formed written consent.
2.2. Procedures
Sociodemographic datawere collected and clinical assessments con-
ducted at screening (the Alcohol Use Disorders Identiﬁcation Test
(AUDIT) [31] and the BDI). There was some dropout before the baseline
assessment using theMini International Neuropsychiatric Interview 5.0
(MINI; [32]) and the Montgomery-Åsberg Depression Rating Scale
(MADRS) [33] and 228 (94%) patients were assessed with MADRS at
baseline. According to the MINI administered to 219 patients (data
missing in 23 cases), 88.6%of the patients hadMDD, 4.1% dysthymic dis-
order, 5.5% anxiety disorder and 0.4% alcohol use disorder (AUD) as
theirmain diagnosis, and 1.4% of the patients did notmeet any of the di-
agnostic criteria. Twelve percent (12%) of the patients met the criteria
for lifetime diagnosis of (hypo)manic episode. Sixty-three percent
(63%) of patients with mood disorder as their main diagnosis had co-
morbid anxiety disorders, corresponding well to comorbidity propor-
tions found in other samples in Finnish psychiatric secondary services
[34]. Six patients (3%)withmood disorder as primary diagnosis had co-
morbid bulimia nervosa. Patients' categorical personality disorder diag-
noses were not assessed. In the total sample, 33.6% of the patients
reported that this was their ﬁrst episode of MDD.
At baseline patients attended an appointment with a psychiatrist,
where their medication was evaluated and changed if necessary. Anti-
depressant medication was prescribed to 206 patients (85%) with
mean ﬂuoxetine equivalent daily doses of 33.0 mg (SD ± 18.3). Of
these, 82% had either an SSRI or SNRI as a primary antidepressant. Ad-
herence to antidepressants was monitored during the ﬁrst six weeks
of the study using a paper and pencil diary (for more information see
[16]). All patients received behavioral activation therapy with trained
clinical staff. The median number of therapy sessions with patients
was 6 (IQR= 3–11) with sessions taking place at 1 to 2-week intervals.
The treatment of patients with alcohol use problems (AUP, AUDIT
scores ≥11) was enhanced with motivational interviewing (median
Table 1a
Sociodemographic data on the patient sample.
Men Women Total
N % N % N %
Total 94 38.8 148 61.2 242 100
Marital status
Single 34 36.9 39 29.1 73 32.3
Married or cohabiting 39 42.4 71 53.0 110 48.7
Divorced 19 20.7 21 15.7 40 17.7
Widowed 0 0 3 2.2 3 1.3
Education
Primary school 4 4.3 3 2.2 7 3.1
Comprehensive school 27 29.3 28 20.7 55 24.2
Tertiary education 10 10.9 25 18.5 35 15.4
Vocational school 33 35.9 54 40.0 87 38.3
Upper secondary education 10 10.9 7 5.2 17 7.5
Polytechnic or university 8 8.7 18 13.3 26 11.5
Work status before sick leave
Employed 39 42.9 67 50.0 106 47.1
Unemployed 41 45.1 30 22.4 71 31.6
Housewife/husband 0 0 10 7.5 10 4.4
Pensioner 5 5.5 11 8.2 16 7.1
Student 6 6.6 16 11.9 22 9.8
Self-reported history of depression episode 62 67.4 90 65.7 152 66.4
First degree family history of depression 33 35.9 56 41.5 89 39.2
First degree family history of bipolar disorder 4 4.3 10 7.4 14 6.2
27V. Paavonen et al. / Comprehensive Psychiatry 84 (2018) 26–31
number of sessions 4, IQR= 3–6) at the start of the treatment according
to a speciﬁc treatment intervention procedure (see ClinicalTrials.gov
Identiﬁer NCT02520271, Ostrobothnia Depression Study [ODS], 2016
and [35]). The cut-off point for AUDIT was chosen because in Finnish
clinical practice it indicates a signiﬁcantly increased risk of harm due
to alcohol [36,37]. In the present study setting the aim was to identify
individuals with marked alcohol use problems with high speciﬁcity to
obtain motivational interview as an add-on psychosocial treatment.
After dropout at 6 weeks, 173 patients completed both the TCI-R and
MADRS and were therefore eligible for inclusion in the main analysis of
this study. Of these patients 61 (35%) showedmarked alcohol use prob-
lems (AUP, AUDIT scores ≥11) roughly corresponding to the comorbid-
ity ratio of 2:1 (of substance use disorders in depressed patients)
observed in clinical samples where nearly one third of patients with
major depressive disorder also have substance use disorders [38]. Of
the 61 AUP patients MINI diagnosis had been assessed in 60 cases at
baseline, 44 (73%) of which had been diagnosed with lifetime AUD
and of the other 112 patients (with AUDIT scores b11) MINI diagnosis
had been assessed in 107 cases, only 3 (3%) of which had been diag-
nosedwith lifetime AUD. Seven (16%) patients that had been diagnosed
with AUDhad also other SUD, and two (2%) patients without AUDwere
diagnosed with some other SUD. There was no exclusion of patients ac-
cording to substance use. Alcohol use problems were more common in
male patients: (males 69% vs. females 31%, χ2 = 31.5, p b 0.001;
odds ratio (OR) = 6.6, 95% conﬁdence intervals (CI) = 3.3–13.2).
The follow-up included assessment of patients' MADRS scores again at
6-month and 24-month time-points.
2.3. Statistical methods
Differences in continuous variables (AUDIT and MADRS scores, and
TCI-R dimension scores) between dropouts and other patients were cal-
culated with independent samples t-tests. Differences in nominal vari-
ables between dropouts and other patients and in the prevalence of
AUP between genders were calculated with χ2 statistics.
This study was conducted according to the intention-to-treat proto-
col and in cases of dropout MADRS scores were imputed in the follow-
up according to the last observation carried forward (LOCF) method.
This replaced missing values in MADRS follow-up with their last ob-
served values at earlier follow-up time points. This replaced missing
MADRS values in 32 (17%) cases at 6-month follow-up and in 93
(49%) cases at 24-month follow-up. Exploratory analysis between
LOCF MADRS scores and temperament or character scores was per-
formed with Pearson's correlation coefﬁcients.
A linear mixed effects model was used for the repeated measure-
ment testing in the main analysis of the study. This model predicted
LOCF MADRS scores from 6 weeks to 6 months and to 24 months with
the scores of the seven temperament and character dimensions (NS,
HA, RD, P, SD, C, and ST; at six weeks) used as explaining variables
and was adjusted with AUP, gender, and AUP x gender and AUP x
time interactions. Individual-speciﬁc intercept and slope terms were
used in the model. The −2 log likelihood information criteria was
used in evaluating model ﬁt and model with unstructured covariance
structure was reported. Kenward-Roger adjustment of degrees of free-
dom was applied for estimates of ﬁxed effects. The main analysis was
performed with PROC MIXED, SAS version 9.4 (SAS Institute Inc., Cary,
NC, USA) and all other analyseswere performedwith SPSS forMac (ver-
sion 24.0, IBM Inc., Armonk, New York, USA).
3. Results
The dropout rate in the study was 65 (27%) at six weeks, 91 (38%) at
six months, and 147 (61%) at 24 months, but no gender differences
were seen at any assessment point. Of these patients, the clinical treat-
ment had been concluded in co-operation with the patients in 10 (11%)
cases during the ﬁrst 6 months and in 28 (19%) cases before 24 months.
The dropout analysis of the raw data revealed similar baseline MADRS
scores in dropouts and other patients. Baseline AUDIT scores were
higher in dropouts at both rating points (6 months: dropout 14.0 ±
11.2 vs. other patients 8.9 ± 8.6, p b 0.001; 24 months: 12.0 ± 10.5 vs.
8.7 ± 8.5, p= 0.006 for t-test). Dropouts also had lower Self-
Directedness at baseline than did other patients in dropout analysis at
6 months: dropout 117.9 ± 18.3 vs. other patients 124.2 ± 18.2, p=
0.02 for t-test, and had trending but non-signiﬁcant difference at 24
months (p=0.09). In the LOCF data there were no statistically signiﬁ-
cant differences between dropouts and other patients' 6-month LOCF
MADRS scores in the 6-month dropout analysis (p= 0.2 for t-test).
Dropouts had higher 24-month LOCF MADRS scores in the 24-month
dropout analysis (dropout 12.9 ± 8.9 vs. other patients 8.3 ± 7.6, p b
0.001 for t-test).
The main results emerging as predictors of depression treatment
outcome (measured as MADRS scores) are presented in Table 2. Poorer
outcome of depression was predicted by AUP × Time interaction to-
gether with low RD. The model resulted in steeper negative sloping of
MADRS scores for non-AUP group when compared to AUP group ×
Time. This means that alcohol use problems associatedwith poorer out-
come of depression in the follow-up from 6 weeks to 6 months and to
24 months. Low RD was the only temperament or character trait that
was associated with depression outcome as a predictor of poorer out-
come in the follow-up from 6 weeks to 6 and 24 months.
The distributions (mean ± SD) for LOCF MADRS scores were:
1) 13.6 ± 8.5 at 6 months and 2) 10.6 ± 8.5 at 24 months. The mean
± SD for temperament and character dimensions at six weeks were:
NS 99.7 ± 16.7; HA 113.4 ± 18.9; RD 100.1 ± 17.6; P 99.7 ± 21.5; SD
125.4 ± 17.3; C 131.9 ± 18.0; ST 64.9 ± 15.5. The Cronbach's α values
for TCI-R dimensions have been reported elsewhere [16]. The MADRS
scores, number of responders, remitted patients, and non-responders
in follow-up are presented in Table 3.
Pearson's correlation coefﬁcients between RD, HA and SD and LOCF
MADRS scores were statistically signiﬁcant for RD and MADRS scores
at 6 months (r=−0.32, p b 0.001), HA and MADRS scores at 6 months
(r = 0.18, p= 0.02), SD and MADRS scores at 6 months (r=−0.27,
p b 0.001), HA andMADRS scores at 24months (r=0.26, p=0.001), and
SD andMADRS scores at 24months (r=−0.32, pb 0.001).
4. Discussion
Themain hypotheses in this studywere that temperament and char-
acter traits together with harmful alcohol use (assessed in the early
stages of treatment) explain outcome of depression over a period of
two years. The main ﬁnding in this study was that poorer outcome of
depression was predicted by low Reward Dependence. Alcohol use
problems were also associated with poorer outcome of depression in
the follow-up from 6 weeks to 6 months and to 24 months.
4.1. Outcome of depression (from 6 weeks to 24 months)
Poorer outcome of depression was predicted by low Reward Depen-
dence in the linear mixed effects model adjusted with AUP, gender,
AUP × gender and AUP × time. In contrast to some earlier studies our
present and earlier ﬁndings suggest that Reward Dependence is associ-
ated with depression treatment outcome [4,16,26]. This difference in
Table 1b
Baseline scores on BDI and AUDIT by gender.
Men Women Total
Baseline BDI mean (±SD) 28.5 (6.80) 27.5 (7.59) 27.9 (7.30)
Baseline AUDIT mean (±SD) 15.1 (10.59) 7.9 (8.30) 10.7 (9.88)
Abbreviations: BDI= Beck Depression Inventory; AUDIT= Alcohol Use Disorder Identiﬁ-
cation Test.
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results could be explained by differences in patient samples, as patients
with SUDs have been excluded in those earlier studies but not in this
present one [4,16,26]. Our earlier and present results suggest that low
RD predicts poorer outcome of depression particularly in depressed pa-
tients with comorbid alcohol use problems. In line with these ﬁndings,
one study in which patients with prior SUD were not excluded resulted
in MDD patients in remission having higher RD than currently de-
pressed patients [24]. More speciﬁcally, the presence of SUD together
with severemental illness (SMI, including patients withMDDor schizo-
phrenia) seems to be associated with low RD as dually diagnosed pa-
tients have lower RD than do SUD patients, but there is no signiﬁcant
difference in trait RD between patients with SMI or SUDwithout the co-
morbidity of the other [3]. The ﬁnding of an association between high
RD (at 6 weeks) and better outcome of depression together with our
earlier ﬁnding may be explained by depression state-dependent alter-
ations in brain reward pathway functions in patients comorbid with
SUD, and hence conﬁrm a possible association between Reward Depen-
dence and depression treatment outcome when alcohol use problems
are taken into account [16,39].
Although high HA and low SD have been associated earlier with risk
of recurrences of depressive episodes as well as impaired depression
treatment response [4,5,25], surprisingly, in this study these tempera-
ment and character traits were not statistically signiﬁcant in predicting
the outcome of depression. One possible explanation for this would be
that alcohol use problems in part mediate the association between
these personality traits and depression outcome. This argument is justi-
ﬁed because earlier ﬁndings have shown that AUDs are associated with
both: 1) the development of more chronic courses of depressive symp-
tomatology [1,2], and 2) high HA and low SD. More speciﬁcally high HA
and low SDare both associatedwith dual diagnosis [3], and highHA also
with more severe AUDs [22]. Moreover, it is plausible that lower ability
to organized problem solving or greater distress associated with
avoidant behavior that are associated with low SD and high HA, respec-
tively, could predispose these individuals to a higher risk of alcohol use
problems. Finding the Harm Avoidance and Self-Directedness statisti-
cally non-signiﬁcant in predicting outcome of depression in our analysis
with the control of AUP is in linewith the argument that the association
between high HA and low SD and poorer outcome of depression could
be in part mediated by alcohol use problems.
In the main analysis AUP × Time was highly signiﬁcant predictor of
depression outcome and was associated with slower decline of
MADRS scores in the follow-up when compared to non-AUP. This ﬁnd-
ing demonstrates the disruptive effect of alcohol use problems on the
outcome of depression and is in line with earlier ﬁndings of the detri-
mental effect of AUDs on the course depression [1,2]. Novelty Seeking,
Persistence, Self-Transcendence and Cooperativeness remained non-
signiﬁcant in predicting the outcome of depression when AUPs were
taken into account. Although high NS could cause impaired response
to antidepressive treatment because it is associated with more severe
SUD symptomatology [6,18,20], it seems that high NS is not an impor-
tant trait in the association with poorer outcome of depression when
AUP are controlled. Similarly low Persistence seems to be a marker for
more severe or chronic SUD [21,23,40], but it was not a signiﬁcant
marker in predicting depression outcome in this study. The results
fromdifferent patient samples have beenpartially contradictory regard-
ing associations between trait ST and depressive symptomatology and
the present results suggest that ST alone is not signiﬁcant in predicting
depression outcome nor together with AUP [4,15,26,27]. Although high
Cooperativeness could be protective of depression and associated with
better drinking outcomes in depressed alcohol-dependent patients
[4,6] it was a non-signiﬁcant predictor of the outcome of depression to-
gether with alcohol use problems in this study and this association
should be veriﬁed in larger samples. As gender has not been associated
with severity or recurrence of MDD episodes [2], it was expected that it
would likewise not predict depression outcome in this sample of more
diverse depressed patients.
Table 2
Predictors of depression outcome (LOCFMADRS scores across the follow-up from 6weeks
to 6 months and to 24months).a
Fixed effects LOCF MADRS scores
Estimateb SE t p
Intercept 20.07 10.04 2.00 0.049
NS at 6 weeks 0.04 0.03 1.16 0.25
HA at 6 weeks 0.06 0.04 1.70 0.09
RD at 6 weeks −0.11 0.04 −3.03 0.003
P at 6 weeks −0.03 0.03 −1.10 0.27
SD at 6 weeks −0.06 0.04 −1.59 0.11
C at 6 weeks 0.02 0.04 0.56 0.58
ST at 6 weeks 0.05 0.03 1.49 0.14
Male gender 0.24 1.76 0.14 0.23
AUP 3.67 1.64 2.25 0.12
AUP × Male gender −3.24 2.19 −1.48 0.14
AUP × Time −0.10 0.05 −1.98 0.0002
non-AUP × Time −0.33 0.06 −3.75 0.0002
−2 × log-likelihood= 3530 for the SAS input code and output results.
Abbreviations: LOCF= Last observation carried forward; NS = Novelty Seeking; HA=
Harm Avoidance; RD= Reward Dependence; P = Persistence; SD= Self-Directedness;
C= Cooperativeness; ST= Self-Transcendence; MADRS=Montgomery-Åsberg Depres-
sion Rating Scale; AUP= alcohol use problems.
Signiﬁcant results are presented in bold face.
a Results from the linear mixed effects model with temperament and character di-
mension scores, gender, AUP, and AUP x Gender and AUP x Time interactions as explana-
tory variables.
b B for the temperament and character variables effect on the dependent variable.
Table 3
MADRS scores in raw data, LOCF data, and by patient subgroup and number of responders, patients in remission and non-responders at baseline and follow-up.
Baseline 6 weeks 6 months 24 months
Raw data MADRS scores (mean ± SD) 23.2 ± 6.7; n= 228 16.9 ± 8.0; n= 188 13.1 ± 8.7; n= 156 8.3 ± 7.6; n= 95
Responsea (n, %) 69, 44% 64, 67%
Remissionb (n, %) 49, 31% 50, 53%
LOCF data MADRS scores, n = 188 13.6 ± 8.5 10.6 ± 8.5
Responsea (n, %) 80, 43% 112, 60%
Remissionb (n, %) 52, 28% 80, 43%
MADRS scores of patient subgroups (raw data scores):
Non-AUP (mean ± SD) 22.9 ± 6.7 (n= 136) 16.7 ± 8.0 (n= 123) 12.8 ± 8.7 (n= 105) 6.7 ± 6.2 (n= 66)
AUP (mean ± SD) 23.7 ± 6.7 (n= 92) 17.2 ± 8.1 (n= 65) 13.7 ± 8.7 (n= 51) 12.0 ± 9.2 (n= 29)
Female (mean ± SD) 22.3 ± 6.8 (n= 137) 15.7 ± 7.8 (n= 112) 11.6 ± 8.2 (n= 97) 7.1 ± 6.6 (n= 64)
Male (mean ± SD) 24.6 ± 6.3 (n= 91) 18.6 ± 8.0 (n= 76) 15.6 ± 9.1 (n= 59) 10.8 ± 8.9 (n= 31)
Proportion of men (n, %) 91, 40% 76, 40% 59, 38% 31, 33%
Proportion of AUP patients (n, %) 92, 40% 65, 35% 51, 33% 29, 31%
Number of patients with increase in symptoms from baseline (n, %) 23, 15% 3, 3%
Abbreviations: AUP= Alcohol use problems; MADRS=Montgomery-Åsberg Depression Rating Scale; LOCF= last observation carried forward.
a At least 50% MADRS score decline from baseline.
b MADRS scores b8.
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4.2. Strengths and limitations
In the mixed effects multivariate model we analyzed the factors
predicting the outcome of depression (MADRS scores) across three dif-
ferent time-points (at 6 weeks, 6 months and 24 months). Because de-
pressive episodes are on average of 6 months' duration, the follow-up
period up to 6 months is a good marker for responsiveness to anti-
depressive treatment, whereas follow-up period up to 24 months is
likely to reﬂect considerably more the long-term ﬂuctuation in symp-
toms, also including relapses and recurrences of depressive episodes
[41,42]. It was important to study the outcome across both of these out-
comes, because in themajority of cases recovery from depression is not
a straightforward process but instead takes a ﬂuctuating coursewith re-
missions, relapses, and recurrences of episodes [42]. Moreover, it is pos-
sible that traits associated with responsiveness to treatment could in
part differ from the traits predisposing to recurrence of episodes and
this could be interesting hypothesis to test in future studies in natural-
istic samples [4].
As there was marked dropout in this study, especially at 24-month
follow-up, data imputation was conducted for the main analysis. The
method of last observation carried forward was used even though it
could result in more conservative results. It is possible that the LOCF
method used in this study did not detect all relapses, but the risk that
it would havemarkedly affected the results in this studywas considered
low because the naturalistic study setting allowed patients to continue
in the study even if they had failed to attend at some earlier point.
According to the theory of pathoplasticity, personality has a causal
effect on the clinical course and outcome of depression; e.g., individual
personality determines howpatients recover fromdepression [7]. How-
ever, the association between depression and temperament is more
complex, and the depressive state also leads to higher HA [5]. In addi-
tion, in this patient sample RD also showed potential state-dependent
alterations [16], and increase in SD seems to be associatedwith recovery
from depression [26]. Because depressive symptoms have been shown
to alter temperament and character proﬁles, the six-week TCI-R assess-
ments were considered as better representing the patients' long-term
temperament and character proﬁles andwere used in the GLManalyses
as explanatory variables.
Due to the naturalistic settingwe hadmore lenient inclusion criteria
in this study than in other studies with depressed patients, and because
of that our patient sample likely included more patients with different
subtypes of depressive symptomatology [16]. The patients in this
study also had marked comorbidities including life-time diagnosis of
(hypo)mania in some cases, and a large proportion had AUD. Moreover,
the seasonal patterns of depressive symptomatology or personality dis-
orders were not controlled for in themain analysis. Therefore, these re-
sults are not directly applicable to “pure” MDD patients but are more
easily generalizable to the mixed populations seen in psychiatric sec-
ondary services. A few patients had other SUDs (in addition to AUDs)
that were not speciﬁed but could have had an effect on the personality
proﬁle of these patients. However, because of the low number of pa-
tientswith other SUDs this have not likely affected the resultsmarkedly.
According to the treatment procedure only a portion of the patients
underwent motivational interviewing in addition to behavioral activa-
tion therapy, and, although temperament is considered to reﬂect rela-
tively stable traits, it is possible that this difference in treatment
affected the results. Dropout in follow-up was linked with high AUDIT
and low SD at baseline, which may also have affected the results.
4.3. Conclusions
Possibly due to the modifying effect of alcohol use problems, high
Reward Dependence was associated with better anti-depressive treat-
ment outcome at 6 months. Harm Avoidance and Self-Directedness
did not predict depression outcome when alcohol use problems were
controlled.
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A B S T R A C T
Background: Individual temperament is associated with psychiatric morbidity and could explain diﬀerences in
psychiatric comorbidities. We investigated the association of temperament proﬁle clusters with anxiety disorder
comorbidity in patients with depression.
Methods: We assessed the temperament of 204 specialized care-treated depressed patients with the
Temperament and Character Inventory (TCI-R) and their diagnoses with the Mini International Neuropsychiatric
Interview. Two-step cluster analysis was used for deﬁning patients’ temperament proﬁles and logistic regression
analysis was used for predicting diﬀerent anxiety disorders for various temperament proﬁles.
Results: Four temperament clusters were found: 1) Novelty seekers with highest Novelty Seeking scores
(n=56),2) Persistent with highest Persistence scores (n=36), 3) Reserved with lowest Novelty Seeking scores
(n=66) and 4) Wearied with highest Harm avoidance, lowest Reward Dependence and lowest Persistence
scores (n=58). After adjusting for clinical variables, panic disorder and/or agoraphobia were predicted by
Novelty seekers’ temperament proﬁle with odds ratio [OR]= 3.5 (95% conﬁdence interval [CI]= 1.8− 6.9,
p<0.001), social anxiety disorder was predicted by Wearied temperament proﬁle with OR=3.4 (95%
CI=1.6− 7.5, p= 0.002), and generalized anxiety disorder was predicted by Reserved temperament proﬁle
with OR=2.6 (95% CI= 1.2− 5.3, p= 0.01).
Limitations: The patients’ temperament proﬁles were assessed while displaying depressive symptoms, which may
have aﬀected results.
Conclusions: Temperament clusters with unique dimensional proﬁles were speciﬁcally associated with diﬀerent
anxiety disorders in this study. These results suggest that TCI-R could oﬀer a valuable dimensional method for
predicting the risk of anxiety disorders in diverse depressed patients.
1. Introduction
The comorbidity between depressive and anxiety disorders is
marked and co-occurrence of more than one disorder is more of a rule
than an exception (Brown et al., 2001; Melartin et al., 2002). In clinical
populations, comorbidity proportions of diﬀerent anxiety disorders in
major depressive disorder (MDD) vary from 2% to 41% and co-occur-
rence of at least two diﬀerent anxiety disorders vary from 36% to 64%
between diﬀerent disorders (Brown et al., 2001). Comorbid anxiety
disorders can lead to increased treatment resistance and chronic de-
pression (Burcusa and Iacono, 2007; Holzel et al., 2011) and better
comprehension of the etiology of these disorders could enable
development of more eﬃcient treatments than currently available ones.
The present categorical classiﬁcation system of psychiatric disorders
has been criticized because of a high rate of comorbidity of diﬀerent
diagnoses (Naragon-Gainey et al., 2016). Certain temperamental traits
have been suggested to be contributors of a dimensional diagnostic
model because they could account for shared symptomatology in both
depression and anxiety disorders (Barlow and Kennedy, 2016; Craske
and Waters, 2005).
Whereas human temperament is generally associated with in-
dividual life choices and behavior (Al-Halabi et al., 2010; Bereczkei and
Czibor, 2014; Campbell et al., 2013; El Sheikh et al., 2014; Otani et al.,
2008), skewed temperament proﬁle is also associated with psychiatric
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disorders (Miettunen and Raevuori, 2012). The most important model
developed from the clinical point of view and in part based on biolo-
gical studies for characterizing human temperament is the psychobio-
logical model of temperament and character (Cloninger, 1986;
Cloninger et al., 1993). According to this model, human temperament is
largely heritable and is a relatively stable part of personality. Human
temperament is considered to present a precognitive bias reﬂected as
individual tendency to 1) avoid possible adverse or threatening situa-
tions (Harm Avoidance, HA), 2) participate in events and activities for
the sake of novelty and thrill (Novelty Seeking, NS), 3) seek social
approval of others (Reward Dependence, RD), and 4) be persistent in
ones eﬀorts, even in the absence of imminent rewards (Persistence, P)
(Cloninger et al., 1993). Although the associations between tempera-
ment and aﬀective disorders are most likely complex (Klein et al.,
2011), certain temperament traits could predispose to psychopathology
via disadvantageous cognitions (e.g., rumination) (Mezulis et al., 2011)
and behaviors (e.g., avoidant behavior or excessive reassurance
seeking) (Cheavens and Heiy, 2011; Kanter et al., 2008; Weinstock and
Whisman, 2007).
The temperament trait ‘high HA’ is associated with MDD and all
anxiety disorders. HA and depression severity are positively correlated
and social phobia or social anxiety disorder (SAD) appear to be asso-
ciated with higher levels of HA than other anxiety disorders (Kampman
and Poutanen, 2011; Kampman et al., 2014; Miettunen and Raevuori,
2012). Indeed, the trait ‘high HA’ could be an important common
etiological factor for depression and anxiety, and according to Clo-
ninger's original theory, it responds to “obsessional” information-pro-
cessing type associated with “cognitive anxiety” (Cloninger, 1986).
Although Cloninger also postulated that high Novelty Seeking would
respond to “histrionic” information-processing type associated with
“somatic anxiety”, (Cloninger, 1986) studies have not systematically
supported associations between this trait and diﬀerent anxiety dis-
orders. Instead, high NS is associated with substance use disorders
(SUDs) and dual diagnosis (Fernandez-Mondragon and Adan, 2015;
Howard et al., 1997; Sher et al., 2000), whereas intermediate and low
levels of NS have been found in panic disorder and in SAD, respectively
(Kampman et al., 2014; Miettunen and Raevuori, 2012). The trait ‘high
RD’ could be associated with panic disorder, but the results are in-
congruent, with diﬀerent directions observed for the association be-
tween genders (low RD for women and high RD for men) (Kampman
et al., 2014; Starcevic et al., 1996). In patients with social anxiety
disorder, results regarding RD have also been mixed and are on average
at an intermediate level according to one meta-analysis
(Kampman et al., 2014). For P patients with anxiety disorders, inter-
mediate scores have generally been observed, while low scores have
shown to be associated with social phobia and alcohol dependence
among patients without anxiety disorders (Kampman et al., 2014;
Miettunen and Raevuori, 2012; Rae et al., 2002). GAD has been asso-
ciated with high HA and impulsive symptoms in patients with GAD
could be associated with high NS and low RD (Kampman et al., 2014;
Piero, 2010).
Although meta-analytic data exist on the association between se-
parate temperament dimensions and diﬀerent anxiety disorders, no
studies have investigated the impact of temperament clusters on oc-
currence of anxiety disorders. Individual proﬁle data on all tempera-
ment dimensions have been suggested to possibly oﬀer more compre-
hensive information of the association between temperament and
diﬀerent anxiety disorders (Miettunen and Raevuori, 2012). In this
study, we aim to explore if temperament proﬁles determined with
cluster analysis are associated with the likelihood of anxiety disorders
(panic disorder and/or agoraphobia [PDA], social anxiety disorder and
generalized anxiety disorder) in a sample of depressed patients.
2. Methods
2.1. Participants
In brief, the study group comprised 242 patients who were referred
to psychiatric services because of depressive symptoms, anxiety, self-
destructiveness, insomnia or substance-related problems. Patients
scoring a minimum of 17 points on the Beck Depression Inventory (BDI,
version 1A, (Beck et al., 1996) and thus reﬂecting at least a moderate
level of depressive symptoms, were included in the study. Patients with
organic brain disease or psychotic (ICD-10 F2*) disorder were excluded
from the study. A description of the study protocol and the screened
patient sample has been presented elsewhere (see ClinicalTrials.gov
Identiﬁer NCT02520271, Ostrobothnia Depression Study [ODS], 2017
and (Paavonen et al., 2016)). Up to 38 (15.7%) patients dropped out
from the study after enrollment, and 204 patients (out of which 120
(59%) were women) were included in the ﬁnal analysis. Socio-
demographic data, MADRS and AUDIT-C scores of the patient sample
are available as supplementary electronic background material.
2.2. Procedures
Included patients completed the forms for the following assess-
ments: The Temperament and Character Inventory (TCI-R)
(Cloninger et al., 1993), and Alcohol Use Disorders Identiﬁcation Test
(AUDIT-C [questions 1–3 of AUDIT questionnaire]) (Bohn et al., 1995).
Sociodemographic data were also collected. The clinical evaluation
included the Montgomery-Åsberg Depression Rating Scale (MADRS)
(Montgomery and Asberg, 1979), the Mini International Neu-
ropsychiatric Interview 5.0 (MINI) (Sheehan et al., 1998), and patients’
medication was also evaluated. The antidepressant doses prescribed to
each patient were converted to ﬂuoxetine equivalents for enabling
comparison of prescribed antidepressants between diﬀerent patient
groups, which has been described in further detail elsewhere
(Paavonen et al., 2016).
According to the MINI, 181 patients (88.7%) met the criteria for
MDD, 17 (8.3%) for dysthymia, 25 (12.3%) for hypomanic episode (life-
time), 49 (24%) for panic disorder, 35 (17.2%) for agoraphobia, 40
(19.6%) for social anxiety disorder, 68 (33.3%) for generalized anxiety
disorder, 15 (7.4%) for obsessive compulsive disorder, 15 (7.4%) for
post-traumatic stress disorder, 66 (32.4%) for alcohol use disorder, 10
(4.9%) for other substance use disorder and 5 (2.5%) for bulimia.
Comorbidity of disorders was marked and 150 (74%) patients were
diagnosed with at least two disorders. As was expected, co-occurrence
of panic disorder and agoraphobia was marked and 69 (33.8%) patients
had either panic disorder or agoraphobia or both. An overlap was also
observed for GAD with other anxiety disorders (PD, AP, OCD, SAD,
PTSD) and 41 patients (20.1%) had GAD without these comorbidities.
In this study, we focused on the four most prevalent anxiety disorders in
the sample: panic disorder and/or agoraphobia (PDA), SAD and GAD.
2.3. Ethical issues
The study was approved by the local Human Subjects Review
Committee and participants gave their informed written consent. All
included patients were evaluated as having the capacity to give in-
formed consent because patients with psychotic and organic brain
diseases were excluded. For further information, see ClinicalTrials.gov
Identiﬁer (NCT02520271).
2.4. Statistical methods
A two-step cluster analysis was used for deﬁning patients’ tem-
perament proﬁles. This method allows handling of large data sets by
ﬁrst identifying groupings with quick cluster algorithm (pre-clustering)
and it runs hierarchical cluster models in the second step. Temperament
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dimension scores of NS, HA, RD and P were used in the cluster model.
Number of clusters were set to automatic for achieving natural clus-
tering.
The diﬀerences in discrete variables (age, antidepressant dose,
AUDIT-C score and MADRS score) between temperament clusters were
calculated with ANOVA. Diﬀerences between grouping variables
(gender, the use of antipsychotics, and diagnoses) were calculated with
χ2-statistics.
To adjust for possible confounding variables (age, gender, depres-
sion severity and alcohol use) binary logistic regression models were
used for predicting the following diagnoses: 1) panic disorder and/or
agoraphobia (PDA), 2) social anxiety disorder (SAD) and 3) generalized
anxiety disorder (GAD). The diagnoses were predicted with the tem-
perament cluster which had the highest prevalence of the dependent
diagnosis (these prevalences are reported in Table 1.) and the models
were adjusted with 1) age and gender in Model 1, 2) age, gender and
MADRS scores in Model 2, and 3) age, gender, MADRS and AUDIT-C
scores in Model 3. The used explanatory (binary) temperament cluster
variables were: 1) Novelty seekers cluster vs. others in models pre-
dicting PDA, 2) Wearied cluster vs. others in models predicting SAD,
and 3) Reserved cluster vs. others in models predicting GAD. All ana-
lyses were performed with SPSS for Mac (version 24.0, IBM Inc. Ar-
monk, New York, USA).
3. Results
Based on TCI-R temperament dimension scores, the two-step cluster
analysis produced four temperament clusters with fair overall quality.
After their assessment, these four temperament clusters were named
with descriptive labels according to the temperament proﬁle reﬂecting
the combination of scores in diﬀerent temperament dimensions: 1)
Novelty seekers with highest NS, n=56, (NS= 119.4 ± 9.0,
HA=111.0 ± 14.2, RD=103.3 ± 13.5, P= 98.0 ± 15.5;
mean ± SD), 2) Persistent with lowest HA and highest P, n=36,
(NS= 99.6 ± 17.1, HA=87.3 ± 11.0, RD=107.9 ± 15.6,
P= 125.0 ± 12.6), 3) Reserved with lowest NS, n=66,
(NS= 88.1 ± 12.3, HA=119.9 ± 11.5, RD=104.5 ± 14.6,
P= 105.4 ± 15.6), and 4) Wearied with highest HA and lowest RD
and P, n=58, (NS=95.7 ± 10.4, HA=129.8 ± 14.8,
RD=84.7 ± 14.3, P= 82.4 ± 15.3) (Fig. 1).
No diﬀerences were observed between the temperament clusters in
gender distribution, depression severity, alcohol use or in the use of
antipsychotics or prescribed antidepressant doses (Table 1). Persistent
and Reserved patients were younger compared with Wearied patients.
The Persistent cluster had the lowest occurrence of all anxiety disorders
and PDA was most prevalent in Novelty seekers, SAD in Wearied and
GAD in Reserved. The prevalence of diﬀerent diagnoses in each of the
temperament clusters of and χ2 and p values for the diﬀerences in the
occurrence of the disorders between clusters are presented in the
Table 1.
The Novelty seekers cluster had higher odds (odds ratio
[OR]=3.28–3.52, p≤ 0.001) for PDA compared with other patients in
the three logistic regression models adjusted with 1) gender and age, 2)
gender, age and depression severity, and 3) gender, age, depression
severity and alcohol use. In the three models explaining SAD, the
Wearied cluster had higher odds (OR=3.17− 3.41,
p=0.002 − 0.003) for SAD compared with other patients and in the
three models explaining GAD, the Reserved cluster had higher odds
(OR=2.53 − 2.60, p= 0.009 − 0.01) for GAD compared with the
other patients. The results of these regression models are presented in
Table 2.
4. Discussion
Our main ﬁndings were that Novelty seekers, Reserved and Wearied
temperament clusters were uniquely associated with diﬀerent anxietyTa
bl
e
1
C
lin
ic
al
ch
ar
ac
te
ri
st
ic
s
an
d
di
st
ri
bu
ti
on
s
of
an
xi
et
y
di
so
rd
er
s
an
d
th
ei
r
di
ﬀ
er
en
ce
s
be
tw
ee
n
th
e
fo
ur
te
m
pe
ra
m
en
t
cl
us
te
rs
(N
ov
el
ty
se
ek
er
s)
.
C
lin
ic
al
va
ri
ab
le
s
D
ia
gn
os
es
Te
m
pe
ra
m
en
t
cl
us
te
rs
A
ge
*
(m
ea
n
±
SD
)
M
al
e
ge
nd
er
(n
,
%
)
A
nt
ip
sy
ch
ot
ic
s
in
us
e
A
nt
id
ep
re
ss
an
t
do
se
(m
ea
n
±
SD
)
A
U
D
IT
-C
sc
or
es
(m
ea
n
±
SD
)
M
A
D
R
S
sc
or
es
(m
ea
n
±
SD
)
PD
A
(n
,%
)
SA
D
(n
,%
)
G
A
D
(n
,
%
)
1.
N
ov
el
ty
se
ek
er
s
(n
=
56
,
26
%
**
)
36
.7
±
12
.5
29
,5
1.
8%
16
,2
8.
6%
27
.2
±
21
.4
5.
64
±
3.
64
22
.4
±
6.
6
28
,5
4.
9%
10
,1
9.
6%
7,
13
.7
%
2.
Pe
rs
is
te
nt
(n
=
36
,1
7%
**
)
42
.5
±
12
.2
12
,3
3.
3%
7,
19
.4
%
25
.2
±
18
.7
4.
31
±
3.
43
23
.1
±
7.
7
5,
14
.3
%
1,
2.
9%
8,
22
.9
%
3.
R
es
er
ve
d
(n
=
66
,3
0%
**
)
41
.4
±
11
.6
22
,3
3.
3%
15
,2
2.
7%
25
.0
±
21
.0
4.
39
±
3.
29
22
.6
±
6.
1
14
,2
2.
2%
10
,1
5.
9%
20
,3
1.
7%
4.
W
ea
ri
ed
(n
=
58
,2
7%
**
)
34
.8
±
11
.4
25
,4
3.
1%
22
,3
7.
9%
32
.4
±
19
.2
4.
93
±
3.
24
24
.5
±
5.
4
22
,4
0.
0%
19
,3
4.
5%
6,
10
.9
%
D
iﬀ
er
en
ce
be
tw
ee
n
th
e
cl
us
te
rs
χ2
5.
28
5.
08
20
.8
1
14
.5
7
9.
67
p
0.
00
3a
0.
15
b
0.
16
6b
0.
18
a
0.
16
a
0.
26
a
<
0.
00
1b
0.
00
2b
0.
02
b
Pe
rs
is
te
nt
,R
es
er
ve
d
an
d
W
ea
ri
ed
).
A
bb
re
vi
at
io
ns
:
A
U
D
IT
-C
=
A
lc
oh
ol
us
e
di
so
rd
er
id
en
ti
ﬁ
ca
ti
on
te
st
(q
ue
st
io
ns
1–
3)
;P
D
A
=
Pa
ni
c
di
so
rd
er
an
d/
or
A
go
ra
ph
ob
ia
;S
A
D
=
So
ci
al
an
xi
et
y
di
so
rd
er
;G
A
D
=
G
en
er
al
iz
ed
an
xi
et
y
di
so
rd
er
.
Pe
rc
en
ta
ge
s
in
cl
in
ic
al
va
ri
ab
le
s
an
d
di
ag
no
se
s
ar
e
pr
op
or
ti
on
s
of
th
e
te
m
pe
ra
m
en
t
cl
us
te
rs
.
*D
iﬀ
er
en
ce
s
w
er
e
si
gn
iﬁ
ca
nt
be
tw
ee
n
cl
us
te
rs
2
an
d
4,
an
d
be
tw
ee
n
cl
us
te
rs
3
an
d
4
in
Bo
nf
er
ro
ni
an
al
ys
is
.
**
Pr
op
or
ti
on
of
th
e
w
ho
le
pa
ti
en
t
sa
m
pl
e.
Si
gn
iﬁ
ca
nt
di
ﬀ
er
en
ce
s
ar
e
in
bo
ld
fa
ce
.
a
Fo
r
A
N
O
V
A
be
tw
ee
n
th
e
te
m
pe
ra
m
en
t
cl
us
te
rs
.
b
Fo
r
ch
i-
sq
ua
re
be
tw
ee
n
th
e
te
m
pe
ra
m
en
t
cl
us
te
rs
.
V. Paavonen et al. ?????????????????????????????????????????????????
???
disorders, whereas the Persistent temperament cluster was associated
with signiﬁcantly lower prevalence of anxiety disorders. More speciﬁ-
cally, panic disorder and/or agoraphobia were predicted by the Novelty
seekers temperament, social anxiety disorder by Wearied temperament
and generalized anxiety disorder by Reserved temperament in this
sample of diverse depressed patients.
4.1. Panic disorder and agoraphobia
Panic disorder and/or agoraphobia were most highly prevalent in
the Novelty seekers cluster, and their lowest occurrence was observed
in the Persistent cluster. Considering the speciﬁcations of panic disorder
and agoraphobia in the Diagnostic and Statistical Manual of mental
disorders (DSM-IV-TR (2000) 4th ed., text rev.), these disorders likely
associate with both types of anxiety deﬁned in Cloninger's original
theory, namely cognitive and somatic, with panic attacks responding to
somatic anxiety and continuous concern of attacks or agoraphobia to
cognitive anxiety. Thus, the anticipated result was that the highest
prevalence of PDA would be observed in the Novelty seekers cluster,
which was characterized by highest scores in NS (presumably asso-
ciated with somatic anxiety) and above the population norm in HA
(presumably associated with cognitive anxiety) (Jylhä and Isometsä,
2006). In the logistic regression models (adjusted with depression se-
verity, alcohol use, age and gender), the odds for PDA for Novelty
seekers were over three times as high as that for other patients, thereby
suggesting a strong association between the Novelty seekers tempera-
ment proﬁle and panic disorder. Earlier evidence has mainly suggested
no associations between the trait ‘high NS’ and panic disorder co-
morbidity in depressed patients and one earlier study has found an
inverse relation between the two (Ampollini et al., 1999; Kennedy
et al., 2001; Ongur et al., 2005). However, these studies likely included
patient samples with less variance in NS compared with our sample due
to excluding patients with substance use disorders (Ampollini et al.,
1999; Kennedy et al., 2001; Ongur et al., 2005), who 1) are likely to
have higher NS scores (Howard et al., 1997) and 2) have a high pre-
disposition to panic disorder (Zvolensky et al., 2006). This diﬀerence in
samples could explain our novel ﬁnding of a strong association between
Novelty seekers temperament (with high NS) and higher risk for panic
disorder.
Neuropsychologically the increased morbidity in panic disorder and
agoraphobia in Novelty seekers could be associated with aberrant
functioning in paralimbic brain areas that are associated with both
0
20
40
60
80
100
120
140
Novelty seekers Persistent Reserved Wearied
Temperament dimension (Mean±S.E.) scores of the four 
temperament clusters
Novelty Seeking Harm Avoidance Reward Dependence Persistence
Fig. 1. Temperament dimension (Mean ± S.E.) scores of the four temperament clusters.
Table 2
Likelihood of anxiety disorders (PDA, SAD and GAD) according to the temperament clusters in the logistic regression models.
PDA SAD GAD
OR 95% CI p OR 95% CI p OR 95% CI p
lower upper lower upper lower upper
Model 1
Temperament cluster* 3.28 1.67 6.41 0.001 3.17 1.49 6.76 0.003 2.60 1.27 5.33 0.009
Model 2
Temperament cluster* 3.52 1.78 6.96 <0.001 3.19 1.47 6.90 0.003 2.53 1.23 5.21 0.01
Model 3
Temperament cluster* 3.48 1.76 6.91 <0.001 3.41 1.55 7.49 0.002 2.55 1.24 5.27 0.01
Model 1: adjusted with gender and age.
Model 2: adjusted with gender and age, and MADRS scores.
Model 3: adjusted with gender, age, MADRS scores and AUDIT-C scores.
*Binominal variables: 1) Novelty seekers cluster vs. others explaining PDA, 2) Wearied cluster vs. others explaining SAD, and 3) Reserved cluster vs. others explaining
GAD.
Abbreviations: PDA=Panic disorder and/or agora phobia; SAD= Social anxiety disorder; GAD=Generalized anxiety disorder; MADRS=Montgomery Åsberg
depression rating scale; AUDIT-C=Alcohol use disorder identiﬁcation test (questions 1–3), OR=odds ratio, CI= conﬁdence interval.
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Novelty Seeking and panic disorder (De Cristofaro, et al, 1993; Sugiura
et al., 2000). These brain areas including right anterior cingulate cortex
and anterior/posterior insula constitute in part networks associated
with interoceptive functions and with panic disorder (Cui et al., 2016;
LeDoux and Pine, 2016; Sugiura et al., 2000). Psychological theories
have also suggested that interoceptive functions (e.g. interoceptive
conditioning and/or catastrophic misappraisals of bodily sensations)
are central in the etiology of panic attacks and panic disorder (Bouton
et al., 2001; Craske and Waters, 2005). High Novelty Seeking could be a
moderator of the association between interoceptive functions and panic
disorder hypothetically via “histrionic” information processing style
(Cloninger, 1986). This kind of moderating eﬀect would be in line with
our ﬁnding of highest prevalence of PDA in patients with a tempera-
ment proﬁle including the highest NS scores (Novelty seekers) and
signiﬁcantly lower prevalence in patients with a temperament proﬁle
including the lowest NS scores (Reserved).
Earlier studies have shown that panic disorder is associated with
high HA (Kampman et al., 2014), and in addition to high NS observed
in Novelty seekers, increased HA could be an important part of this
temperament proﬁle, thus explaining the high prevalence of panic
disorder (and SAD) found in this patient group.
4.2. Social anxiety disorder
The highest prevalence of social anxiety disorder was observed in
the Wearied cluster and the lowest in the Persistent cluster. After ad-
justing with clinical variables, the Wearied temperament proﬁle,
characterized by highest HA and lowest RD and P, predicted SAD in the
regression models with a higher odds that was over three times as high
as that for other patients. Earlier evidence has shown that high HA is
associated with all anxiety disorders with highest levels found in SAD,
which is well in line with our ﬁnding of Wearied cluster patients
(having the highest HA) having the high prevalence of diﬀerent anxiety
disorders and the highest prevalence of SAD (Kampman et al., 2014;
Miettunen and Raevuori, 2012). HA is also associated with severity of
depressive symptoms and all these ﬁndings together suggest that the
highest scores in HA are associated with SAD and more severe de-
pression (Kampman and Poutanen, 2011). According to high HA's de-
ﬁnition, this trait is associated with avoidant behavior and according to
Cloninger's original theory, high HA is also associated with obsessional
information processing type (Cloninger, 1986,1987). These kinds of
behavioral avoidance and cognitive unconstructive repetitive thinking
patterns could be the link between high HA and both SAD and de-
pression (Kanter et al., 2008; Watkins, 2008; Weinstock and Whisman,
2007). This would lead to interpreting the preceding ﬁndings as sug-
gesting that more severe depression and SAD are more strongly asso-
ciated with avoidance and ruminative or repetitive thinking patterns
compared with other anxiety disorders. This kind of common etiolo-
gical factor could explain the higher comorbidity rate of SAD compared
with other anxiety disorders in MDD patients (Brown et al., 2001) and
suggest that the etiology of SAD resembles more to that of severe de-
pression than other anxiety disorders in these cognitive and behavioral
aspects. As negative mood valent rumination is associated with heigh-
tened neural activity in default mode network (Graham et al., 2013;
Malhi et al., 2015), high HA could be linked to depression via similar
neuropsychological mechanisms.
Negative aﬀectivity or neuroticism, which represent traits similar to
HA (Capanna et al., 2012), have been proposed by earlier studies as
posing a higher-order personality trait common to depressive and an-
xiety disorders and that other unique factors diﬀerentiate between se-
parate disorders (Clark and Watson, 1991; Craske and Waters, 2005).
Although the highest scores of HA could be associated especially with
SAD and more severe depression, as discussed in a previous paragraph,
HA is likely to also present more general factors predisposing to psy-
chopathology, similarly to neuroticism (Kampman and Poutanen, 2011;
Kampman et al., 2014; Miettunen and Raevuori, 2012). Moreover, our
results suggest that emotional detachment and low ambition (reﬂected
as lower RD and P in the Wearied patients’ temperament proﬁle)
compared with other patients could be an important distinctive char-
acteristic of this temperament proﬁle associated speciﬁcally with higher
risk for SAD.
4.3. Generalized anxiety disorder
Generalized anxiety disorder had the highest prevalence in the
Reserved cluster and the lowest in the Persistent cluster. GAD was
predicted by the Reserved temperament proﬁle in the regression models
with over two times as high odds than that of other patients. Reserved
patients were characterized by lowest NS, high HA, and had RD and P
traits roughly corresponding to those observed in the Finnish general
population (Jylhä and Isometsä, 2006). Evidence of the associations
between temperament and GAD is scarce, but the main ﬁnding has been
in line with our results, with GAD suggested to be associated with high
HA (Kampman et al., 2014). In addition to this, our results suggest that
low NS could be an important part of the temperament proﬁle asso-
ciated with GAD even though a similar association has not been found
previously (Ongur et al., 2005; Piero, 2010). As discussed in chapter
4.1, panic disorder is suggested to be associated with interoceptive
functions and Novelty seekers temperament proﬁle (with high NS re-
sponding to “histrionic” information processing) could be a moderator
of this association. Thus, Reserved patients could be at lower risk for
panic disorder due to being less aﬀected with “histrionic” or impulsive
information processing. Instead, the present results suggest that the
proclivity to slow and rigid decision making, slow engagement to new
interests or preoccupation in details associated with low NS could
predispose these individuals to generalized anxiety when experienced
together with other traits predisposing to development of psycho-
pathology, such as high HA (Cloninger, 1987; Miettunen and Raevuori,
2012).
4.4. Persistent temperament proﬁle
The lowest prevalence in all analyzed anxiety disorders was asso-
ciated with the Persistent cluster which was characterized by highest P
and lowest HA when compared to the other temperament clusters.
Moreover, the Persistent patients could likely be associated with higher
P when compared to general population because markedly lower scores
(P=114.6 ± 17.3) have been found in Finnish general population
earlier (Jylhä and Isometsä, 2006). However, the lack of a control group
prevents conclusions of the relative diﬀerences between these popula-
tions. Finding the Persistent patients having lower prevalence of an-
xiety disorders was a plausible result because high P has been asso-
ciated with positive emotionality and well-being (Cloninger et al.,
1998; Garcia, 2011), especially together with low HA and character
trait low Self-Directedness (Cloninger et al., 2012). Our results are in
line with these ﬁndings and support a hypothesis that the combination
of low HA and high P associates with lower comorbidity of anxiety
disorders in depressed patients.
4.5. Strengths and limitations
Because individual temperament presents a precognitive bias re-
sulting in diﬀerent behaviors, the cluster analysis provided complete
temperament proﬁles reﬂecting more comprehensively the individual,
temperament-oriented behavior in patients. Although meta-analytic
data exist on how diﬀerent temperament traits are uniquely predis-
posing to diﬀerent aﬀective disorders, it was important to test the hy-
pothesis of whether individual complete proﬁle data (in terms of tem-
perament clusters) predict the occurrence of anxiety disorders in
depressed patients. Moreover, it is possible that these temperament
clusters would reﬂect endophenotypes predisposing to diﬀerent dis-
orders because they were associated with diﬀerent disorders in this
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study. These kinds of endophenotypes could be more closely associated
with the biological background of psychiatric symptoms compared with
categorical diagnoses or separate temperament traits and could help in
the progress of ﬁnding biomarkers for psychopathology (Service et al.,
2012). Testing the possible associations between temperament clusters
and candidate genes of anxiety disorders would be interesting in future
studies (Sharma et al., 2016).
Although the temperament proﬁles of the studied four temperament
clusters showed strong associations with diﬀerent anxiety disorders, the
lack of a control group in the study posits some limitations that have to
be considered when interpreting the results. Firstly, the four tempera-
ment clusters may or may not be a unique feature of depressed popu-
lations and studies with non-depressed controls are needed to give more
insight on this question. Secondly, the patients’ temperament proﬁle
was assessed during depressive symptoms and may not represent their
long-term temperament proﬁle because depressive states are known to
be associated with elevation in temperament trait Harm Avoidance
(Kampman and Poutanen, 2011). However, the main focus of this study
was to evaluate the associations between temperament clusters and the
occurrence of anxiety comorbidities. In these analyses the depression
severity was controlled for to avoid the bias towards higher risk of
comorbidities with more severe depression. Thirdly, because of the high
level of comorbid disorders in our sample it is also possible that the
current ﬁnding of the four temperament clusters is speciﬁc for de-
pression with anxiety disorder and substance use comorbidities.
Moreover, although human temperament is considered relatively stable
over one's life-span (Cloninger et al., 1993) and the temperament
clusters predicted speciﬁcally higher risk for diﬀerent anxiety disorders
in this study, the cross-sectional setting does not allow interpretations
of the possible causal relations between the temperament proﬁles and
the studied anxiety disorders. Longitudinal studies in general popula-
tion are needed for making conclusions of the possible causality and
could have more marked clinical implications compared to studies with
cross-sectional settings. Due to the study design using cluster analysis
for creating temperament clusters and aiming at analyzing their asso-
ciations with anxiety disorders, we had no a priori hypotheses in this
study, which may also be considered to be a limitation. The use of a
semi-structured MINI interview (based on the DSM-IV) could have re-
sulted in overdiagnosing the patients with SAD and PDA because no
exclusion criteria according to the hierarchy of these diagnoses were
used. However, the diagnosis of GAD was excluded in cases of any other
anxiety comorbidities. We combined patients with panic disorder and/
or agoraphobia into one group (PDA), which limits the generalizability
of these results to clinical settings. Moreover, when interpreting the
results, it must also be noted that 25 patients had undergone a previous
hypomanic episode, which limits the generalizability of these results to
MDD patients. Instead, the results reﬂect more of the associations be-
tween temperament proﬁles and more diverse patients with current
depressive symptoms.
5. Conclusions
Temperament clusters with unique dimensional proﬁles were spe-
ciﬁcally associated with diﬀerent anxiety disorders in this study. These
results suggest that TCI-R could oﬀer a valuable dimensional method
for predicting the risk of anxiety disorders in diverse depressed patients.
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